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Nitric oxide (NO) has been implicated in the pathogenesis of liver cancer or 
hepatocellular carcinoma (HCC). However, the exact role(s) of NO and the expression 
pattern of its enzymes, nitric oxide synthases (NOS), remain unclear. Thus, this study 
was designed to investigate the expression and regulation of NOS in both human and 
animal HCC samples. An animal model of HCC was established and this allowed the 
tracking of NOS expression during the progression of HCC. NOS selective inhibitors and 
NO donors were administered to determine the possible role(s) of NO in HCC in an 
animal model.  
 
Microarray analysis was initially used to examine several liver diseases from patient 
samples, viz, liver cirrhosis, primary HCC, HCC with hepatitis B infection and secondary 
HCC. These were compared to normal liver samples. Expression patterns were distinct 
for each liver disease examined. Gene expression changes in selected transcripts were 
confirmed with quantitative real time PCR. Of these transcripts, NOS was furthered 
studied in detail. Nitrates and nitrites, a measurable form of NO, alongside NOS 
expression and activity were found to be increased in liver cirrhosis and HCC. Rac2 and 
caveolin-1, endogenous post-translational regulatory factors of inducible NOS (iNOS) 
and endothelial NOS (eNOS) were also examined. Both were found to be highly 
expressed in the disease states. This suggests the regulatory factors are likely to 
contribute to NOS regulation. However, the expression of soluble guanylate cyclase 




An animal model for HCC was established with the administration of diethlynitrosamine 
(DEN) in drinking water. This treatment resulted in the development of cirrhosis in the 
liver prior to the development of visible foci, similar to the progress of HCC in humans. 
DEN was given to male Sprague-Dawley rats ad libitum for a period of 4, 6, 8, 10, 12, 14 
and 16 weeks. Apart from visible foci formations, glutathione S-transferase-π (GST-π), a 
commonly used marker for neoplasms, staining was carried out to confirm the 
development of neoplastic lesions. With time, DEN-treated rats were found to have 
increased NO and NOS, Rac2 and caveolin-1 expression. However, eNOS and iNOS, the 
two isoforms of NOS studied, showed differential expression activities which were most 
distinct at week 10. 
 
To further investigate the role of NO in the progression of HCC, NOS selective inhibitors 
and NO donors were administrated to rats after 10 weeks of DEN treatment. Again the 
levels of NO and NOS expression and activities were studied. NOS selective inhibitors, 
N-nitro-L-arginine (L-NNA) and N-1-iminoethly-L-lysine (L-NIL), were selected for 
their high inhibitory effects against eNOS and iNOS respectively. NO donors, isosorbide 
dinitrate (ISDN) and molsidomine were selected as these are currently used in 
prescription drugs for humans. Interestingly, NOS inhibitors exacerbated HCC 
progression, which implies a protective role for eNOS. NO donor treatments on the other 
hand, showed decreased visible foci, cirrhotic lesions and GST-π positive staining. This 




In conclusion, we found that the different isoforms of NOS, iNOS and eNOS, are 
expressed differently in human liver diseases. During the progression to neoplasm as 
studied in our HCC model, iNOS and eNOS play different roles as suggested by the 
differential expression and activity patterns. Administration of NOS inhibitors and NO 
donors more clearly defined the role of NO in foci formation. NOS inhibitors did not 
alleviate HCC formation. In contrast, the systemic and liver specific NO donors, both 
showed dramatic improvement in reducing neoplasm formation. This could be used as a 


















Chapter 1: Introduction 
1.1 Liver Cancer 
The liver, or hēpar in Greek, is one of the largest glandular organs in vertebrates 
including humans. In humans, the liver contains more than 10% of the body’s total blood 
at any one time.  It has a gamut of functions that affect the entire organism. Some of its 
major roles include carbohydrate metabolism, lipid metabolism, production of 
coagulation factors, drug metabolism, detoxification, production of bile, breakdown of 
heamoglobin, storage of glycogen and iron. As such, any damage or disease to the liver 
has widespread effects on the well-being of the organism.  
 
Cancer, once thought to be a loss of equilibrium of the body’s humors, is now known to 
be essentially a multi-factorial disease, whereby one, or more typically, several mutations 
are required for cellular transformation. Cell proliferation or division is a fundamental 
physiological process. This is delicately balanced with programmed cell death or 
apoptosis to maintain tissue and organ integrity. Mutations in the DNA can cause 
uncontrolled and often rapid proliferation. This tips the balance and a cell mass or 
tumour, benign or malignant, can form. Benign tumours remain in situ and is rarely life 
threatening unless by sheer mass, the tumour compresses or displaces vital organs. 
Malignant tumours, christened carcinos by Hippocrates, on the other hand, are invasive 
and often life threatening. Hippocrates later added the suffix –oma, Greek for swelling, 
resulting in carcinoma, often used now to describe cancers deriving from cells of the 












Primary liver cancer, twice as common in men as in women, has two main cellular 
origins. Cholangiocarcinoma, arises from bile duct cells, while hepatocellular carcinoma 
(HCC) arises from hepatocytes, the main cell type of the liver. The latter is the most 
prevalent form of primary liver cancer, HCC. As illustrated in Figure 1.1, HCC accounts 
for nearly 85% of all primary liver cancers (Lag et al., 2005).  
 
 
Figure 1.1: Pie chart showing the different types of primary liver cancer. The highest 
prevalence is HCC at 84%.  Cholangiocarcinoma, cancer arising from bile duct cells is 
second at 14%. More rare are angiosarcoma, cancer arising from blood vessel 
endothelium, and fibrolamellar carcinoma in which malignant hepatocytes are intersected 








HCC is one of the most common malignancies worldwide, representing more than 5% of 
all cancers  (Llovet et al., 2003). It is the third most common cause of cancer-related 
death globally (Mann et al., 2007). HCC has a yearly fatality ratio of nearly 1, this 
indicates that most patients do not survive a year after diagnosis; a five-year survival rate 
is only 6.5% (Yoshida et al., 2005).  Although the highest prevalence of HCC is in 
developing countries like Africa and parts of Asia, the United States and Europe have 
increasing HCC incidence. An estimated 0.25 million to a million new cases of HCC are 
diagnosed globally every year (Llovet et al., 2003).  
 
1.1.1 Etiology and Prevalence 
 
The incidence of HCC shows an irregular distribution. Two main epidemiological 
characteristics governing this have been identified. Firstly, HCC often occurs in a 
previously diseased liver, some examples include alcoholic cirrhosis, viral infections 
(hepatitis B and C), metabolic disorders (haemochromatosis, α-1 antitrypsin deficiency) 
and alfatoxin infection. Secondly, the causes of the underlying liver disease can be 
differentiated by geographical distribution.  
 
In the United States and Northern Europe, usually with lower incidences of HCC, HCC is 
often related to alcoholic cirrhosis. In Southern Europe, Egypt and Japan, areas of higher 
HCC incidence, hepatitis C is the most common causative factor (Michielsen et al., 
2005). In China, where an estimated one third of new cases worldwide originate; 
aflatoxin B1 is one of the leading causes of HCC (Schafer et al., 1999).  In Southeast 
Asia and Africa, which have the highest HCC incidences, hepatitis B infection is the 
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main cause. A chronic infection increases the risk of cancer about a hundred fold. It has 
been estimated that more than 50% of HCC in these regions is related to hepatitis B virus 
(HBV) (Cougot et al., 2005). In countries with high incidence of HBV infections, the 
younger the age of infection, the more likely the development of chronic infection. 
Vaccination against HBV in young children has been shown to decrease HBV infection 
and HCC (Chen et al., 2000). 
 
In Singapore, cancer is the 2
nd
 major cause of death. The proportion of deaths caused by 
cancer has risen steadily from 14.8% (1968-1972) to 27.1% (1998-2002). Of the 78,048 
deaths from 1998 to 2002, 21,156 were from cancer. Within the same period, lung cancer 
was the main cause of cancer deaths in both males (26.1%) and females (16.4%) of all 
races. Liver cancer was found to be the 2
nd
 highest in males (12.6%) and 5
th
 highest in 
females (5.6%). Of the liver cancer patients from 1998 to 2002, 86% of males were 
Chinese; 88% of females were Chinese. Onset is predominantly in the older age group, 




HCC has a high lethality rate, with life expectancies of about 6 months from time of 
diagnosis and less than 5- 10% survival rate over 5 years (Clark et al., 2005; Yoshida et 
al., 2005). This is often due to diagnoses occurring in the later stages of the disease, 
thereby disallowing potentially curative treatment options. HCC is often asymptomatic in 
the early stages, and as such, the cancer is allowed to progress unchecked. By the time 
some general symptoms like unexplained weight loss, abdominal pain, swelling, 
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tenderness and jaundice are present, the cancer would have progressed to the more 
advanced stages (Clark et al., 2005).  
 
HCC is traditionally, as with other tumour types, established by histological or 
cytological proof. Histological examination of liver biopsy has, for many years, 
represented the gold standard in the diagnosis of HCC (Llovet et al., 2003; Yoshida et al., 
2005). However, the routine use of needle biopsy of HCC is controversial both in clinical 
practice and research. In small or early tumours, the tumours may be too difficult to reach 
or biopsy results may return false negatives. These false negatives have been documented 
to be as high as 40% (Llovet et al., 2003) in some areas. In the case of larger tumours, 
there is a risk of complications, including intraperitoneal or intrahepatic haemorrhaging 
or needle track seeding. To circumvent these limitations, more emphasis has been 
recently placed on non-invasive imaging techniques.  
 
Current imaging techniques include real-time ultrasound scan (US), computerized 
tomography (CT) and magnetic resonance imaging (MRI). Ultrasound scan or US is a 
technique with minimum invasion for the patients (Kudo, 2005). However, sensitivity in 
tumour detection is variable, largely dependent on the operator’s expertise and experience 
(Yoshida et al., 2005). US results are generally regarded as having lower objectivity than 
CT or MRI.  However, with the use of contrast agents, increased accuracy may be 
obtained. Contrast agents have also been employed in CT scans, often considered the 
gold standard in HCC imaging diagnostics. With intravenous contrast enhancement, CT 
scan can provide precise anatomical localization of lesions across the lobes of the liver. 
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Other key diagnostic information include the number of lesions, the presence of 
metastases, ascites, varices and cirrhosis. Hepatomas preferentially accumulate and retain 
lipiodol, a common contrast reagent. Hepatic angiography with lipidol provides a 
vascular map for surgery and chemo-embolization (Szklaruk et al., 2007). 
 
MRI, another popular imaging diagnostic technique, has its share of limitations. 
However, recent advances in MRI hardware and software have improved the quality of 
the images generated. Generally, MRI utilizes superparamagnetic iron oxide particles to 
provide enhanced images. Patients allergic or sensitive to CT contrast agents have an 
alternative of non-invasive imaging tools (Yoshida et al., 2005). Further advances include 
using double-contrast MRI. Sequentially acquired images from gadobenate dimeglumine-
enhanced and resovist-enhanced MRI were found to be as sensitive and as accurate as CT 
hepatic arteriography (Kim et al., 2007). 
 
The European Association of the Liver  has developed a well-defined set of non-invasive 
criteria to establish HCC diagnosis (Llovet et al., 2003) which are listed below:  
1. The coincidental findings of two techniques, either US, CT or MRI and 
angiography showing a nodule greater than 2 cm with arterial 
hypervascularization, or 
2. A single imaging technique associated with serum α-fetoprotein (AFP) 




Serum α-fetoprotein or AFP is a glycoprotein produced in the fetal liver, but suppressed 
in adults. Over 70% of HCC patients show elevated AFP concentrations (Zhou et al., 
2006).  Forty years after its discovery, AFP remains one of the most widely used tumour 
markers for HCC. Its detection is minimally invasive and considered a fairly routine lab 
test at low cost. The specificity and sensitivity of AFP as a tumour marker depends very 
much on the cut-off value chosen. The specificity and sensitivity can range from 65% to 
94% and 40% to 99% if cut-off levels are set at 20ng/mL to 200ng/mL. At cut-off value 
of 400ng/mL, specificity has been found to be as high as 99% and while sensitivity is a 
modest 17% (Yoshida et al., 2005).   Unfortunately, AFP interpretation is complicated by 
nonspecific fluctuations in patients with chronic viral hepatitis or cirrhosis without HCC. 
In addition, the positive predictive value of AFP is markedly lower in HCC patients with 
viral etiology than without. Furthermore, AFP is rarely increased in patients with small 
tumours (Zhou et al., 2006). To circumvent the nonspecific fluctuations of AFP, a more 
specific fraction of AFP has recently been used. Len culinaris agglutinin A-reactive AFP, 
or AFP-L3 has also been found to be increased in HCC. Apart from AFP and AFP-L3, 
des-gamma-carboxy prothrombin (DCP) has also been utilized as a serological tumour 
marker or to assess the efficacy of various HCC treatments. DCP, alongside AFP and 
AFP-L3, has been found to be elevated in patients and increases with the progression of 
the disease. Poor prognosis has been reported in patients with all three tumour markers 
elevated (Toyoda et al., 2007; Yoshida et al., 2005). 
 
Another tool in the arsenal of diagnostics is the liver panel or liver function test.  Various 








Albumin 4.0-4.8 Protein specifically synthesized in the liver; low 
levels indicative of impaired liver function/liver 
damage. 
Total Bilirubin 5-30 umol/L Bilirubin is a product in the clearing of heam from 
red blood cells, a function specific to the liver. 
Excessive bilirubin leads to the typical yellow 
colouration in jaundiced patients. 
Direct Bilirubin 0-5 umol/L Conjugated bilirubin or direct bilirubin is measured 
to determine bile duct obstruction.  
Alanine transaminase 
(ALT) 
24-53 Hepatocyte specific enzyme that is released into the 
blood stream upon liver damage; increased levels 
indicative of liver damage. 
Aspartate 
transaminase (AST) 
77-157 An enzyme found in liver, red blood cells and 




132-312 Enzyme found in bile ducts; excessive levels in blood 
indicative of bile duct obstruction. Enzyme also 
found in bone.  
Gamma glutamyl 
transpeptidase (GGT) 
0-3 Enzyme used to determine cholestatic damage if ALP 





Clotting assay; increased clotting time indicative of 
abnormal levels of clotting factors, including vitamin 






Enzyme not exclusive to the liver, found in heart and 
muscle, but elevated levels indicative of liver damage 
when taken with other parameters. 
Table 1.1 Liver function test parameters. Most of these are part of the routine liver 
function test or liver panel test, however, some like GGT and LDH, are carried out only if 
the liver function test results prove to be abnormal. Normal human range is provided by 





In conclusion, liver function test, serological tumour markers and diagnostic imaging, 
taken together can diagnose HCC successfully. However, as intimated earlier, diagnosis 
is often at the symptomatic stage when liver damage caused by tumour growth is 
extensive enough to cause discomfort. One method in place to prompt early stage 
diagnosis is to screen and conduct surveillance of patients at high risk of developing HCC 
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(Blum, 2005; Yoshida et al., 2005). Patients in this category are often patients already 
diagnosed with alcoholic cirrhosis or chronic hepatitis B or C infections. This may allow 
detection of HCC at an earlier stage where curative treatments are viable, increasing the 
survival rate. The identification of small (<2cm) tumours is important as this is the 
current criterion for surgical resection, a potentially curative treatment as small tumours 
are less likely to have invaded the surrounding liver tissue. However, surveillance is not 
economically viable in many of the areas, like Southeast Asia, where HCC is prevalent 
(Llovet et al., 2003).  
 
1.1.3 Current Treatments 
 
The main treatments currently available to HCC patients fall under two main categories, 
curative or palliative. 
 
The two curative treatments are surgical resection and transplantation. For the latter, liver 
transplantation is fraught with limitations, among which is the scarcity of donors. As 
recipients wait, the tumour could develop and infiltrate the blood stream or expand 
beyond the liver capsule, rendering them invalid for transplantation (Bruix et al., 2006).  
From 1990 to 2004, only 100 liver transplants have been performed in Singapore, of 
which 44 were in young children or babies (Wai et al., 2006b). Low cadaveric donations 




To get around long waiting lists and low cadaver donor numbers, living donor liver 
transplants can be considered. To date, more than 4000 cases of living donor liver 
transplants have been performed worldwide and have thus far, shown similar success to 
cadaveric transplant. The move towards living donors liver transplant over the past few 
years has somewhat attenuated the waiting time for those on the transplant list. However, 
living donor liver transplant is not adopted worldwide and surgical procedures are far 
more complicated than that of cadaver donors. In developing regions where HCC is 
highly prevalent, the lack of sufficiently trained surgeons and prohibitively higher costs 
of living donor liver transplant render this treatment option invalid for many (Varela et 
al., 2003). 
  
The 3-year survival rate of recipients of liver transplant have been reported to be as high 
as 80% (Bruix et al., 2006; Schafer et al., 1999). However, if patients with disease that is 
too advanced are given priority, the long term survival rate drops drastically. 
Transplantation management systems are also increasing the stringency of eligible 
patients, selecting those with higher chances of full recovery and lower recurrence rates 
based on prognostic tests (Sutcliffe et al., 2006; Varela et al., 2003), aiming to boost 
survival rates. Furthermore, resection, the only other potentially curative surgical 
treatment is appropriate in 10-15% of cases where patients have solitary defined tumours 
of size 2cm or smaller (Blum, 2005). Background cirrhosis leads to complications; as 
liver failure is likely if the remaining hepatic reserve cannot adequately support liver 
function (Bruix et al., 2006; Schafer et al., 1999). In resection or transplantation, in spite 
of being potentially curative, more than 80% of patients suffer from recurrence of HCC 
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(Bruix et al., 2006). In another study, patients with single tumours of less than 5cm 
achieved a 70% survival rate of 5 years and a recurrence rate of 15% (Yoshida et al., 
2005). This indicates that selection criteria are crux to determining survival and 
recurrence rates. Consensus is that patients should be listed for transplantation only when 
there is more than 50% chance of the patients’ survival for more than 5 years after the 
transplant (Llovet et al., 2003). Another challenge for the transplanted liver is the 
recurrence of viral hepatitis infection. However, this can be effectively controlled by 
current anti-viral treatments (Wai et al., 2006a). 
 
Palliative treatments, on the other hand, are not associated with survival benefit but aim 
to alleviate symptoms and improve the lifestyle and comfort of the patient. Some 
common forms of palliative therapy include, chemotherapy, embolization and 
percutaneous ablation. 
 
Precutaneous ablation can cause complete necrosis of the tumour and improve survival 
rates. Again, eligibility conditions for this treatment comprises of patients with 4 or less 
small (<3cm) tumours. Larger tumours (>3cm) show low success rates and often run the 
risk of incomplete ablation and thus recurrence (Yoshida et al., 2005). Transcatheter 
arterial embolization (TACE) is suitable for patients with non-surgical HCC and 
ineligible for percutaneous ablation. This treatment can cause >50% necrosis in tumours, 
reducing tumour markers and tumour size appreciably. However, biopsy often reveals 
incomplete tumour necrosis and viable neoplastic cells which results in high recurrence 
rates (Yoshida et al., 2005).  
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In other treatments, for example, lipiodol chemo-embolization, retardation and reduction 
of tumour growth was apparent but consequential acute liver failure complicated further 
treatment and did not improve survival (Blum, 2005; Bruix et al., 2006; Varela et al., 
2003; Yoshida et al., 2005).  
 
Some of these treatments, although applied to patients presenting with similar 
histological grading, have no positive effect on some patients, while showing appreciable 
improvements in others. Some other established treatments include systemic 
chemotherapy, radiation using Iodine-131, proton beam radiation, anti-androgens, 
interferon therapy and immunotherapy. These often have deleterious and notorious side 
effects such as hair loss, weight loss and severe nausea. Furthermore, these treatments 
have shown no improvement in survival rates although limited anti-tumour effects have 
been observed in vitro (Varela et al., 2003). 
 
1.2 Nitric Oxide 
 
Nitric oxide or NO, is one of the 10 smallest molecules (only 30 Daltons) occurring in 
nature. One of the first known effects of NO was as a gaseous air pollutant, largely 







Molecular formula NO 
Molar Mass 30.0061g/mol 
Appearance Colourless gas 
Melting point -163.6°C 
Boiling point -151.7°C 
Structure Linear 
Water Solubility 0.074 v/v 
Half Life <5 seconds 
Major hazard Inhalation and Reactivity 
Toxicity 25 ppm 
Odour Slightly Irritating 
                      Table 1.2: Some chemical properties of NO 
 
 
 For over a hundred years, nitroglycerin was clinically used to treat agina pectoris. Yet its 
mechanism of action has only been established recently. However, it took only six years, 
1980-1986, to identify that Endothelium Derived Relaxing Factor (EDRF) as NO.  The 
definitive experiment was the shift in Soret absorption from 433 to 406nm when NO 
reacts with deoxyhemoglobin in the presence of endothelial cells and calcium (Ignarro et 
al., 1988a; Ignarro et al., 1987a; Ignarro et al., 1987b; Ignarro et al., 1988b; Moncada et 
al., 1988).  That NO could be synthesized in mammalian cells had a dramatic effect in its 
research. From its disrepute as a noxious air pollutant from car exhaust to Molecule of the 
Year 1992 (Koshland, 1992), the simple molecule NO has come a long way. 
 
Consisting of one atom of nitrogen and one atom of oxygen, an unpaired electron confers 
NO its paramagnetic properties and its free radical status (Stamler et al., 1992). In spite 
of its free radical nature, NO is slow to react with itself, unlike other free radicals. In 
oxygenated aqueous solutions, NO has a half-life of as long as 4 minutes. In biological 
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systems, its half-life is estimated to be about 5s. NO is also uncharged, thus it is able to 
diffuse freely within and across cell membranes within milliseconds, lending it its unique 
signaling capacity (Bruckdorfer, 2005).   
 
In this, NO represents the first instance of an intercellular messenger for which the 
membrane is not a barrier and interaction with specific receptors unnecessary to initiate a 
signaling cascade. Instead, signal transduction is not directed by molecular shape but 
rather by reactions with different cellular components. As such, NO is able to participate 
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Figure 1.2: Roles of NO. Some regulatory roles of NO are presented here, including 
its known protective and detrimental functions. NO at different time-points and/or 
different concentrations can elicit varied physiological and pathological reactions. 




1.2.1. Reactions of NO  
 
NO has an amazing repertoire of physiological functions, including homeostasis, 
immunological defense mechanisms, neurotransmission, vasodilatation, platelet 
aggregation, apoptosis and cellular respiration. To effect these physiological processes, 
NO must be able to react with various cellular components. These reactions can be 
broadly divided into direct and indirect effects. Generally, direct effects occur at low NO 
concentrations (<1µM); NO can react directly with haem-containing proteins such as 
guanylate cyclase, oxyhemoglobin and cytochrome P450.  
 
Indirect effects, involving reactive nitrogen oxide species (RNOS) formation, become 
significant at higher concentrations (>1µM) (Stamler et al., 1992).  Indirect effects, 
mediated by RNOS, formed through the reaction of NO with either oxygen or superoxide 
anion, has been linked to lipid peroxidation and nitrosation of tyrosine residues in 
proteins (Bruckdorfer, 2005). NO is rapidly inactivated by oxidation to its metabolites: 
nitrites and nitrate. These readily diffuse into circulation, thus nitrite/nitrate 
concentrations are taken as indicators of the presence of NO. These products can release 
NO upon acidification. 
 
1.2.1.1 Direct reactions of NO 
 
One of the direct targets of NO is soluble guanylatel cyclase (sGC). sGC is expressed in 
most cell types and is composed of two subunits (α and β) and function as a heterodimer. 
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NO binds  directly to the haem prosthetic group of the enzyme (Ignarro, 1992), increasing 
its catalytic activity by 200 fold, thereby increasing the production of cGMP. sGC 
catalyzes the conversion of guanosine triphosphate (GTP) to cGMP. cGMP acts on three 
different effectors, namely cGMP-dependent protein kinase (cGK), cGMP-gated ion 
channels (CNG) and cGMP-regulated phosphodiesterase. These mediate protein 
phosphorylation, cation influx and cyclic nucleotide metabolism, through which cGMP 
mediates many physiological functions of NO, including endothelium-dependent 
relaxation, platelet aggregation and neurotransmission (Bruckdorfer, 2005).   
 
Other haem-NO interactions include cytochrome P-450, nitric oxide synthase (NOS) and 
haemoglobin (Tsai, 1994). Cytochrome P-450s are a group of enzymes that are involved 
in the synthesis and catabolism of biomolecules such as fatty acids, steroids, 
prostglandins, and leukotrienes. NOS is responsible for endogenous NO production and 
binding of NO to NOS can attenuate its activity, serving as a negative feedback inhibition 
(Buga et al., 1993; Griscavage et al., 1993). NO is able to react with haemoglobin, which 
binds NO five to six times faster than oxygen, producing methaemoglobin and nitrate. 
This is one of the major metabolic fates as well as a primary detoxification mechanism of 
NO (Bruckdorfer, 2005). These reactions are rapid and relevant under both physiological 







1.2.1.2 Indirect reactions of NO 
 
Indirectly, NO exerts its effects through two major routes, nitrosation and oxidation 
(Wink et al., 1996). Nitrosation reactions affect amines and thiols. Nitrosation of amines 
results in nitrosamines, which are potentially carcinogenic. Decomposition of N-nitroso 
compounds produces powerful alkylating agents which damage DNA. Nitrosation of 
thiols leads to a variety of different consequences, from inhibition of enzyme activity to 
formation of S-nitrosothiol adducts that modulate signal transduction (Hussain et al., 
2003). Examples of these include S-nitrosocysteine, S-nitrosoglutathione and S-
nitrosoalbumin and these are capable of releasing NO and exhibit properties similar to 
that of NO itself (Upchurch et al., 1995). Furthermore, it is possible for the NO to be 
transferred to other thiol groups by a process known as trans-nitrosation which appears to 
be promoted by enzymatic activity. This forms the basis of post-translational 
modification of proteins by NO (Bruckdorfer, 2005; Hussain et al., 2003). Excessive NO 
may have unwanted effects and therefore referred to as nitrosative stress, which may 
contribute to neuropathies and other diseases. Nitrosative stress is primarily driven by 
N2O3, which is formed by the autoxidation of NO.  
 
NO has both pro- and anti-oxidant properties. NO can stimulate lipid oxidation and at the 
same time, mediate antioxidant reactions. NO can react with superoxide, forming 
peroxynitrite anion (ONOO-), a powerful oxidant capable of causing lipid peroxidation. 
Although peroxynitrite is important in host defense, generation of excessive amounts of 
the anion leads to oxidative injury. Peroxynitrite nitrates phenolic residues of tyrosine, 
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forming nitrotyrosine. Conversely, the antioxidant effects of NO include scavenging free 
radicals or result from its reactions with intermediates formed during lipid peroxidation, 
resulting in lipid radical chain reaction termination (Kanner et al., 1991).  NO is also able 
to stimulate the activation of several proteins which are protective against oxidative 
stress, such as, haem oxygenase, superoxide dismutase and endonuclease IV. NO is able 
to modulate and reduce injury from ischemia-reperfusion (Kanner et al., 1991), as well as 
form iron-nitrosyl complexes, thus reducing iron availability in pro-oxidant reactions and 
inhibiting oxidases involved in respiratory burst (Fang, 1997). 
 
A respiratory burst consists of reactions between reactive oxygen species and NO or  
reactive nitrogen species (RNS), and is responsible for the anti-microbial actions of 
activated macrophages. Reaction products like peroxynitrite have greater cytotoxic 
effects than either NO or oxygen radicals alone. Increased formation of the potent 
hydroxyl radical in the presence of iron species contributes to the efficacy of the 
respiratory burst. Activated macrophages have been found to have increased inducible 
NOS (iNOS) activity and expression levels. The efficacy of anti-microbial actions are 
much attenuated in the presence of iNOS inhibitors (Fang, 1997). NO is highly cytotoxic 
in host defense, able to cause apoptosis and free radical damage (Li et al., 2000). Yet, at 
the same time, NO is key in many physiological processes such as neurotransmission and 
control of vascular tone.  Thus, it might be difficult to reconcile all of NO divergent 
attributes. However, this simple molecule of one nitrogen and one oxygen belies the 




 1.2.2. Biosynthesis of NO 
 
In a 2-step process, nitric oxide is produced during the conversion of L-arginine to L-
citrulline, via the formation of an intermediate: N 
ω
-hydroxy- L-arginine. This involves a 
total transfer of 5 electrons, 3 substrates, namely L-arginine, molecular oxygen and 
NADPH, and 5 prosthetic groups (Bruckdorfer, 2005). All this is catalysed by the nitric 










L-arginine          N-hydroxy-L-arginine       L-citrulline     
 
Figure 1.3: Reaction catalyzed by NOS. Substrates include L-arginine, oxygen and 
NADPH, forming L-citrulline and NO. 5 other co-factors are involved and each has a 
specific binding site on the enzyme. The availability of these co-factors also plays a part 
in determining the activity of the enzyme. This reaction is part of amino acid metabolism 
where L-citrulline can be converted back to L-arginine, implying that NO is part of the 
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Studies using radioisotopes have found that the nitrogen atom in NO derives from the 
guanidine-nitrogen in arginine while the oxygen atom in NO derives from molecular 
oxygen (Bruckdorfer, 2005; Moncada et al., 1989). 5 electrons are involved in the 
process. These electrons are donated from NADPH. NADPH binds to a site near the C-
terminus of NOS, where it is in proximity to FAD. There, NADPH reduces FAD to 
FMN. In this way, the electron is transferred from the C-terminus to the N-terminus of 
NOS where the haem domain is found (Moncada et al., 1989). This electron transfer is 
activated by the binding of calmodulin to a specific binding site in NOS (Bruckdorfer, 
2005; Su et al., 1995). For neuronal and endothelial NOS (nNOS and eNOS 
respectively), binding of calmodulin is dependent on intracellular calcium concentrations. 
This couples NO synthesis to physiological stimuli. This is not so for inducible NOS or 
iNOS where calmodulin is bound tightly regardless of intracellular calcium levels. 
Calmodulin binding however does not affect the binding affinity of NOS for arginine, 
implying that arginine has a discrete active site (Su et al., 1995).  
 
 
1.3 Nitric oxide Synthase 
 
The initial distinction between the different NOS isoforms was whether it was 
constitutive or inducible. Currently, three different types of NOS have been identified, 
each encoded by a distinct gene. The genes for human NOS isoforms have been localized 
to chromosomes 12, 17 and 7, for nNOS, iNOS and eNOS respectively.  The first isoform 
to be discovered was nNOS, purified from rat cerebellum neurons, hence the 
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nomenclature nNOS. Inducible or iNOS was the next to be discovered, first isolated in 
mouse macrophages. Lastly, eNOS was discovered in bovine aortic endothelial cells 
(Bruckdorfer, 2005; Sessa, 1994). The tissue site of their initial discovery led to the 
naming of nNOS, iNOS and eNOS. However, with more recent findings, the 
nomenclatures based upon their initial sites of discovery have been shown to be 
inadequate. Renamed for the order of the discovery, nNOS is now designated NOSI, 
iNOS is NOSII and eNOS is NOSIII (Table 1.3) (Forstermann et al., 1994). However, in 






Renamed to: Molecular weight 
of monomer (kDa) 
Gene Locus 
nNOS NOS I 161 12q24.2-12Q24.3 
iNOS NOS II 130 17cen-q11.2 
eNOS NOS III 133 7q25-7q36 
Table 1.3: Table listing the 3 known isoforms of NOS. Specific binding sites to the 
various co-factors required for NOS activity are essential in all isoforms. The primary 









 1.3.1. Structure of NOS 
 
NOS is only active in its homodimer form, associating with two molecules of calmodulin 
(one for each dimer). This whole complex, in addition to the co-factors, forms a  
functional 300kDa complex, which synthesizes the 30 Da product, NO (Bruckdorfer, 
2005). An average homology of 50% can be found between the isoforms. Between 
mammals, the same isoforms of NOS can have as high as 90% homology, indicating that 
NOS is  highly conserved (Nathan et al., 1994b). 
 
NOS incorporates several domains in a single polypeptide: the P450-like haem domain 
that binds a tetrahydrobiopterin (BH4) cofactor and is the site of oxidation of arginine to 
nitric oxide and citrulline; a P450-reductase domain that has binding sites for FMN, 
FAD, and NADPH and is responsible for providing electrons to the haem domain, and a 
connecting peptide between the haem and flavin domains that binds calmodulin in a 
Ca
2+
-dependent manner for eNOS and nNOS forms and essentially Ca
2+
-independent 
manner in iNOS (Nathan et al., 1994b). Figure 1.4 illustrates the many domains of NOS 















Figure 1.4: Structural similarities between the NOS isoforms.   
a) The various domains found on the isoforms of NOS. 
b) A dimer formation of NOS. The oxygenase domain is linked via a helical peptide to 
the reductase domain. Binding of calmodulin acts as a ‘switch’, enabling electron flow 
from FAD to the haem group in the N-terminus. Oxygenase domain also contains a BH4 
prosthetic group, this activates heme-bound oxygen by a single electron donation. 






NH2- -COOH NADPH FAD nNOS 
iNOS 
Oxygenase domain Reductase domain 
Calmodulin binding site 
FMN binding site 
ARG/Heme/BH4 binding site 
-COOH NH2- NADPH FAD 










Characteristic nNOS iNOS eNOS 
Subcellular 
localization 
Cytosolic; except in 
skeletal muscle 
where it is 
membrane bound 
Cytosolic Membrane bound 
Regulation of 
expression 




Level of NO 
produced 
pmoles nmoles pmoles 
Calcium ions 
dependency  
Yes; binding of 
calmodulin occurs 




Yes; binding of 
calmodulin occurs 
when calcium levels 
increase 
Major function Neuronal messenger Immune system Relaxation of 
vascular smooth 
muscle 
Table 1.4: List of NOS isoforms and their general characteristics.  
 
 
1.3.2. Regulation of NOS 
 
Regulation of NO synthesis could occur at the level of regulation of NOS expression, or 
the regulation of NOS activity.  The regulation of the 3 NOS isoforms results in different 
levels of NO formed. iNOS is known to produce high levels (nmole) of NO for sustained 
periods; where eNOS and nNOS produce pmoles levels of NO for short bursts. This 
indicates that regulation for the differing quantities of NO produced must be 







  1.3.2.1 Transcriptional Regulation 
 
Much is known about the regulation of iNOS transcription. In studies of mouse 
macrophages, cytokines such as tumor necrosis factor (TNF)-α, interleukin-1β, and 
Interferon (IFN)-γ could synergistically activate the gene expression of iNOS. This 
requires the presence of transcriptional factor, nuclear factor-kB (NF-kB).  
 
However, nNOS and eNOS are also to some extent regulated transcriptionally, although 
these 2 isoforms are mostly constituitively expressed. At the transcriptional level, nNOS 
can be regulated by various physiological and pathological conditions. nNOS up-
regulation seems to represent a general response of neuronal cells to various stress 
factors, such as heat, light, colchicine, phenobarbital, allergic substances and nerve 
injuries. Likewise, many factors like sex hormones, transforming growth factor (TGF) 
β1, vascular endothelial growth factor, basic fibroblast growth factor, shear stress can 
increase eNOS transcripts (Forstermann et al., 1994; Kleinert et al., 2004).  
 
1.3.2.2 Post-translation regulation 
 
Like any enzyme, availability of the substrate, in this case L-arginine, affects the activity 
of NOS.  Another mode of regulation is the availability of tetrahydrobiopterin cofactor. 
Cells that were induced to express iNOS also concomitantly activate genes encoding the 




Further regulatory control of NOS activity is administered by its product NO. NO is able 
to negatively regulate NOS activity by negative feedback inhibition. NO binds to the 
haem iron group in NOS and prevents further reactions (Nathan et al., 1994b). Like many 
other enzymes, NOS can be regulated by intracellular Ca
2+
 levels. Calmodulin only binds 
to nNOS and eNOS during influxes of intracellular Ca
2+
. Molecules which increase 
intracellular Ca
2+
 levels, for example acetylcholine, are thus able to influence the rate of 
NOS activity. In contrast, iNOS is not affected by intracellular Ca
2+
 levels as calmodulin 
is already tightly bound.  
 
A third means of NOS regulation is via its covalent modifications. Myristoylation, 
palmitoylation, farnesylation and acetylation are some modifications that changes NOS 
localization to the plasma membrane, cytosol or organelles. nNOS, devoid of anchoring 
sites to the plasma membrane, has instead a PDZ domain, targeting it to nerve synapse. 
Phosphorylation by specific protein kinases is another post-translational regulatory 
mechanism of NOS. Both the activity and localization within the cell are affected by the 
degree of phosphorylation. Sheer stress can induce the phosphorylation of serine residues 
in eNOS, increasing its activity independently of Ca
2+
 levels (Nathan et al., 1994b). In 
contrast, phosphorylation decreases nNOS activity in neuronal cells (Zhang et al., 2003). 
The reactive and diffusive nature of the NO signal also requires that the synthase be 
localized in proximity to its downstream targets. Other regulatory interactions of NOS are 








Protein Binding site Function 
nNOS Calmodulin CaM binding domain Activation 
 NOSIP aa366-486 Inhibition 
 PIN aa228-244 Inhibition 
iNOS Rac2 Oxygenase domain Activation 
 Kalirin N-terminal Prevents dimer formation 
 NAP110 N-terminal Prevents dimer formation 
eNOS Caveolin-1 aa350-358 Inhibition 
 Caveolin-3 N-terminal Inhibition 
 Dynamin-2  Activation 
 Porin  Activation 
 NOSTRIN aa98-366 Intracellular trafficking 
 NOSIP aa366-486 Inhibition 
Table 1.5: Some regulatory interactions of the three isoforms of NOS. Table 




1.4  NO and diseases 
 
NO plays a role in multiple physiological pathways and in regulating diverse organ 
functions. Aberrations in the NO pathway could therefore lead to various 
pathophysiological states. NO related diseases or pathologies could occur with nearly 
every human physiological system ranging from the cardiovascular to the nervous 
system. On the whole, pathological states related to inappropriate release of NO can be 
grouped into two categories, those with overproduction of NO and those with deficiency 
of NO. However the changes of NO levels in some diseases such as liver cirrhosis is not 
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always consistant.  In these diseases, the role of NO is multi-dimensional. NO anomalies 
can arise from the levels of NO produced - either too little or too much. Pathologies can 
also arise from the duration of NO over-production or under-production. A third factor to 
consider is the location of NO production. Whether NO produced is at the right time, at 
the right place, in the right amounts and for the right duration, is important for health, 
while dysfunction in any of these aspects could lead to pathologies. Below, a few 
examples of NO implicated in human diseases have been discussed.  
 
1.4.1. Diseases associated with overproduction of NO 
 
  1.4.1.1. Septic shock 
 
Septic shock is the life-threatening complication due to overwhelming systemic infection. 
The host defense releases numerous inflammatory mediators, resulting in 
pathophysiological vasodilation, hematological abnormalities, and even organ 
dysfunction and failure. NO has been found to cause direct toxicity, including nuclear 
damage, protein and lipid peroxidation, and inhibition of mitochondrial respiration. NO is 
also responsible for vasodilation and vascular hyporeactivity to vasoconstrictors. The 
involvement of NO in septic shock was confirmed by the therapeutic use of NOS 








Inflammation can be characterized as the local response to tissue injury or infection. 
Typically inflammations are associated with the infiltration of leukocytes and 
macrophages. Both local and systemic inflammation can be characterized by the 
overproduction of NO (Wildhirt et al., 1995). As such, the roles of eNOS and iNOS in 
inflammation have been extensively studied.  
 
Infiltrating macrophages, the source of most of the NO at sites of inflammation, have 
been found to over-express iNOS. Induction of iNOS can be triggered by multiple pro-
inflammatory cytokines, lipid mediators and both gram-positive and gram-negative 
bacteria. Such stimuli may be transient or prolonged, leading to transient stimulation of 
NO production by iNOS or sustained NO production. Sustained release of NO confers the 
antimicrobial property of macrophages (Nathan et al., 1991).  
 
eNOS, induced by sheer stress or acetylcholine, produces pulses of NO which inhibit 
platelet activation and causes vasodilation. NO produced locally causes local 
vasodilation; systemic inflammation leading to overproduction of NO, causes extensive 
systemic vasodilation (Bruckdorfer, 2005)s. Endothelial dysfunction in inflammation is 
contributed by the over-production of NO by eNOS. NOS inhibitors have been applied 
therapeutically to good effect (Ohshima et al., 1994), preventing the development of 




  1.4.1.3. Neurodegenerative diseases 
 
Chronic neuronal degeneration has been linked to the excessive amounts of NO released 
in or near neurons. Parkinson’s, Alzheimer’s, Huntington’s, and amyotrophic lateral 
sclerosis are a few diseases that have been positively associated with the overproduction 
of NO. In many of these, oxidative damage is present suggesting that ROS and RNS are 
both contributive to the disease (Feinstein et al., 1994). ROS and RNS are implicated in 
causing mitochondrial dysfunction leading to neuronal damage. Nitrosative stress has 
been found to cause neuronal and endothelial degeneration found in Alzheimer’s 
(Malinski, 2007) and Parkinson’s disease (Kavya et al., 2006).  
 




Interestingly, a dysfunctional NO pathway has been shown to be one of the earliest 
events in atherogenesis. A reduction in NO production may contribute to the initiation 
and progression of atherosclerosis. In the presence of excessive levels of cholesterol or 
hypercholesterolemia, regulation of vascular tone by NO is diminished. This may be due 
to a reduction in activity eNOS, impaired NO diffusion from endothelium to vascular 





 Reduced NO may also lead to lowered scavenging ability within the vascular 
microenvironment, resulting in increased levels of superoxide and hydroxyl radicals. As 
such, treatment with L-arginine has proved to be effective in treating vascular 




NO has been found to be a major player in precipitating hypertension. When NO 
production is normal, vascular tone and pressure is maintained. In hypertension, NO 
mediated endothelium relaxation or vasodilation is impaired, causing increased pressure.  
Vascular remodeling is a dynamic process of adaptation of the vascular beds to increase 
hemodynamic workload. The development and maintenance of both hypertension and the 
abnormal vascular remodeling that occurs in such circumstances as atherosclerosis and 
after myocardial injury is probably due in part to a loss of NO and, more important, to an 
imbalance among angiotensin II, NO, and O2 (Bredt, 2003).  
 
Portal hyptension is a common complication arising from liver cirrhosis. This increases 
the risk of developing ascites and/or hepatic encephalopathy or hepatic hemorrhage. In 
cirrhosis deriving from chronic hepatitis B or C infections (Ohshima et al., 1994), 
overproduction and overexposure of NO is one of the main causes of liver scarring, 
fibrosis and eventual cirrhosis. At the same time, portal hypertension develops due to 
insufficient NO production in the endothelium. This contradiction has been the subject of 
investigations for some years and to date, the exact causes of either remains hypotheses. 
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1.5  NO and cancer 
 
Cancer is another example of disease in which NO effects has more than one side. 
Tumour formation is a process of several stages: initiation, promotion and progression. 
Over the last decade, it has been found that NO is implicated in some stages of cancer, 
with varying outcomes which could be positive or negative to the host (Hon et al., 2002). 
 
NO is able to act as a mutagen, forming mutagenic nitrosamines that directly modify 
DNA or through RNS or the inhibition of DNA repair enzymes (Sawa et al., 2006). Thus, 
NO can be considered a tumor initiating agent. NO has also been known to be responsible 
for the promotion of tumours through angiogenesis. Angiogenesis can contribute to the 
growth and spread of primary liver cancer foci (Fukumura et al., 1998; Nishikawa et al., 
2004; Peng et al., 2003).  
 
On the other hand, numerous studies have shown that NO also has a cytostatic and/or 
cytotoxic effect on tumor cells. NO from activated macrophages, Kupffer cells, natural 
killer cells, and endothelial cells have demonstrated tumoricidal activity (Nishikawa et 
al., 2004). Similarly, NO has been found to promote apoptosis at high or continued NO 
exposure. Conversely, NO at low concentrations is also able to inhibit apoptosis (Chung 
et al., 2001; Kim et al., 1999).  
 
Thus the role of NO in cancer could vary, with strong implications and equally numerous 
contradictions depending on the cell lines or animal model studied. 
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1.6 Aims of study 
 
NO in chronic inflammation of the liver more often than not results in irreversible 
fibrosis leading to cirrhosis (Ohshima et al., 1994). 80% or more of HCC develops from a 
cirrhotic liver. Furthermore, NOS has been reported to be involved in tumours of the 
colon, pharynx, reproductive organs, breast, and central nervous system (Ekmekcioglu et 
al., 2005; Hussain et al., 2003).   
 
While the ubiquitous distribution of NOS and the diffusibility of NO and its diverse 
reactions are involved in multitudinous physiology and pathology, the following 
discussion shall be limited to liver cancer. The involvement of NO in various 
pathological conditions in the liver has yet to be clearly defined. This may be due in part 
due to the different models employed as well as experimental conditions. Furthermore, 
the activity of NO produced by human cells is lower than that of rodent cells (Wei, 2002).  
 
The roles of NO in liver cancer formation and/or progression has remained controversial 
decades after its discovery. NO production has been found to be increased in many 
hepatic diseases, including those caused by hepatitis virus and cirrhosis. While results 
demonstrate that NO is elevated in viral hepatitis, its role is ill defined. NO may serve as 
an anti-viral agent employed as a defense mechanism against viral infections. Increased 
risk of cancer has been associated with chronic exposure to high concentrations of NO 
which, in time could induce mutations. NO’s mutagenic effects are well documented, as 
high levels of NO can cause nitrosative deamination or oxidation of DNA bases, leading 
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to DNA damage and mutation. At the same time, low levels of NO have been found to be 
protective against LPS-induced apoptosis. Its anti-apoptotic effect may serve to prolong 
hepatitis infection as apoptosis is the major mechanism by which infected hepatocytes are 
eliminated (Hussain et al., 2003). In addition, NO mediates capillary leakiness, 
supporting angiogenesis and limiting leukocyte infiltration. All these serve to implicate 
NO in tumour formation/progression. 
 
NO’s role in liver cancer has been studied previously. However, much of the reseach 
done focused on the result of chronic infection and the resulting liver insult by NO 
overproduction. These studies have found that plasma nitrite/nitrate concentrations in 
HCC patients correlate with tumour burden and these has been suggested as tumour 
markers in conjunction with AFP. These are consistant with the hypothesis that chronic 
infection leads to the overproduction of NO, leading to scarring, cirrhosis and the 
eventual initiation of cancer.  
 
Apart from excessive NO production due to prolonged inflammation, the elevated NO in 
HCC may arise by three other mechanisms. Firstly, tumour cells may directly stimulate 
macrophages and Kupffer cells to produce NO. Secondly, tumour cells or pre-malignant 
cells secrete cytokines that may stimulate hepatocyte production of NO. Thirdly, 
deterioration of liver function in HCC may be associated with increased systemic 




To complicate matters, NO and its cytotoxic and cytostatic effects are also well 
established, making it tumour suppressive as well. Its role in apoptosis is also well 
documented in various cell types, including macrophages, thymocytes and neurons.  
While it seems clear that NO participates in pathology of liver diseases, it is unclear 
exactly what role(s) it plays in HCC that is not caused by chronic infection. Initially, 
upon liver insult, NO may be employed as part of a defense mechanism. On the other 
hand, its aberrance could lead to pathologies through genotoxicity or its anti-apoptotic 
effects. The causes of aberrations in such an important signaling molecule have yet to be 
completely determined. 
 
To elucidate the role of NO in cancer progression, we adopt a two-prong approach. 
Firstly, we will study human samples, to establish NO presence and levels at the late 
stages (Stage IIIa and IV) of HCC from different patient groups: vis primary HCC with 
and without hepatitis B infection and secondary HCC. Secondly, we aim to establish an 
animal model that mimics the human HCC as far as possible. Using this model, it is then 
possible to study the changes of NO during the progression of HCC. In this way, NO 
participation in the various stages of disease progression can be tracked and its role 
clarified. Finally, to determine whether NO plays a significant role in HCC progression, 
NO donors and NOS-selective inhibitors will be given to the animals with developed 
HCC. The continued progression of HCC or the retardation of tumour growth with the 
treatment of NO donor or NOS inhibitors will allow us to qualify the role of NO in the 




Chapter 2 General Materials and Methods 
 
 
2.1.  Materials 
 
All chemicals and reagents used were from Sigma-Aldrich, USA, unless otherwise stated, 
and were of analytical or molecular grade. 
 
 
2.1.1 Human samples 
 
 
Primary HCC liver specimens were collected from patients who had undergone 
hepactomy without prior chemotherapy or radiotherapy. Cirrhosis samples were obtained 
from patients diagnosed with cirrhosis due to chronic hepatitis B or C infection. 
Secondary HCC samples were obtained from patients with primary colon cancer; to 
reduce variability other sites of primary cancer were not considered. To reduce genetic 
differences due to race and gender, only Chinese males were selected for this study. 
Based on pathological reports, primary HCC patients were later sub-divided into HBV 
infected (HBV+HCC) or not (HCC). Each patient had provided a written informed 
consent form prior to recruitment into the study. Protocols used conformed to the ethical 
guidelines of the 1987 Declaration of Helsinki and those of the National Medical Ethics 
Committee-Ministry of Health Ethical Guidelines on Research involving human samples 
(1997). All liver tissues were obtained intra-operatively and were frozen in liquid 
nitrogen within 20mins after excision and stored at -80°C until utilized. Venous blood 
was collected in Vacutainer Citrate tubes (BD Biosciences, USA) and centrifuged at 
3000g for 10 mins at 4°C and stored at -20°C until used. 
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2.1.2 HCC Animal model 
 
The relatively short lifespan of a rat of 2-3.5 years makes it an ideal candidate for use in 
the development of a HCC animal model. Carcinogens and/or mutagens would be able to 
induce tumour formation in a matter of weeks, as was the case in our model.  
 
Male Sprague-Dawley rats weighing 160-180g (6-7 weeks old) were purchased from 
Laboratory Animal Center (LAC), NUS. The animals were allowed to acclimatize for a 
week before experiments. HCC was induced chemically in the rats as described 
previously (Ha, Kim et al. 2001) with minimal modifications. The agent used was N-
ethyl-n-nitrosoethanamine or diethylnitrosamine (DEN): a carcinogenic nitrosamine 
derivative with alkylating and mutagenic properties. DEN is a commonly found 
nitrosamine which belongs to a group of N-nitroso compounds. Nitrosamines, including 
Week 0: 0.01%(v/v) DEN-treated drinking water given to randomly 
selected rats, control rats received plain drinking water.  
Weeks after DEN 
administration:   4             6             8            10           12           14           16 
Figure 2.1: Development of a rodent HCC model.  
Animals were sacrificed at the various time-points as shown. At each time-
point 12 animals were sacrificed; control = 6, DEN-treated = 6.  
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DEN, can be found in normal human environments, such as tobacco smoke (0.2ng/L) 
(Brunnemann et al., 1977) and a variety of foods. For example, DEN has been found in 
cheeses (0.5-30µg/kg), soybeans (0.2µg/kg), salted fish (1.2-21µg/kg) and alcoholic 
beverages (0.1µg/kg) (U.S. Department of Health and Human Services, 2005). 
Endogenously, nitrosamine can be formed during the nitrosylation of amines (Lijinsky et 
al., 1981; Martinez-Sales et al., 1981; Peto et al., 1984). 
 
DEN is converted by cytochrome P450 monooxygenase into 2 species, one of which is a 
carbonium ion. It has been found that human liver slices are able to metabolize DEN to 
the same degree as rat liver by various forms of P450 oxygenases. Such studies have also 
found very strong similarities in DNA repair and the processing of alkylated DNA in 
human and rat livers (Deal et al., 1989).  Carbonuim ion is an electrophile and is able to 
alkylate DNA bases. Some susceptible sites include the N-2 and N-3 of guanine, resulting 
in O
6
-alkylguanine. An alkylated guanine is unable to base-pair correctly, resulting in 
mutagenesis (Preussmann et al., 1982).  
 
Various studies have established the specificity of DEN to cause oncogenic/cancerous 
foci formation in rodent liver, even at low dosages (Cortinovis et al., 1991; Deal et al., 
1989; Peto et al., 1984; Preussmann et al., 1982).  In our study, 0.01% (v/v) DEN was 
administered via drinking water for 4 to 16 weeks (Ha et al., 2001). Control rats had 
untreated drinking water and all other conditions similar to DEN-treated rats. The 
animals were sacrificed on the same day after 4, 6, 8, 10, 12, 14 and 16 weeks of 
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consuming ad libitum DEN-spiked water. Each time-point group consisted of 12 rats: 6 
controls and 6 DEN-treated.   
 
 
Animals were euthanized by administering an overdose of Clinical Research Center 
(CRC) anesthesia cocktail consisting of 1 mL of hypnorm (Jansen Pharmaceutica, 
Belgica), 0.315 mg of fentanyl and 10 mg of fluanisone, and 1ml of midazolam (Roche, 
Switzerland) 5 mg of dormicum and 2 mL of water (LAC, NUS). Cardiac puncture was 
used to draw blood from the euthanized animal.  Plasma (collected in Vacutainer Citrate 
tubes, BD Biosciences, USA) and serum (collected in Vacutainer EDTA tubes, BD 
Biosciences, USA) were collected and stored at -20°C until further use. Plasma was 
processed before storage by first centrifuging the tubes at low speed (1500g) for 15 
minutes, thereby removing red blood cells. Body weight was recorded before 
euthanization. Liver was excised and weighed prior to flash freezing in liquid nitrogen. 
The relative liver weight was calculated as the percentage of liver to body weight at each 
time-point. Liver tissues from each lobe were fixed in 10% buffered formalin for 
histological studies and in RNAlater (Qiagen, Germany) for subsequent RNA extraction. 




















Tissues were fixed in 10% buffered formalin for at least 24 hours, but no more than 72 
hours. This was followed by dehydration in increasing alcohol concentrations 
sequentially (30%, 50%, 70%, 80%, 95% and 2 steps of 100% ethanol).  Tissues were 
immersed for 20 mins at each step. Tissues were then cleared by immersion in xylene, 
and subsequently infiltrated and embedded in paraffin. Paraffin blocks were kept 
overnight at 4°C prior to sectioning. The chilled-hardened paraffin wax allowed sharper 
cuts to be made and prevented tissue from creasing or tearing. 4µm sections were 
sectioned on a manual rotary microtome (Leica, Germany) and mounted onto lysine 
coated glass slides which were incubated overnight at 60°C and stored at room 
temperature until use.  
 
Sections were deparaffinized in xylene and rehydrated in decreasing concentrations of 
alcohol, from 100%, 95% to 70% ethanol. Sections were washed thrice in 1x PBS to 
remove any alcohol traces. Subsequently, they were immersed in pre-heated 0.01M 
sodium citrate buffer, pH 6.0 to facilitate the microwave method of antigen retrieval. 
Slides were allowed to cool to room temperature in the sodium citrate buffer.  They were  
washed thrice in 1x PBS and blocked sequentially at room temperature for 30mins each, 
using horse serum and an endogenous peroxide blocker provided in DAKO EnVision 
System (DAKO, Denmark). Specific primary antibody was diluted in DAKO 
Background Reducing Antibody Diluent (DAKO, Denmark) to appropriate working 
concentrations. Slides were incubated with the primary antibody for 1 hour at room 
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temperature. After washing thrice to remove unbound antibodies, slides were incubated 
with secondary-HRP (horse radish peroxidase) linked antibody from DAKO EnVision 
System for 30mins. Thereafter, slides were washed thrice in 1x PBS and peroxidase 
substrate provided in the EnVision System, diaminobenzidine (DAB), was applied onto 
sections for 10 mins. Slides were then counterstained with heamotoxylin (Vector 
Laboratories, USA) for 10mins. Slides were rinsed in water and allowed to ‘blue’ in 1% 
lithium carbonate. Sections were then dehydrated in gradations of alcohol (70% to 100%) 
and xylene and mounted. A light microscope (Olympus, Japan) was used at 200X or 
400X magnifications to visualize the presence of staining on the tissue sections. 
 
 
PRIMARY ANTIBODY RATIO SOURCE 
iNOS 1:200 Transduction Labs, USA 
eNOS 1:200 Transduction Labs, USA 
GST-π 1:200 Transduction Labs, USA 
Caveolin-1 1:200 Santa Cruz, USA 
Rac2 1:200 Santa Cruz, USA 
Table 2.1: List of primary antibodies used in immunohistochemistry. Antibodies 
purchased from Transduction Labs were monoclonal; those purchased from Santa Cruz 
were polyclonal.  Goat anti-mouse and goat anti-rabbit antibodies (DAKO, Denmark) 





2.2.2 RNA extraction 
 
 
Tissues were ground to powder in liquid nitrogen and poured into microfuge tubes 
containing Trizol (Invitrogen, USA). This was homogenized using a handheld 
homogenizer (Pellet Pestle grinder, Kimble Kontes, Sigma-Aldrich, USA.) Total RNA 
extraction was done as per manufacturer’s protocol. Briefly, 0.2 ml chloroform was 
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added to every ml of Trizol used. This was shaken vigorously for 15s and allowed to 
stand at room temperature for 3 mins, allowing protein-RNA complexes to disassociate.   
The aqueous and organic phases were separated by centrifugation at 12,000g at 4°C. 
RNA which remains exclusively in the aqueous phase was carefully extracted and equal 
volumes of isopropanol (Merck, USA) were added to precipitate the RNA. The pellet 
formed was washed in ice-cold 75% ethanol, centrifuged at 7,500g for 5 mins at 4°C and 
allowed to air dry. Diethyl pyrocarbonate (DEPC)-treated or RNase-free water was used 
to dissolve the pellet. The dissolved RNA was stored at -80°C until further use.  
RNA was quantitated by spectrophotometry measurements (Pharmacia Biotech Ultraspec 
2000) with an OD260   reading of 1 being equivalent to 40µg/ml of RNA. The ratio of 
OD260/OD280 more than 1.8 was taken to be indicative of the purity of the isolated RNA. 
Integrity of RNA was checked by visualization of 2 distinct rRNA bands on a denaturing 
1% formaldehyde-agarose gel.  
Briefly, 0.5g of molecular grade agarose (BioRad, USA) was heated in 43.5 ml of DEPC-
treated water. Upon cooling to 60°C, 5ml of 10X MOPS buffer (0.2 M 
Morpholinopropanesulphonic acid, 0.05M sodium acetate and 0.01M EDTA, pH 5.5, 
autoclaved) and 1.5ml 37% formaldehyde was added prior to gel casting. 2µg of RNA 
was added to 10µl of freshly prepared loading buffer before loading onto the gel (Table 
2.1). Electrophoresis was then carried out in 1X MOPS at 110V for 60minutes. Discrete 












Deionized formamide 144 
37% formaldyhyde 52 
10X MOPS 32 
DEPC-treated water 20 
Glycerol 16 
10mg/ml Ethidium Bromide 2 










2.2.3 Reverse Transcription 
 
 
Reverse transcription (RT) was performed with oligo(dT) primer using Superscript II 
RNase H
-
 Reverse Transcriptase (Invitrogen, USA) following the manufacturer’s 
protocol. Briefly, 5µg of total RNA was incubated at 65°C with oligo(dT)12-18 primer  
(500µg/ml) for 10 mins and immediately chilled on ice. This step allows oligo(dT) to 
anneal to the poly(A) tails of linearized RNA.  RT reaction mix (Table 2.2) including 
recombinant RNasein Ribonulease inhibitor (Promega, USA) were subsequently added to 
a total volume of 50µl and incubated for 1hr at 42°C. The reaction was inactivated by 
heating at 70°C for 15 mins. RT was performed on Hybaid OMN-E thermal cycler 
(Hybaid Limited, UK.) The cDNA obtained was stored at -20°C until further use.  
 
Table 2.2: Components of RNA loading buffer. 
RNA loading buffer was prepared fresh each time. 10µl of loading buffer was added 
to 2µg of RNA and heated at 65°C for 5mins to linearize the RNA. Deionized 






 RT COMPONENT VOLUME 
12.5µM dNTPs 5µl 
500µg/ml  oligo(dT)12-18 primer   1µl 
5X First Strand buffer 10µl 
0.1M DTT 5µl 
Superscript II RNase H
-
 RTase (20U/L) 0.8µl 
RNasein Ribonulease inhibitor (5U/µl) 1µl 
DEPC-treated water + 5µg total RNA 27.2µl 






2.2.4 Conventional PCR 
 
 
2.2.4.1 PCR reaction 
 
 
Polymerase Chain Reaction (PCR) was performed to exponentially amplify target cDNA 
sequence. 0.5U Taq polymerase (Qiagen, Germany) was used in each PCR reaction 
which consisted of the reagents listed in table 2.2. An initial denaturation step at 94°C, 
was carried out for 10mins preceeded the cycling conditions. Cycling conditions 
generally consist of a 30s denaturation, 30s of annealing and a 72°C elongation for 45s. 
This is followed by a final elongation step of 72°C for 10mins. Annealing temperatures 
are specific for each pair of primers used and have been optimized prior to obtaining PCR 
products for use as standards in real-time PCR. These are listed in Table 2.3. PCR 
reactions were performed using a Techne Genius (Techne Inc, Barloworld Scientific, 
USA) PCR machine. 





 PCR REACTION COMPONENTS VOLUME 
2.5µg cDNA 2.5µl 
2.5mM each dNTPs 0.5µl 
0.2 µM forward and reverse primers 0.5µl each 
10X PCR buffer 2.5µl 
5X Q buffer 5µl 
0.5U Taq polymerase 0.2µl 
DEPC-treated water 13.3µl 






2.2.4.2 Agarose Gel Electrophoresis 
 
 
The PCR products obtained were then analysed by DNA gel electrophoresis. Agarose 
was heated in 1X TBE buffer, this was allowed to cool to 50°C and ethidium bromide 
(1µl of 10mg/ml per 40ml of agarose) was added prior to solidification. 10µl of PCR 
product was mixed with 2µl of 6X DNA loading buffer (Fermentas, USA) and was 
separated on a 1.8% agarose gel. Electrophoresis was carried out in 1X TBE at 110V for 




2.2.4.3 Gel Clean-up of PCR products 
 
 
PCR products were purified with QIAquick
® 
Gel Extraction kit (Qiagen, Germany). All 
steps taken were closely adhered to the manufacturer’s protocol. Briefly, gel containing 
the band of interest was excised as closely as possible. 3 volumes of buffer QG was 
added to the gel slices and incubated at 50°C for 10 mins. This dissolved the agarose 
Table 2.4: Components in the PCR reaction mix.  
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while maintaining the integrity of the PCR products. An equal volume of isopropanol was 
added; this increased the yield of the PCR fragments that were less than 500bp. The 
resulting solution was applied to a QIAquick spin column and centrifuged for 1 min, 
13,000g at room temperature. An additional 500µl of buffer QG was applied to the 
column and centrifuged. This step ensures complete removal of agarose. DNA bound to 
the filter in the QIAquick spin column was washed with buffer PE, containing ethanol. 
After which, the column was centrifuged again to remove residual traces of PE buffer and 
ethanol. PCR products were eluted in EB buffer and quantitated using a Pharmacia 
Biotech Ultraspec® 2000 spectrophotometer. The purified PCR products were sent for 
sequencing to confirm the amplicon of interest and stored in -20°C until further use. To 
generate the standards for standard curve for real time quantitative PCR, serial dilutions 








2.2.5. Real Time PCR 
 
Quantitative real time PCR (QPCR) is the method of choice in determining gene 
expression, being more sensitive and quantitative than RT-PCR and relative quantitation 
RT-PCR. QPCR’s main advantage is a wide dynamic range, and, like the name suggests, 
detects the amplification in real-time through fluorescent probes or intercalating dyes like 
SYBRGreen. Its sensitivity makes this technique ideal for detecting low-abundance 
mRNA or cDNA. Previous limitation imposed by limited sample quantites can now be 
circumvented. Since detection is in real time, end-point processing required in 
competitive or relative quantitation RT-PCR is no longer required by QPCR.  
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In our experiments, we utilized DyNAmo™ SYBR® Green qPCR Kits (Finnzymes, 
Finland) and the reactions were performed with Rotor-Gene™ 2000 or 3000 system 
(Corbett Life Science, Australia).  
 
SYBR Green is a fluorescent dye that binds to the minor groove of double stranded (ds) 
DNA; it exhibits minute fluorescence in solution but releases strong fluorescent signal 
upon intercalating with dsDNA. Although SYBR Green is not gene specific like Taqman 
or similar probes, specificity can be determined by dissociation curve (single melt point) 
and gel electrophoresis (single band). A dissociation curve is the function of fluorescence 
and temperature; fluorescence of SYBR Green rapidly decays upon the denaturation of 
the dsDNA PCR products. The temperature at which the dsDNA denatures is dependent 
on the GC/AT ratio, its length and sequence, thus, a dissociation curve can be used to 
distinguish between PCR products (Ririe, Rasmussen et al. 1997).  
 
Figure 2.2: Representative Disassociation Curve. Disassociation curve was measured 




 Both the dissociation curve (Figure 2.2) and gel electrophoresis (not shown) were used 
to confirm that the product of interest is obtained. Triplicates of each sample and 
standards were typically prepared per run. Duplicates of non-template control were 
prepared where sterile water replaced cDNA templates to act as negative controls. Total 




  2.2.5.1 Standard Curve 
 
 
A standard curve was obtained using previously generated cDNA. Figure 2.3 shows a 
typical standard curve. One advantage of this method is that both the standards and 
samples use the same primers for the reactions, thus the thermodynamics of primer 
annealing and amplicon length, sequence and GC/AT ratios are kept constant. 
Furthermore, standard curves are highly reproducible; triplicates within the same run 
showed low intra-assay variation. Standard curve quantitation allows run-to-run 
normalization; each assay generated independent standard curves, thus allowing intra-
assay validation.  This method – absolute quantitation- was selected as studies have 
shown that frequently used housekeeping genes such as glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH) have significantly different levels of transcription between 
individuals (Orlando et al., 1998; Rutledge et al., 2003).  Figure 2.3 illustrates a typical 













Figure 2.3 Typical standard curve obtained for each  real time PCR run. Red lines 
indicate error bars at each concentration. r
2
 values and efficiency for each  real time PCR 






  2.2.5.2 Real time PCR 
 
 
Real time PCR was carried out with DyNAmo™ SYBR® Green qPCR Kits using Rotor-
Gene 2000 or 3000 (Crbett Life Sciences, Australia). Table 2.5 and Table 2.6 lists the 
annealing temperatures, expected size and primer sequences of the genes of interest 













β-actin 58 25 560 
Calmodulin-2 55 40 140 
c-met 62 40 132 
eNOS 62 35 143 
HGF 45 40 173 
HGFA 48 40 210 
HIF-1 60 35 143 
IGF2 61 30 193 
IGFBP3 60 35 201 
iNOS 62 40 187 
MDK 55 35 192 
NTN 62 40 193 
NTN2L 62 40 184 
Rac2 62 38 196 








β-actin 55 30 678 
c-met 60 40 311 
eNOS 60 40 186 
HGF 62.5 40 150 
HGFA 60 45 101 
iNOS 60 40 217 























2.2.6 Extraction and quatitation of proteins from tissues 
 
Samples (~100mg) were grounded in liquid nitrogen and homogenized with a handheld 
homogenizer in tissue protein extraction reagent (T-PER, Pierce, USA) supplemented 
with protease inhibitors (Roche Applied Sciences, Switzerland). Homogenates were 
HUMAN FORWARD PRIMER REVERSE PRIMER 
β-actin 5’-GTGGGGCGCCCCAGGCACCA-3’ 5'-CTCCTTAATGTCACGCACGATTC-3' 
Calmodulin-2 5’-TGCACTATGCAAACGGGTGTAT-3’ 5’-TCATTTTTCTTGCCATCATTGTC-3’ 
c-met 5’-TGATGATGAGGTGGACACA-3’ 5’- CTATGGCAAGGAGCAAAGA-3’ 
eNOS 5’-TGGTACATGAGCACTGAGATCG-3’ 5’-CCACGTTGATTTCCACTGCTG-3’ 
HGF 5’-TCAAGGAGAAGGCTACAG-3’ 5’-CACAACGAGAAATAGGGC-3’ 
HGFA 5’-AGGACACAAGTGCCAGATTG-3’ 5’-GTTGATCCAGTCCACATAGT-3’ 
HIF-1 5’-CGTTCCTTCGATCAGTTGTC-3’ 5’-TCAGTGGTGGCAGTGGTAGT-3’ 
IGF2 5'-AAAGCCAATTTCTGAGCTTTTGTG-3' 5'-ACCACGGACGTTTCCATCAGGTTC-3' 
IGFBP3 5'-TTCTGCATAAAGCCTGTGCG-3' 5'-AGCACAGCACCCAGACTTCA-3' 
iNOS 5'-GACATTGAGAGCAAAGGGCTGC-3' 5'-CGGCTTGTCACCTCCTGG-3' 
MDK 5’-CGCGGTCGCCCAAAAAGAAAG-3’ 5’-CAGTCGGCTCCAAACTCCT-3’ 
NTN 5'-TGCAAGAAGGACTATGCCGTC-3' 5'-GCTCGTGCCCTGCTTATACAC-3' 
NTN2L 5'-CGTCCGTGTAGTGCTCAAAGG-3' 5'-GAGCTCGGTGGCTGCGTAGGAG-3' 
Rac2 5’-ATGCAGGCCATCAAGTGT-3’ 5’-CTAGAGGAGGCTGCAGGC-3’ 
ST13 5’-AGGCAGACGAACCATCAAGT-3’ 5’-TCTCCTCCGTTATCTCCGCA-3’ 
   
RAT FORWARD PRIMER REVERSE PRIMER 
β-actin 5’- GATATCGCTGCGCTCGTCGT -3’ 5’- CAGTGGCCATCTCTTGCTCG -3’ 
c-met 5’-TGTGCATTCCCCATCAAA-3’ 5’-CACCACCTGCATGAAGCG-3’ 




HGFA 5’-CGGAGGCACCTGCCACC-3’ 5’- GCAGCGGTGCTGGCCAC-3’ 
iNOS 5’-AGCGGCTCCATGACTCTC-3’ 5’-CGGACCATCTCCTGCATT-3’ 
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centrifuged at 13,000g for 15 mins at 4°C and the cleared supernatant was transferred 
into a clean microfuge tube. Protein was quantitated using Bio-Rad (USA) DC assay 
without deviation from supplier protocol. Briefly, protein content was estimated by 
modification of the Lowry Method using serial dilutions of bovine serum albumin (BSA) 
(5mg/ml) in lysis buffer as a standard. This assay was based on the reaction of protein 
with copper in an alkaline tartrate solution and the subsequent reduction of Folin reagent 
by the copper-reacted protein. Folin reagent is reduced by the loss of oxygen, producing 
blue colour compounds with a maximal absorbance at 750nm and a minimum at 405nm. 
Colour development is mainly due to tyrosine and tryptophan and to some extent, 
cysteine and histamine. Readings were taken at 680nm after 15 mins incubation at room 






50µg of total protein of each sample was first separated by molecular weight on a 6% or 
8% Sodium dodecyl sulfate polyacrylamide (SDS-PAGE) gel and subsequently 
transferred to a PVDF membrane.  
 
 2.2.7.1 SDS-PAGE 
 
Discontinueous SDS-PAGE is a rapid and cost-effective method for separating proteins 
based on their molecular weight. The effective range of protein separation is from 12 – 
212 kDa (Weber et al., 1969). Components for resolving (or separating) and stacking gel 
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are listed in Table 2.7. After the gel has polymerized, it was mounted on a BioRad Mini-
Protean II or III gel set and immersed in 1x TrisGlycine SDS running buffer (5x SDS/ 
glycine electrophoresis buffer: 15.1 g/L tris base, 72 g/L glycine, 5 g/L SDS.). Samples 
were reduced by heating at 95°C for 5 mins and immediately cooled on ice to prevent re-
folding.  Samples were loaded with a bromophenol blue-glycerol loading buffer and 
electrophoresis was carried out at 100V for 90mins.  
 
 
COMPONENTS SEPARATING GEL STACKING 
 6% gel (ml) 8% gel  (ml) 4 % gel (ml) 
Water 5.3 4.63 2.7 
30% bis-acrylamide 2.0 2.67 0.67 
Tris Buffer * 2.5 2.5 0.5 
10% SDS 0.1 0.1 0.04 
10% ammonium persulfate 0.1 0.1 0.04 
TEMED 0.012 0.012 0.008 
Table 2.7: Preperation of SDS-PAGE gels. * Separating gels use 1.5M Tris-HCl, pH 





PVDF membrane was pre-wet with 100% methanol for several minutes, then soaked in 
transfer buffer (Protein transfer buffer: 25 mM Tris, 190 mM glycine, 20% methanol, 
0.05% SDS) along with filter paper and sponges used in wet transfer. Mini TransBlot 
cells (also from BioRad) were used. The transblot sandwich was assembled in the 
following order starting from the cathode side: sponge, 2 sheets of filter paper, gel, PVDF 
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membrane, 2 sheets of filter paper, sponge. Blotting was carried out for 120V for 90mins 
with an ice pack and pre-chilled transfer buffer. Gel was retained to ascertain blotting 
efficiency, while the membrane was subjected to immunodetection.  
 
  2.2.7.3 Checking gel for blotting efficiency 
 
After transfer, gels were routinely stained with Coomassie blue to check for transfer 
efficiency. Briefly, gel was immersed in staining solution containing 25g Coomassie Blue 
R-250, 45ml methanol, 45ml water and 10ml glacial acetic acid for 30mins at room 
temperature and under constant gentle shaking. De-staining was done by shaking the gel 
in 500ml methanol, 100ml acetic acid and 400ml of water. Good blotting or transfer 
efficiency results in no detectable bands following Coomassie staining.  
 
  2.2.7.4 Immunodetection 
 
The membrane was rinsed in wash buffer (10mM Tris-HCL, pH 7.4, 100mM NaCl, 0.1% 
Tween 20) for 5 min and subsequently blocked (5% skim milk in wash buffer) for at least 
1 hr at room temperature before incubation with primary antibody overnight at 4°C. Anti-
iNOS (1:500) and anti-eNOS (1:500) were monoclonal anibodies purchased from 
Transduction Laboratories, USA. Anti-sGC (1:200), anti- Rac2 (1:500) and anti-caveolin-
1 (1:500) were from Santa Cruz Biotechnology Inc, USA. Membranes were washed 
thoroughly in wash buffer for 3x 10mins. This was followed by incubation with a HRP-
conjugated secondary antibody. Following thorough washing, signal detection was 
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performed using SuperSignal West Pico Chemiluminescence from Pierce, USA. Briefly, 
equal volumes of the peroxide and Luminol solutions were mixed prior to application on 
the membranes. Membranes were exposed to CL-XPosure film (Pierce, USA) in the dark 
room and developed (Kodak X-omatic developer, USA). Relative densities of the bands 
were analyzed using the Kodak 1D imaging system.  
 
 
2.2.8. NOS activity assay 
 
 
Protein expression level of NOS would be incomplete information without the 
corresponding enzymatic activity. Hence, a radioactive assay was used to determine the 
level of activity of inducible and constitutive NOS. This method was chosen because it is 
sensitive and relatively robust, for it is unaffected by the presence of impurities that will 
inactivate NO and does not require optically clear enzyme extracts 
 
NOS activity assay is based on the formation of equimolar ratios of NO and L-citrulline 
in the conversion of L-arginine to L-citrulline. Thus, 
3
H-L-arginine (Perkin Elmer, USA) 
was utilized, generating 
3
H-L- citrulline and NO in the reaction. Capitalizing on the 
change in net charge of the substrate (L-arginine: positive) and product (L-citrulline: 
neutral) (Wei, Khoo et al. 2002), separation of the two can be carried in an anion-
exchange column.  This is based on the principle that at pH 7.2, the negatively charged L-
arginine would bind to the resin, while the neutral L-citrulline would not. Dowex 50WX-
8.400 ion-exchange resin was equilibrated with 0.5 M sodium phosphate buffer (pH 7.2) 
overnight and the resin was washed extensively with 0.1M sodium phosphate buffer (pH 




Briefly, 75µg total proteins from rat or human samples were incubated in 100µl 
incubation media A, B or C for 45 mins at 37°C. Reaction was stopped by the addition of 
400µl of Dowex ion-exchange resin equilibrated in 0.5M sodium phosphate buffer, pH 
7.2. Tubes were vortexed for 3 mins and the resin allowed to settle. Supernatant was 
extracted, with care taken to avoid any resin particles, and transferred to scintillation 
vials. 5ml of scintillation fluid (PerkinElmer, USA) was added and radioactivity was 
measured with a liquid scintillation counter (Beckman Coulter, USA). 
 
Incubation media A consisted of 50mM HEPES and 1mM EDTA buffer, pH 7.4, 
containing 1mM DTT, 1.25mM CaCl2, 10µg/ml calmodulin, 1mM NADPH, 10µM FAD 
and 100µM  BH4.  
 
Incubation media B is as A but containing 1mM L-N
G
-Nitroarginine methyl ester (L-
NAME) and incubation media C is as A but containing 2mM EGTA.  
 
Reagent blank (homogenizing buffer without protein) and purified bovine eNOS (Sigma 
Aldrich) incubated in media B showed similar radioactivity levels. Ca
2+
-dependent or 
constitutive NOS activity was calculated as radioactivity in incubating media A minus the 
radioactivity in incubating media C (i.e. the difference in the activity in the presence and 
absence of 2mM EGTA, a Ca
2+
 chelator).  Ca
2+
-independent or inducible NOS activity 
was measured as total NOS activity minus Ca
2+
-dependent activity. These were expressed 





2.2.9 Plasma nitrate/nitrite assay 
 
 
NO is rapidly inactivated by oxidation to its metabolites: nitrites and nitrate. These 
readily diffuse into circulation, thus nitrite/nitrate concentrations are taken as indicators 
of the presence of NO (Moriyama, Tabaru et al. 2000; Bruckdorfer 2005). Plasma NO 
was measured using Total NO and Nitrate/Nitrite Parameter Assay Kit (R&DSystems, 
USA) according to manufacturer’s protocol. Briefly, NO was measured indirectly as a 
total of nitrate and nitrite. This assay determines total nitrite concentrations based on the 
enzymatic conversion of nitrate to nitrite by nitrate reductase. The reaction is followed by 
colorimetric detection of nitrite as an azo dye product of the Griess Reaction which 




2.2.10 Statistical analysis 
 
 
Results were expressed as means with their standard deviation (SD). The two-way 
ANOVA and the unpaired Student’s t-test were used for comparison of data with the 












Chapter 3: Gene expression studies in liver cirrhosis and HCC 
 
 
3.1  Introduction 
 
 
Since the sequencing of the human genome, vast interest has been given to the 
transcriptome or gene expression profiles of nearly every disease, from leukemia to 
ischemia; head and neck to colorectal cancers. Expression profiling allows the screening 
of hundreds to thousands of genes at a time, potentially identifying hitherto unknown 
candidate genes that play critical roles in the progression of the pathology. cDNA 
microarray gives insight into potentially the entire transcriptome in physiology or 
pathology, providing opportunity to identify novel diagnostic and therapeutic targets.  
 
HCC presents disparate clinical and histopathological phenotypes including various 
grades of differentiation/proliferation, dedifferentiation, metastatic capability, angiogenic 
potential and sensitivity to chemotherapeutic agents. Thus, the analysis of expression 
profiles of a large number of genes in the different presentation of human HCC is an 
essential step towards clarifying the common mechanisms of hepatocarcinogenesis and 
identifying target molecules for the development of novel therapeutics and diagnostic 
tools. 
 
Expression profiling on HCC have been done by others with more extensive sample 
numbers (Chung et al., 2002; Iizuka et al., 2002; Paradis et al., 2003). Expression 
profiling not only serves to distinguish molecular markers in various diseases, but also 
serves as a prognostic guide (Lee et al., 2004), a check for recurrence (Ho et al., 2006) or 
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a guide for transplant recipients selection (Mas et al., 2006). However, the integration of 
multiple data sets or meta-analyses of data have shown that up to 10% of genes are false 
positives (Choi et al., 2004).   
 
We compared cirrhotic and non-cirrhotic liver samples, as well as HCC against normal 
liver, and liver cirrhosis with HBV infection against normal liver. cDNA microarray 
analyses allows a global view of gene expression profiles and this can be employed to 
great effect in obtaining distinct sets of genes that are specific to HCC and liver cirrhosis. 
Several studies have already demonstrated the expediency of this technique for 
identifying novel cancer-related genes and for classifying human cancers at the molecular 
level (Chung et al., 2002; Lau et al., 2000; Mas et al., 2006; Xu et al., 2001b).  
 
 
3.2 Specific Materials and Methods  
 
 
3.2.1 Patients samples 
 
 
Patient samples were provided by Dr Lim Seng Gee, National University Hospital. RNA 
was extracted from liver cirrhosis samples, non-cirrhotic samples, liver cirrhosis with 













3.2.2.1 RNA extraction and purification 
 
 
RNA was extracted as described in Chapter 2.  Extracted total RNA was purified using 
Oligotex mRNA purification system (Qiagen, Germany) without deviation from 
manufacturer’s protocol.  
 
3.2.2.2 Reverse transcription (RT) 
 
 
mRNA was reverse transcribed and labeled with aminoallyl-dUTP, the components of the 
reaction were shown in Table 3.1. The various reagents were mixed, vortexed and 




REAGENT VOLUME (µL) FINAL 
CONCENTRATION 
dATP(100mM) 5 12.5mM 
dCTP(100mM) 5 12.5mM 
dGTP(100mM) 5 12.5mM 
dTTP(100mM) 3 7.5mM 
aa-dUTP(100mM)* 2 5mM 
Nuclease-free Water 20  
Total Volume(µl) 40  
Table 3.1: Components of the 25x dNTP mix for use in RT- reaction. Solutions were 
thawed on ice and after mixing, was stored aliquoted and stored at -20°C until use. *aa-
dUTP was resuspended in filtered 10mM Tris-HCl, pH 8.0, 0.1mM EDTA and stored at -









REAGENT VOLUME (µL) 
10x RT buffer 2 
dNTP mix 0.8 
Oligo dT, 10µM 2 
Omniscript RT(4U/µl) 1 
mRNA (2µg) Variable 
Nuclease-free water Top up to 20µl 
Table 3.2: Components of RT reaction. The various reagents were incubated at 37°C 
for 1 hour. After which, RNA was hydrolysed by the addition of filtered hydrolysis 
solution (10µl of 1M NaOH and 10µl of 0.5M EDTA). This was incubated at 65°C for 
15mins and neutralized with 25µl of filtered 1M Tris, pH 7.4.  
 
 
The RT reaction was cleaned up with a Microcon filter, YM-30 to remove the free 
dNTPs. Initially, 450µl nuclease-free water was added to the filter. The hydrolysed RT 
mix was then added to this. After centrifuging at 11,000g for 12 mins, the flowthrough 
was discarded. The washing steps were repeated twice, discarding the flow-through each 
time. The Microcon was then inverted into a clean microfuge tube and centrifuged at 
1000g for 30s to elute the bound RT products. The eluate was then dried in Speed Vac 
and stored at -20°C until use.  
 
 
3.2.2.3 Preparation of Dye Pack 
 
 
Cy3 and Cy5 dyes were purchased from Amersham Biosciences. Dyes were resuspended 
in 72µl DMSO and 4.5µl were aliquoted into tubes. These were dried in Speed Vac and 











RT product/cDNA was resuspended in 4.5µl nuclease-free water and Cy3 and Cy5 were 
resuspended in 4.5ul 0.1M carbonate buffer, pH 8.5. The dye was mixed with cDNA and 
allowed to bind in the dark for 1hr at room temperature. At the end of 1 hr, un-reacted 
dye was quenched with 4.5µl 4M hydroxylamine for 15 mins in the dark at room 
temperature. Subsequently, 35µl 100mM NaOAc, pH 5.2 was added to each reaction. 
Both reactions, Cy3-labelled cDNA and Cy5-labelled cDNA, were combined into a 
single tube for subsequent clean up using Qiagen PCR purification kit. Briefly, 500µl PB 
buffer and samples were added o the QIAquick column and centrifuged for 13,000g at 
room temperature for 1 min. The flow-through was discarded and 750µl PE buffer added. 
This was centrifuged and the flow-through discarded. A second centrifugation was done 
to remove excess ethanol that may have remained on the column. The column was then 
transferred to a clean microfuge tube and eluted with 25µl EB buffer.  
The aa-dUTP labelled cDNA was prepared as probe for subsequent hybridization as 
stated in table 3.3.  
 
REAGENT VOLUME (µL) FINAL 
CONCENTRATION 
20X SSC 1.9 2.6X 
Cot-1 DNA (10µg/µl) 1 10µg 
cDNA probe 10.6 2µg 
2% SDS 1.5 0.2% 
Total Volume 15  
Table 3.3: List of reagents in the probe preparation.   
SDS was added last to prevent precipitation. This mix was denatured at 95°C for 2mins 











A teflon-coated cover slip (Erie Scientific, USA) was placed over the slide (Operon or 
Stanford Human Chip). Probe was introduced into the space between the cover slip and 
slide; capillary action allowed the whole slide to be covered evenly with the probe 
mixture. The slide was then placed into a hybridization chamber. SlideBooster 
SB401/800 from Advalytix, Germany, was used to incubate the slides at 60°C. This 
allowed uniform diffusion and independent distribution of the probe during the 16 hours 
of incubation.  
 
After the 16 hours of hybridization, the slides were removed and washed in 2X SSC, 
0.2% SDS until the cover slip falls off. This was followed by a 0.2X SSC wash to remove 
traces of SDS. The last wash consisted of 0.05X SSC. Slides were dried in the dark by 






Slides were scanned by GenePix 4000B Microarray Scanner (MDS Analytical 
Technology, Canada). Cy3 was read at 535nm, while Cy5 was read at 635nm. Ratio of 
635/532 was used to determine relative abundance within each slide. To compensate for 
dye bias, Cy3 and Cy5 were used to label the same pair samples but in opposition. Table 





SLIDE CY3-CDNA CY5-CDNA 
1 Normal Liver Cirrhotic Sample 1 
2 Normal Liver Cirrhotic Sample 2 
3 Cirrhotic Sample 1 Normal Liver 
4 Cirrhotic Sample 2 Normal Liver 
Table 3.4: Cross Labeling of Cy3 and Cy5 to eleminate dye bias. This table presents 
an example of cross labeling that was done with our samples. Only genes that were found 
to be differentially expressed 2-fold or more in both reactions were taken into 





3.2.2.7 Data Analysis 
 
 
Data obtained was normalized by GenePix Pro (Acuity 4.0) software (that came with the 
scanner), which conducted intra-slide and inter-slide normalization. Prior to 
normalization, scan area for each spot was manually aligned. A 2-fold or more change 
was taken to show differentially expressed genes. 
 
 
3.2.3 Real Time PCR 
 
 
Please refer to section 2.3.4 for detail protocols. 
 
 
3.2.4 Hepatocyte Growth Factor ELISA 
 
 
Hepatocyte growth factor (HGF) ELISA was purchased from Quantikine®, R&D 
Systems, USA. It was used to determine HGF levels in the patient plasma samples. 
Procedures were according to the manufacturer’s protocol. Standards were prepared by 
serial dilution as provided in the kit. 150µl of Assay Diluent was incubated with 50µl of 
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standards or plasma samples for 2 hours at room temperature in the ELISA plate. Each 
well was then aspirated and washed for four times with the Wash Buffer. 200µl of HGF 
conjugate was added to each well and incubated for 2 hours at room temperature. Wells 
were washed for four times prior to the addition of 200µl of Substrate Solution. The 
ELISA plate was incubated for 30 minutes at room temperature in the dark. 50 µl of Stop 
solution was then added and the optical density of each well was read at 450nm.  
 
 
3.3  Results and Discussion 
 
 
3.3.1. Microarray results 
 
 
Operon’s array allowed us to test over 3000 transcripts in triplicates, which were 
classified according to their known involvement in aging, apoptosis, cancer, cell cycle, 
inflammation,  heat shock proteins, neurobiology and transcription factors.   
 
Liver samples from cirrhosis patients with or without HBV infection were compared 
against non-cirrhotic normal liver. Primary HCC samples were also compared to non-
cancerous livers. Intra- and interslide normalization was done with Acuity 4.0 software 
prior to statistical analysis. Figure 3.1 shows the various classifications and 
representation of transcripts that were up or down regulated in the various liver diseases.  
 
In the three liver diseases examined, 2-fold or more up-regulated transcripts were found 
to be more prevalent in some classifications, while 2-fold or more down-regulated 
transcripts were fewer. Since reciprocal dye-labeling was performed to account for dye-
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bias, it suggests that within these transcripts under investigation, more are up- than down-
regulated in liver disease. 
Our findings showed that in primary HCC, more transcripts (13 transcripts) related to 
inflammation were found to be down regulated than in liver cirrhosis with (2 transcripts) 
or without HBV (1 transcript). Correspondingly, liver cirrhosis with and without HBV 
show 11 more transcripts up-regulated than HCC. This is in line with the development of 
cirrhosis, where the key pathogenic factor is the occurrence of immune reactions against 
antigens. Inflammation arising from circulating antibodies and intrahepatic mononuclear 
cell infiltrates are characteristic of cirrhosis. This chronic infection leads to scarring, 
fibrosis and eventually cirrhosis (Goh et al., 2006; Wei, 2002). 
 
Microarray acts as an overview that provides some perspective into the different 
transcripts involved in each liver condition. However, it is more useful to examine the 
individual transcripts implicated in the different pathologies. 
To that effect, we used the programme Cluster (Eisen et al., 1998) to align the different 
liver pathologies alongside each other (Figure 3.1). This reveals general trends in the 


































































Figure 3.1: Heat map of transcripts in the Operon Array tested against various liver 
diseases. Cirrhotic tissues were compared against normal liver tissue to determine the 
relative increase or decrease expression. Samples from 3 different patients presenting the 
same disease were tested against the same normal sample (1, 2, and 3). 
HCC: primary HCC tested against normal liver. LC: cirrhotic samples tested against 
normal sample. LC+HBV: Cirrhotic samples with HBV tested against normal liver. 
Green represents down regulation, while red represents up regulation when compared to 
normal. Black indicates no difference against normal. Gene classification was according 







From the heat map presented in Figure 3.1, differential gene expression within the 
Operon array can be observed in the various liver diseases under investigation. However, 
the number of samples available (n=3 for each group) is insufficient for hierarchal 
clustering or accurate statistical analysis. To ascertain these results, either more samples 
are required to determine expression patterns that can distinguish the various disease 
states from one another, or quantitative real time PCR should be performed to more 
accurately determine the differential expression levels of various genes in liver disease.  
 
As such, we conducted further microarray experiments with HCC or HCC+HBV against 
normal samples (n=4 each) on Stanford cDNA arrays with a more extensive transcript list 















Calmodulin 3.21 1.85 2.74 2.90 
HGFA 10.91 12.32 8.12 0.35 
HGF 6.51 -- 16.35 8.08 
IGF2 4.22 4.35 0.27 1.77 
IGFBP3 5.76 6.25 1.21 2.87 
iNOS 6.43 6.98 18.54 4.87 
NTN 13.56 -- 8.6 9.12 
NTN2L 4.69 -- 3.89 4.06 
Table 3.5: List of some genes found to be differentially expressed in liver diseases 
investigated. The ratios presented here represent the average taken from 4 individual 
samples with the reported liver condition, compared against a normal sample. Normal 
liver used was one of two samples. These genes were selected for further verification 






Although the Stanford DNA array had more transcripts, not all from Operon arrays were 
represented in it. Similarly, some of those found in Stanford were not reflected in the 
Operon targets. Lists of all genes found to be changed in either the Operon or Stanford 
cDNA array by 2 or more fold are found in Appendix A.  Appendix A lists the genes that 
were found to be differentially expressed at least 2 fold in the Operon and the Stanford 
microarrays. 
 
There are several overlaps between the two arrays used and Table 3.5 presents some of 
these. The HCC samples used in Operon and Stanford arrays were not identical, although 
care was taken to select those with similar histolopathological presentation, keeping 
gender and race constant. However, these factors may account for the discrepancies seen 








Figures 3.2 and 3.3 show the results of quantitative real time PCR of the various 
transcripts that showed similar trends in both arrays.  
From figure 3.2 calmodulin transcript levels are moderately increased in HCC, HCC + 
HBV and secondary HCC compared to control. However, these increases are not 
statistically significant. This could in part be due to the small number of normal samples 
(n = 2). In cirrhotic livers, there seems to be less deviation from normal calmodulin 
levels.  
Calmodulin plays an important role in cellular processes including cell proliferation, by 
regulating intracellular calcium ions and in turn, calcium dependent kinases (Kahl et al., 
2003). Interestingly, a group has found that calmodulin show decreased protein 
expression in hepatic matastasis from colon cancer (Yu et al., 2004). In contrast, our 
findings do not show that secondary HCC have reduced calmodulin mRNA expressions. 
Yu et al. (2004) have proposed this reduced expression of calmodulin plays a role in 
initiating hepatic metastases from the colon by increasing available intracellular calcium 
ions. This is in line with observations that multi-drug resistant cells have a greater 
intracellular calcium ion concentration than non-resistant cells (Mayur et al., 2006). This 
implies that calmodulin is a potential therapeutic candidate. Increasing the number of 
normal samples is important in determining the expected normal levels of calmodulin. 







Figure 3.2: Real time PCR results of various genes found to have differential 
expression in preliminary microarray experiments. We expanded the different liver 
conditions and tested liver cirrhosis (n=23), primary HCC (n=26), primary HCC+HBV 








Figure 3.3: Real time PCR results of HGFA, HGF and the receptor c-met. . We 
expanded the different liver conditions and tested liver cirrhosis (n=23), primary HCC 
(n=26), primary HCC+HBV (n=56), secondary HCC (n=16) and normal (n=2).  
* indicates significant difference with p<0.05. 
























































































































One of the foremost axon guidance molecules discovered is Netrin 1 (NTN). NTN is 
essential in neuronal development. It works in conjunction with its receptor deleted in 
colorectal cancer (DCC) to induce axon outgrowth (Nguyen et al., 2006).  Recently, NTN 
has been found to be involved in angiogenesis via the production of NO by eNOS 
(Nguyen et al., 2006). Data from microarray showed that NTN and netrin-2 like 
(NTN2L), a homolog to NTN, is highly up regulated in HCC and cirrhosis (Table 3.5). 
Results from real time PCR confirm these findings (Figure 3.2).   
 
Insulin-like growth factors (IGF) are potent autocrine and paracrine mitogens involved in 
cell proliferation. These growth factors are regulated by binding to IGF-binding protein 3 
(IGFBP-3). In Figure 3.2, IGF2 mRNA was found to be significantly decreased in 
cirrhotic samples, while markedly increased in HCC and secondary HCC, reflecting the 
trend observed from the microarray analysis.  IGF2 is usually produced by the liver and, 
like AFP, its expression is much higher during fetal development than in adults (Scharf et 
al., 2001). In both human and animal studies, IGF2 has been identified in HCC as a 
potential tumour marker. IGF2 mRNA has been detected in various cell types in the liver, 
including the hepatocytes, Kupffer cells, endothelial cells and hepatic stellate cells 
(Alexia et al., 2004; Mukherjee et al., 2005; Scharf et al., 2001). In line with our 
findings, others have also found that HCC showed higher expressions of IGF2 than 
cirrhosis or chronic hepatitis (Dong et al., 2005). Due to its specificity to liver cancer, 
IGF2 has been proposed as a HCC marker as well as target for therapies (Qin et al., 2002; 
Tomizawa et al., 2006). Another potential therapeutic target is IGFBP3; treatment of 
hepatic cell lines with anti-IGF2 antibody or IGFBP3 recombinants decreased cell 
proliferation (Huynh et al., 2002).  
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In cirrhosis and HCC, IGFBP3 has been shown to have attenuated protein and mRNA 
expression (Hanafusa et al., 2002; Huynh et al., 2002; Luo et al., 2005).  Our findings 
also show that in cirrhotic liver, IGBP3 mRNA expression was indeed significantly 
reduced. However, HCC levels were not different from normal. This could be attributed 
to the insufficient number of normal samples (n=2). Our findings also showed that 
IGFBP3 expression was not reduced in hepatic metastases.  Likewise, increased IGFBP3 
was found in metastatic endocrine neoplasms (Hansel et al., 2004). In the same study, c-
met mRNA was also found to be elevated in metastatic pancreatic endocrine neoplasms.  
 
Since IGF and its associated binding proteins are intimately involved in cell proliferation, 
it is not suprising to find them elevated in HCC or in secondary HCC. Unexpectedly, 
IGF2 and IGFBP3 were not elevated in cirrhosis. In cirrhosis, proliferating bile duct and 
activated stellate cells have overwhelmed the normal landscape of the liver. As such, 
increased growth factors should be apparent. While there is little correlation of mRNA 
levels to protein, our findings so far suggest that other growth factors may be more 
critical in stimulating proliferation in cirrhosis. Such a growth factor that plays a vital 
role in the liver is hepatocyte growth factor (HGF). HGF, its ligand and the ligand’s 
activator, HGFA, were both found to be highly expressed in the microarray data (Table 
3.5 and Appendix A).  
 
Hepatocyte growth factor (HGF) has been widely found to be involved in liver 
regeneration (Mizuno et al., 2007), cell proliferation and metastasis (Weidner et al., 
1993). HGF Activator (HGFA), the most potent activator of HGF, was also found to be 
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increased significantly in our cirrhotic samples. Hence, the over expression of HGF in 
liver cirrhosis (Figure 3.3) is not surprising and has been previously documented (Mizuno 
et al., 2007).  HGF elevated expression in our secondary HCC samples confirms previous 
work (Weidner et al., 1993) in the involvement of HGF and metastasis.  
 
When compared to the cirrhotic samples expression, HCC and secondary HCC appeared 
to have decreased expression of HGFA. In actuality, the expression levels were 
significantly higher than normal, verifying the microarray data.   
Although c-met, the receptor of HGF, was not in the Operon array, we examined its 
transcript levels to obtain a clearer picture of HGF involvement in the liver diseases 
studied. Our results showed that c-met, a protooncogene (Galimi et al., 1993; Zarnegar et 
al., 1993), was not significantly different when compared to normal (Figure 3.3). This 
could be again due to the small number of normal samples, rather than a real absence of 
difference.  
To determine if protein levels of HGF showed the same mRNA trends in the different 

















Figure 3.4 HGF levels in patient plasma samples. Data as expressed as mean ± SD for 
HCC, n = 12; HCC+HBV, n = 15 and Sec HCC n=13. Normal HGF levels in plasma: 





 Although, HGF levels showed no difference between the different liver pathologies 
examined, these were approximately 4-fold higher than normal HGF levels as determined 
by Shiota, 1995.  High levels of HGF at mRNA levels correspond to the high amout of 
HGF protein in all HCC samples (primary, with HBV and secondary).  In contrast, 
HGFA mRNA expression was not different from normal. This could mean that HGFA 
may not be the main activator of HGF in these pathologies. On the other hand, mRNA 
levels low correlation with protein expression and post-translational modifications must 
also be taken into consideration.   
 
Apart from growth factors, other genes were also selected from the preliminary 
microarray data. Using the Stanford DNA array, we have identified several transcripts 
that were differentially expressed in HCC and HCC+HBV (See Appendix A for details). 
















These were found to show significant differences between the two etiologies of HCC. To 































Figure 3.5: Real time PCR results of genes showing differential expression between 
HCC and HCC+HBV samples in the Stanford DNA array. We expanded the different 
liver conditions and tested liver cirrhosis (n=23), primary HCC (n=26), primary 
HCC+HBV (n=56), secondary HCC (n=16) and normal (n=2). * indicates significant 





Midkine, a protein encoded by MDK, is associated with liver regeneration as well as 
inflammation (Ochiai et al., 2004). Real time PCR results (Figure 3.5) confirmed the 
microarray data and showed that MDK was highly over expressed in liver cirrhosis. This 
significant elevation was also apparent in HCC+HBV and secondary HCC. This 
differential expression pattern in the various diseases makes MDK a potential candidate 
for diagnostics.  MDK has been found to be positively  associated with HCC and has been 
suggested as a potential tumour marker (Jia et al., 2007). 
 
HIF-1 or hypoxia inducing factor-1 was also examined more closely after results in the 
microarray showed differences in its expression between HCC and normal liver. Real 
time PCR results in Figure 3.5 showed that HIF is significantly increased in cirrhosis. 
Interestingly, HIF has been associated with angiogenesis (Wada et al., 2006). 
Furthermore, HIF has been found to play a role in the early stages in mice and human 
hepatocarcinogenesis (Tanaka et al., 2006) and in transforming neoplastic nodules into 
malignancy (Nakamura et al., 2007) in human samples. However, in our results, normal 
samples seem to have similar expression levels as the diseased livers. More non-




ST13 or suppression of tumorigenicity 13, is the gene encoding Hsp70-interacting-protein 
or Hip. ST13 functions as a co-factor and aids Hsp70 in protein folding, repair and the 
regulation of steroid receptors (Huang et al., 2005; Shi et al., 2007). ST13 has been found 
to have decreased expression in colon cancer (Huang et al., 2005; Wang et al., 2005). 
Interestingly, in our secondary liver samples from patients with primary colon 
adenocarcinoma, ST13 is significantly elevated. ST13 is also found to be markedly 
increased in cirrhosis and HCC+HBV, but not in HCC. In the cirrhotic samples and 
HCC+HBV, histopathology reported widespread cirrhosis which is absent in HCC. 
However, secondary HCC also lacks cirrhosis, but has far greater expression than either. 
Further work has to be done to verify the role of ST13 in the various liver diseases, 
including secondary HCC which showed the highest expression.  
 
Previous work in our lab has found iNOS to be elevated in liver cirrhosis in both animal 
model (Wei et al., 2002) and human cirrhotic samples (Goh et al., 2006). To continue our 
investigations into iNOS and NO, we examined the transcript L09210, encoding iNOS, 
found classified within the apoptosis group (Figure 3.1, Table 3.5). Within the Stanford 
DNA array, iNOS was also found to show increased expression (Table 3.5). At the same 
time, eNOS also showed moderate increase in mRNA expression. The involvement of 
NO and NOS in liver cirrhosis and HCC have been examined in greater detail in the 







Chapter 4: NO in liver cirrhosis and HCC 
 
 
4.1. Introduction to liver cirrhosis 
 
 
Liver cirrhosis is the end-point of a progressive and irreversible damage of hepatic 
parenchyma cells and normal liver sinusoidal architecture, with eventual compromised 
organ function. Fibrosis precedes cirrhosis. Cirrhosis can develop from various chronic 
liver diseases, for example hepatitis B or C infection. Non-viral etiologies include 
alcoholic hepatitis, drug-induced hepatitis and auto-immune hepatitis. The etiology of 
liver cirrhosis, like that of HCC, is dependent on geographic distribution. The most 
common cause of cirrhosis in the western world is heavy alcohol consumption, while in 
most developing countries, is due to chronic viral hepatitis. It has a considerable social-
economical impact all over the world. However, to date, there are few effective 
therapeutic strategies for treating liver cirrhosis, except liver transplantation. 
 
In cirrhosis, increased hepatic accumulation of extracellular matrix distorts the sinusoidal 
architecture of the liver. In addition, this affects the normal function and phenotype of 
liver cells. As the disease progresses, two major consequences are likely: hepatic failure 
and portal hypertension. Hepatic failure may lead to jaundice, encephalopathy, ascites 
and hepatic haemorrhage. In addition, there may be the appearance of other symptoms 





Portal hypertension is a common syndrome in cirrhotic patients, characterized by chronic 
increase of portal venous pressure. Portal hypertension is the main factor in 
complications in cirrhosis including gastrointestinal bleeding, ascites and hepatic 
encephalopathy (Sarela et al., 1999a). The generation of portal hypertension can be 
derived from Ohm’s law: 
∆Pa = Q x R 
∆Pa is the intrahepatic pressure and Q is the blood flow from systemic circulation and R 
is the intrahepatic vascular resistance. Increasing either or both Q and R results in an 
elevation of portal pressure. Increased hepatic vascular resistance is thought to be a 
consequence of architectural abnormalities comprising of vascularized connective tissue 
which interrupt the normal organization of liver parenchyma (Goh et al., 2006; Shah et 
al., 2001).  This establishes vascular shunts between afferent (portal and hepatic artery) 
and efferent (hepatic vein) vessel. Portal hypertension is often accompanied by 
concomitant splanchnic vasodilation and is aggravated by the accommodation of the 
portal system to whatever is provided by the vasodilated splanchnic viscera.  
 
Enhanced NO production has been implicated in this syndrome (Wei et al., 2005b). A 
large body of evidence indicates that peripheral vascular NO production is enhanced in 
patients with liver cirrhosis (Campillo et al., 1996; McNaughton et al., 2002; Sarela et 
al., 1999a). Normalization of NO production by NOS inhibitors has been shown to 





4.2. Specific Materials and Methods  
 
 
Patient blood samples were sent to NUH Reference Laboratories and routine liver 
function tests were carried out on the samples. Other methods used have been described 
in Chapter 2.  
Figure 4.1: Liver function test on patient samples. Venous blood was collected from 
patients and submitted for routine liver function test. This shows that the function of the 
liver was severely compromised in the samples used. One way ANOVA was used to test 
for difference for each liver function test. Various liver conditions were liver cirrhosis 
(n=23), primary HCC (n=26), primary HCC+HBV (n=56), secondary HCC (n=16) and 
normal (n=10).  * indicates significance, p<0.05. 






















































































































4.3. Results and discussion 
 
 
Patient samples were classified according to the etiology of liver disease through post-
operative histopathological analysis. From this, we have sub-divided the patient samples 
into several groups: 
 1) Patients with liver cirrhosis (LC) due to billiary obstruction or other non-viral 
etiology,  
2) Patients with primary liver cancer (HCC),  
3) Patients with primary liver cancer and HBV infection, most likely with cirrhosis 
(HCC+HBV),  
4) Secondary HCC patients whose primary cancer site is colon adenocarcinoma, liver 
presents no cirrhosis or viral infection (Sec HCC). 
 
Patient plasma samples were routinely assayed for liver function test using standard liver 
function test. These benchmarks of liver dysfunction show the difference in liver function 
in differing etiologies.  As shown in Figure 4.1, albumin and prothrombin time are not 
significantly different between the different types of liver diseases studied. This is in 
contrast to the other test parameters, where marked difference can be seen. Interestingly, 
secondary HCC and normal liver show very similar patterns within the various 
parameters tested, especially in terms of AST and ALT levels. This similarity continues 
in AFP levels—sceondary HCC and normal liver plasma show hardly any AFP 
expression. This implies that the tumourigenesis methodology of secondary HCC is very 
different from primary cancers. Intiutively, this difference can be attributed to the source 
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of the initiating factors. In secondary HCC, maglignant cells from the colon have spread 
to the liver. In primary HCC and in liver cirrhosis, the source is not as well defined. 
 Since most HBV+HCC livers present underlying cirrhosis, it is not surprising that these 
2 show similar trends as well. This is also the case with primary HCC.  
 
Along with elevated AFP (where >400µg/L is considered diagnostic of liver disease) 
(Zhou et al., 2006), plasma total nitrate/nitrite levels have also been found to be elevated 
in patients with liver disease (Guarner et al., 1993; Moriyama et al., 2000; Moussa et al., 
2000). We found that total nitrite was elevated in cirrhotic as well as patients with liver 

















Figure 4.2:  Total plasma NO
-
x from patient samples. Total plasma NO
-
x was assayed 
using a kit from Research Diagnostics. The detailed protocol can be found in Chapter 2. 
The different liver conditions are liver cirrhosis (n=23), primary HCC (n=26), primary 
HCC+HBV (n=56), secondary HCC (n=16) and normal (n=10). * indicates significance 































x was assayed and found to be significantly higher in cirrhosis (71.2 
±6.88 µmol/L) and HCC+HBV (62.27±3.43 µmol/L) patient samples when compared to 
normal (36.07±3.65 µmol/L) samples. Although plasma nitrite in our primary HCC 
(82.83±22.75 µmol/L) and secondary HCC (64.44±8.09 µmol/L) were elevated, these 
were not statistically significant (p>0.05). This could be due to our limited sample size of 
normal plasma (n = 10). One caveat is that this measurement is of systemic nitrite levels, 
which may not necessarily reflect elevated NOS expression or activity found in the liver. 
We therefore investigated iNOS and eNOS expressions and activity within the diseased 
liver tissues. 
 
To obtain a more accurate determination of iNOS and eNOS mRNA expressions, we 
used real-time PCR to quantify their expression. As seen in Figure 4.3a, iNOS showed 
significantly (p>0.0001) increased expression in cirrhotic patient samples compared to 
normal. This has been documented by our previous studies on both human and cirrhotic 
rat models (Goh et al., 2006; Wei et al., 2002) as well as others (McNaughton et al., 
2002; Nasser A Mohammed et al., 2003).   Interestingly, HCC with and without HBV 
infection both showed increased (p<0.05) in iNOS mRNA when compared to secondary 
HCC. iNOS mRNA has also been found elevated in other studies (Ikeguchi et al., 2002; 






































Figure 4.3 Real time PCR results of iNOS and eNOS. Real time PCR was carried out 
to confirm microarray data as well as to determine quantitatively the expression of iNOS 
and eNOS in the various liver diseases. The different liver conditions are liver cirrhosis 
(n=23), primary HCC (n=26), primary HCC+HBV (n=56), secondary HCC (n=16) and 
normal (n=10). * considered significant against normal at p<0.05; ** represents 








































































































eNOS mRNA was also significantly elevated in cirrhotic liver samples (p<0.05) and 
corresponded to our previous findings in both the microarray assays and cirrhosis rat 
model (Wei et al., 2002) and studies by other groups (McNaughton et al., 2002; 
Mohammed et al., 2003). However, no significant differences were found between the 





























Figure 4.4 Protein expression of iNOS and eNOS in various liver diseases by 
Western blot. Densitometry readings were taken of 50µg total protein of each sample. 
The different liver conditions are liver cirrhosis (n=23), primary HCC (n=26), primary 
HCC+HBV (n=56), secondary HCC (n=16) and normal (n=2).  * represents significant 
difference compared to normal, p<0.001. ** represents significance against normal, 
p<0.05 
 










































































However, mRNA levels do not necessarily correspond to protein expression. 
Accordingly, western blot analysis was carried out as illustrated in Figure 4.4. The results 
show that cirrhotic liver samples had increased iNOS (p<0.0005) (Figure 4.4a). This is 
not unexpected as the main mechanism of iNOS expression regulation is via 
transcription. HCC and HCC + HBV samples also showed higher protein expression 
when compared with normal (p<0.05). In HCC + HBV, it is not unexpected to find 
increased iNOS as a possible defense mechanism against chronic infection (Kandemir et 
al., 2002). Increased iNOS has also been found elevated in other studies of HCC 
(Mohammed et al., 2003). In Figure 4.4b, eNOS expression in cirrhosis is also elevated 
(p<0.01), corresponding with mRNA measured and previous results (Mohammed et al., 
2003; Wei et al., 2002; Yokomori et al., 2002). Normal eNOS protein expression levels 
were comparable to the various sub-groups of HCC. 
 
We followed up that protein expression analysis with evaluation of enzymatic activity. In 
Figure 4.5, NOS activity of both constitutive NOS (cNOS) and iNOS were determined as 
a percentage of NOS activity in normal tissue. iNOS activity was found to be 
significantly different from eNOS activity in the various disease states (p<0.05). 
Noteworthy, are the increased iNOS activity of cirrhotic and HCC+HBV livers, 
corresponding to the elevated protein levels measured in immunoblots as shown in Figure 
4.4a. It is of interest to note that cNOS activity is reduced in HCC samples (only about 
60% of normal) while secondary HCC shows only mildly elevated activity. In cirrhosis 
samples, there is no change from normal eNOS activity. These findings are similar to 
previous results from cirrhotic animal model (Shah et al., 2001; Wei et al., 2002) as well 




Figure 4.5 NOS activity as determined by radioactive labeling of a NOS substrate, 
L-arginine.  NOS activity was measured as described in Chapter 2 and normalized 
according to normal livers. The different liver conditions include liver cirrhosis (n=23), 






To determine the possibility of  post-translational regulation of NOS, we accessed the 
levels of caveolin-1, an endogenous negative regulator of eNOS (Goligorsky et al., 
2002a; Kone et al., 2003b; Sato et al., 2004). Caveolin-1 has been found to be increased 
in cirrhosis in both rat and human studies (Shah et al., 2001; Yokomori et al., 2002; 
Yokomori et al., 2003)  
 
We also examined Rac2, an endogenous activator found to bind to iNOS directly (Kone 
et al., 2003b; Kuncewicz et al., 2001; Zhang et al., 2003). Since iNOS activity was found 
to be increased (Figure 4.5), it stands to reason that its activator would show a similar 
increase.  



























Apart from examining possible regulators of NOS, we also studied the expression of 
soluble guanylatel cyclase (sGC). NO has been found to be able to bind to sGC directly 
via the heme group found on sGC (Denninger et al., 1999), thus effecting the release of 
cGMP, an important second messenger in vascular regulation and neurotransmission 











































































4.6: Protein levels of caveolin-1, Rac2 and sGC as determined by Western Blot. 
Caveolin-1 is an endogenous negative regulator of eNOS, while iNOS has been found to 
be positively regulated by Rac2. One of the earliest known targets of NO, sGC, is directly 
activated by NO to release cGMP which is required for numerous downstream reactions. 
The different liver conditions are liver cirrhosis (n=23), primary HCC (n=26), primary 
HCC+HBV (n=56), secondary HCC (n=16) and normal (n=2). * represents significant 
difference compared to normal, p<0.05.  











































































































As shown in Figure 4.6a, Caveolin-1 expression is significantly elevated in cirrhotic 
samples (nearly twice that of normal), in HCC and in HCC +HBV (more than triple the 
normal expression). Caveolin-1 has been found to bind to the calmodulin binding site on 
eNOS, thus preventing the interatction of eNOS with calmodulin and inhibiting eNOS 
activity. This increase in caveolin-1 may play significant a role in the decreased activity 
of eNOS seen in these disease sub-groups. Others have also found Caveolin-1 to be 
increased in HCC and cirrhosis (Shah et al., 2001; Yokomori et al., 2002; Yokomori et 
al., 2003). While increased caveolin-1 could explain the decreased cNOS activity; other 
regulatory mechanisms may also be in place. Secondary HCC caveolin-1 expression was 
not significantly different from normal; this tallies with the activity of cNOS in Figure 
4.5 where secondary cNOS has very similar activity compared to normal (about 10% 
difference from normal). 
 
High activity of iNOS in HCC+HBV may in part be due to the host immune response, 
and in part due to to increased Rac2 expressions (Figure 4.6b) as well as the high mRNA 
expression (Figure 4.4a). Cirrhosis, on the contrary, showed markedly reduced Rac2 
expression when compared to HCC, HCC + HBV and secondary HCC. However, 
cirrhotic samples showed no difference from normal samples. Yet, cirrhotic samples 
showed distinctly higher (nearly two-fold) iNOS activity, suggesting that iNOS activity 
in cirrhosis is induced mainly by transcription or some other protein interaction(s) not 
investigated here. In HCC, iNOS mRNA and both iNOS and Rac2 protein levels are 
increased. Nonetheless, iNOS activity is not different from normal. This indicates an 
alternative regulation of iNOS within the confines of HCC. iNOS has been found to be 
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negatively regulated by caveolin-1 in colon cancer (Felley-Bosco et al., 2002). Thus, the 
elevated caveolin-1 in HCC may not only decrease cNOS activity, but also iNOS.  
Interestingly, secondary HCC shows high Rac2 expression, but very low (similar to 
normal) mRNA expression of iNOS. Protein levels of iNOS in secondary HCC were not 
different from normal. Taken together, this suggests that the moderate increase of iNOS 
activity in secondary HCC may be due to Rac2 rather than being transcriptionally 
regulated.  This suggests different routes of regulation for iNOS in secondary HCC than 
in HCC or HCC+HBV. This probably reflects the different etiologies of the cancer.  
 
From the expressions in both mRNA and proteins of iNOS, eNOS and the common 
endogenous regulators of these, it is apparent that they are differentially expressed and 
regulated in the different presentations of HCC and liver cirrhosis.  
 
sGC, one of the direct effector molecules of NO (Bruckdorfer, 2005; Koesling et al., 
2004), was also found to be differentially expressed (Figure 4.6c) in our patient samples. 
Its expression was not dissimilar in cirrhotic and HCC patients when checked against 
normal samples. On the other hand, sGC exhibited markedly raised levels in HCC+HBV 
and secondary HCC samples (p<0.05). This suggests that the increase of NO in these 
pathologies may utilize cGMP-dependent signaling pathways more so than cirrhosis and 
HCC. However, whether sGC is involved in the progression of these diseases is not clear 
as patient samples are necessarily collected at end point.   
 
A majority of HCC usually presents with underlying cirrhosis, indicating that cirrhosis 
preceeds the neoplastic formation of the tumour. In which case, cirrhosis and HCC 
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should have similar pathways of disease progression. In this consideration, it is not 
surprising that a distinct pattern of expression of sGC is found between the sub-groups of 
cirrhosic livers and HCC. This trend in also seen in HCC+HBV and secondary HCC sub-
groups.  
 
The NO-cGMP pathway has been found to contribute to the activation of the VEGF-
dependent ERK1/2 (Parenti et al., 1998). This activation is intimately involved in 
angiogensis (Van Buren et al., 2006) and  possibly accounts for its elevation in secondary 
HCC. NO may mediate angiogenesis by interations with VEGF, leading to endothelial 
cell proliferation, furthermore, increased NO is able to increase vascular permeability and 
decrease leukocyte-endothelial interactions, in line with the promotion of tumour growth 
(Konopka et al., 2001).   
 
Taken together, our results from patient samples suggest that NO is present at high levels 
in the advanced stages of liver cirrhosis and HCC. In cirrhosis, it has been suggested that 
iNOS is a causative factor and the use of iNOS-selective inhibitors have given that 
hypothesis weight by reducing liver damage (Islas-Carbajal et al., 2005; Wei et al., 
2005b), although not halting nor reversing cirrhosis. In addition, portal pressure is 
regulated by NO produced from endothelial cells within the liver (Shah et al., 1997). 
Immunohistochemical analysis showed that caveolin-1 was found to localize mainly in 
the membrane of the endothelial cells lining liver sinusoids (Figure 4.7). This further 
reduces the available eNOS and cNOS activity as shown, contributing to the increase in 
portal pressure. In chronic HBV-infection, increase iNOS activity, has been implemented 
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in disease etiology. Excessive iNOS induced by the chronic infection releases high levels 
of NO. This results in RNS formation which has been found to contribute to 
carcinogenesis. (Hon et al., 2002; Kandemir et al., 2002; Sawa et al., 2006).  
 
Immunohistochemistry (Figure 4.7) showed that iNOS is highly expressed in cirrhotic, 
HCC, HCC+HBV and secondary HCC samples, not only in the Kupffer cells which are 
the immune cells of the liver, but also in hepatocytes and endothelial cells. Normal 
tissues show less intensity of staining for iNOS. Interestingly, eNOS showed distinct 
localization in not only HCC + HBV tissues, but also in the other liver disease. In Figure 
4.7, normal liver showed mostly cytoplasmic and endothelial localization of eNOS. 
However, intense staining for eNOS was observed at the nuclei in HCC and HCC+HBV 
samples. To determine if this nuclear staining was an artifact, we obtained a liver panel 
tissue array from Chemicon, USA. We found striking staining similarities of eNOS 
localization at the nuclei (data not shown) within the liver panel with our liver samples. 
This localization of eNOS was also identified in Caucasian HCC samples (McNaughton 











Figure 4.7: IHC of iNOS, eNOS and Caveolin-1 in patient liver sections. LC –liver 
cirrhosis; HCC – primary liver cancer; HCC+HBV-HBV infected HCC; sec HCC-
secondary HCC; NOR-normal liver. Brown coloration indicates the binding of antibody 
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to the antigen of interest and intensity corresponds to amount of antigen present. Blue 





Caveolin-1 was also shown to have intense staining at or around the nuclei (Figure 4.7) in 
HCC, HCC+HBV and secondary HCC samples. In cirrhosis and normal samples, 
caveolin-1 remains at the plasma membrane. The co-localization of caveolin-1 and eNOS 
at the nuclei periphery suggests that eNOS activity is down-regulated by increased 
caveolin-1 expression, this is especially evident in HCC and HCC+HBV samples.  
 
 
In HCC, the role of NO is not yet clear. While we have studied the expression of the 
NOS, NOS regulators and the effector, sGC, this data only shows us that NO is involved 
in liver disease. Whether NO is part of the host defense or it contributes to tumorigenesis 
remains unknown. The duality of its roles in promoting tumour growth or its tumouricidal 
effects has been debated for decades. Patient samples in late diagnosis, are usually at the 
advanced stage 3 or 4 of the disease where the tumour(s) is (are) often too large for 
surgical resection. Thus, to seek to better understand the role of NO in the progression of 
HCC, human samples alone are insufficient as human samples are typically at the end 
stages of cancer. An animal model that can be analysed for NOS expression and activity 






















The lab had previously investigated the role of NO in liver cirrhosis with a bile-duct 
ligation model. Rat liver samples were obtained from bile-duct ligated (cirrhotic) animals 
and sham-operated (normal control) animals. RNA was extracted and analysed by 
microarray analysis (n= 3 for each group) (Clontech, USA). Results showed more than 2-
fold increase in iNOS and eNOS mRNA expression in the cirrhotic samples. Further 
confirmation was carried out with competition PCR (data not shown) as described in 
(Wei, 2002).   
 
HCC, more often than not, develops from underlying cirrhosis (Schafer et al., 1999). We 
thus decided to investigate NOS expression in an animal model that develops cirrhosis 
prior to HCC. This allows us to determine how NO and its enzymes change over time 
during the progression from cirrhosis to HCC. These changes of NO over the progression 
towards neoplasticity could lead to understanding the role of NO in HCC. 
 
This model would be especially important, as human data cannot provide information on 
the changes over the progression of the disease. In practice, the tumour would be 
removed if it is detected at a resectable stage and it is also more common that patients are 
diagnosed only in the late stages. In our previous chapter, we have identified differences 
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in the roles of NO at the late stages of patients with cirrhosis, primary HCC with and 
without HBV infection and secondary HCC. However, these do not reflect how NO 
affects the progression of the cirrhotic pathology- particularly whether it advances the 
pathology or is a manifestation of a defense mechanism of the host.   
 
A HCC rat model can be developed by various means, from implantation of human 
cancer cells to transgenic introduction of hepatitis viral genes, to chemically-induced 
tumours. Some examples include: choline-deficient-L-amino acid diet, implantation of 
human hepatoma and the Solt-Farber resistant hepatocyte model (Espandiari et al., 2005). 
The Solt-Farber resistant hepatocyte model has been used extensively in HCC research. 
Diethylnitrosoamine (DEN), by various routes of administration (intra-peritoneal, skin, 
inhalation, intrarectal injections, drinking water, feed or gavage) has been found to 
induce liver tumours in rats (11
th
 Carcinogen Report, 2005, US Dept of Health and 
Sciences, National Toxicology Program).  
 
Briefly the Solt-Farber model is set up as follows. Animals are initiated by intra-
peritoneal  injections with DEN and allowed to recover for one week (Rangan et al.). 2-
acetylaminofluorene (Hasegawa et al.), phenolbarbital (Lupberger et al.) or 
thioacetamide (TAA) is administered orally as a chronic promoting agent. Lastly, partial 
hepatectomy (PH) is performed to induce liver regeneration. Cancerous cells that have 
faster replication and lack contact inhibition or other proliferation controls would 




However, these models of liver carcinogenesis give rise to tumours directly in the 
absence of cirrhosis, which does not phenocopy the case in humans. In our study, a rat 
model of DEN-induced liver injury, which reproduces the progression of cirrhosis 
towards HCC (Ha et al., 2001). In another study, oral administration of DEN resulted in 
MRI image features and digital subtraction angiographs that were similar to that of 
human primary liver cancer  (Li et al., 2005).  
 
 
5.2. Specific Materials and Methods 
 
 
5.2.1. Development of a HCC model 
 
 
Briefly, as described in Chapter 2, 0.01% (v/v) DEN was given ad libitum to male 
Sprague-Dawley rats via drinking water for 4 to 16 weeks. Control rats had untreated 
drinking water. The animals were sacrificed on the same day after 4, 6, 8, 10, 12, 14 and 
16 weeks treatment. Each time-point group consisted of 12 rats: 6 controls and 6 DEN-
treated. Further details are described in Chapter 2: General Materials and Methods, 
section 2.2.2: HCC animal model.  
 
 5.3      Results and discussion 
 
 
5.3.1. Development of a HCC model 
 
 
A HCC animal model was developed based on the method described in Sectio 2.1.3. Rats 
drinking DEN-treated water were generally found to be thinner, more lethargic and 
lacked a glossy fur coat. In addition, they appeared to have distended abdomens. This is 
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especially so for those drinking DEN-spiked water for 10 weeks or more. Food and water 
intake were also decreased. Food intake measured was approximately 5g/100g 
bodyweight/day; water intake was approximately 10-12ml/100g bodyweight/day in 
normal control rats for the duration of each time-point. In DEN treated rodents, both food 
and water intake decreased to about 60% at the end of the 16 weeks. This is similar to the 
general symptoms of weight loss, loss of appetite and abdominal distension found in 
HCC patients. These symptoms are not diagnostic of liver cancer but act as general 
signposts of illness. Similar to human patients, liver function tests conducted on the 
animal model also showed increased AST and ALT enzyme levels with time. Figure 5.1 
shows the AST and ALT data collected, other markers analyzed in the liver function test 





Figure 5.1: AST and ALT levels of control and DEN-treated animals over time. 
Terminal cardiac blood was collected from the euthanatized animals, serum extracted and 
sent to NUH Referral Laboratories for routine Liver Function tests. The increasing AST 
and ALT levels over time are an indication of liver failure in the animals drinking DEN-
treated water. This shares similarities with our patients’ results, where at the late stages of 
HCC, AST and ALT were significantly increased. 2-way ANOVA was used to analyze 
our data. As such, DEN-treatment was found to significantly increase AST and ALT 




























Figure 5.2: Liver weight expressed as a percentage against body weight in the 
animal study. Animals were weighed prior to administering euthanasia. Whole livers 
were surgically removed from euthanatized animals and weighed prior to storage. * 





The animals were sacrificed after 4, 6, 8, 10, 12, 14 and 16 weeks of ad libitum DEN-
spiked water. From Figure 5.2, it can be seen that DEN-treated rats have increasing liver 
mass to body weight ratios. In the control animals, body weight increases over time, 
while the liver mass does not fluctuate in the adult animal. However, in DEN-treated 
animals, we expect that body mass would decrease due to loss of appetite, but liver mass 
would increase due to growth of neoplastic lesions or foci, explaining the distended 
abdomen. In Figure 5.3, representative images of the livers are presented. It is clear from  


























Figure 5.3: Livers of the animals during the development and progression of HCC 
by 0.01% (v/v) DEN treatment over 4-16weeks. a: 4 weeks; b: 6 weeks; c: 8 weeks; d: 
10 weeks; e: 12 weeks; f:14 weeks; g:16 weeks. 1: Controls given drinking water; 2: 
randomly selected animals given 0.01% (v/v) DEN in the drinking water. Black arrows 
on c2 point out visible liver foci. From 10 weeks onwards, lesions have become more 





these photos that DEN-treatment induces foci appearance and foci quantity and size 
increases with the length of exposure to DEN.  
 
Apart from an increasing numbers of visible foci, a more accurate determination of the 
development of HCC is required. Glutathione S-transferase (GST) is a family of enzymes 
capable of conjugating reduced glutathione via the sulfhdryl group to various substrates. 
Of interest to us is the π- form or GST-π. GST-π is specifically induced in preneoplastic 
foci, and it has been used as a marker for screening of carcinogens as well as confirming 
the onset of cancer in animal studies (Satoh et al., 2002). As such, we employed IHC 
staining for GST-π to determine the onset and severity of HCC at the various time points 
in our model. Indeed, IHC staining for GST-π showed increasing staining intensity over 
time (Figure 5.4). In the same figure, it is also apparent that fibrosis is present and 
becomes worse over time. Fibrosis is indicated by black arrows in Figure 5.4. Disruption 
to the normal architecture of liver sinusoid is observed as the disease progresses to more 
advance stages. Of note, at 10 weeks, GST-π staining is apparent in a larger number of 
cells and the initial signs of fibrosis are seen, a marked change from week 8. From weeks 
12 to 16, an obvious decline in normal liver sinusoid architecture is seen as wells as 
increase in the staining intensity for GST-π and developing fibrosis. The beginnings of 
capsule formation, which is indicative of cirrhosis (Wei, 2002), are also evident in Figure 
5.4 g2 (red dash lines).  From these, it is apparent that DEN is able to induce primary 










To understand how NO effects, or is affected, by the onset and progression of HCC, we 
used the DEN treatment animal model as a platform to study NO and NOS levels at the 
various time-points. As shown in Figure 5.5, NO
-
x was found to be significantly increased 
in DEN-treated animals when compared to controls at the corresponding time-point (p 
<0.05). This is in agreement with the results from the many human studies where NO
-
x 
has been found increased in various cancers including HCC (Hon et al., 2002; Moriyama 
et al., 1997; Moussa et al., 2000). Some investigators have even suggested that serum 
nitrate/nitrite levels may be used as tumour markers or prognostic tools (Moriyama et al., 
2000; Zhou et al., 2006).  Interestingly, our data shows the steepest increase of NOx- 
between weeks 8-10; this reaches the maxima during weeks 10-12- then plateaus off until 
week 16. This may be indicative of a change in the roles of NO during the progression of 
HCC or may indicate the host defense response is more highly activated, possibly 
reacting to some changes in disease progression.  
 
To understand the role of NO in the progression of HCC, we analysed the gene 
expression of NOS in the livers of control and DEN treated animals. Real time PCR 
assays (Figure 5.6) showed that both eNOS and iNOS have significantly higher 
expression levels in the liver of DEN treated animals over time (p <0.05). Between the 
two isoforms of NOS, some differences in expression pattern were observed. Firstly, the 
relative increase of the 2 isoforms vary, although this is not surprising considering that 


























Figure 5.4 IHC of GST-π on liver sections of control and DEN-treated animals over 
time. a: 4 weeks; b: 6 weeks; c: 8 weeks; d: 10 weeks; e: 12 weeks; f:14 weeks; g:16 
weeks. 1: Controls given drinking water—these show no staining for the tumour marker 
GST- π; 2: randomly selected animals given 0.01% (v/v) DEN in the drinking water. 
Brown coloration indicates the binding of anti- GST- π and intensity corresponds to 
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amount of GST- π present. Blue stain is picked up by nuclei during counterstaining with 
heamotoxylin. Fibrosis is indicated by the black arrows, showing the disruption of liver 
sinusoids by invasion of hepatic stellate cells. Red dash lines in g2 show the beginnings 








Figure 5.5: Plasma levels of NOx
-
 in DEN treated-animals presented as a percentage 
of control animals at the same time point. NOx
-
 was measured from serum collected 
from terminal cardiac puncture and hence represents systemic circulation of NOx
-
.  As 
shown, total NOx
-
 was increased sharply after 8 weeks of DEN-treatment. p<0.05 as 
analysed by 2-way ANOVA indicates that the treatment induced changes in NOx
- 
levels 







































Figure 5.6: Real time PCR analysis of eNOS and iNOS expression on the DEN 
animal model. QPCR was performed with SYBR Green as the reporter and absolute 
quantitation using a standard curve was performed as described previously. Data obtained 
was expressed as % of control.  eNOS : solid line; iNOS: dotted line.  From the graph, 
both eNOS and iNOS show elevated expression in mRNA over time. iNOS was found to 
increase consistently with time, while eNOS showed some leveling off of expression 







More interestingly, eNOS expression showed a leveling off from 12 to 16 weeks, 
suggesting some equilibria or maxima attained; while iNOS showed a continual upward 
trend. This suggests that the two isoforms have different roles or levels of involvement 
during cancer progression. 
 































iNOS has been found to be constitutively expressed at low levels in several cell types, 
including hepatocytes (McNaughton et al., 2002; Mohammed et al., 2003). iNOS 
expression is mainly regulated by transcription, thus, high levels of iNOS mRNA is 
usually indicative of high levels of iNOS protein and activity.  Sheer stress caused by 
possible hepatic hypertension in the increasingly fibrotic liver in DEN-treated animals 
may be one of the factors perpetuating eNOS mRNA elevation throughout the time points 
examined (Fleming et al., 2003). eNOS expression, however, is not typically regulated by 
transcription (Goligorsky et al., 2002a). Thus, the increased eNOS mRNA levels over 





















Figure 5.7: NOS activity assay of DEN-treated rats over time.  NOS activities were 
measured as described previously (Wei et al., 2005a) using tritium-labeled arginine as the 


































We next measured NOS activities in the liver extracts from the HCC animals.  NOS 
activity assay also supports a general increase of iNOS in the progression of HCC (Figure 
5.7).  Interestingly, a sharp divergence in iNOS and eNOS activities was seen at week 10. 
iNOS activity sharply increases to a level similar to the peak of eNOS activity at week 
10, at approximately 200% of control activity. This high iNOS activity in the animal 
model is in agreement with the human data which shows elevated iNOS activity, albeit to 
differing extents, in HCC and cirrhosis samples. eNOS activity on the other hand, peaked 
at 10 weeks and then decreasing to almost basal (4 weeks) levels after 16 weeks of DEN 
treatment. It is interesting to note that eNOS activity increases initially, but decreases as 
the disease progresses.  
 
In our human data, we have observed that liver eNOS activity in both primary and 
secondary HCC and HCC + HBV patients were very similar to normal livers (Figure 
4.5). From our HCC progression animal model, we observed that after 14-16 weeks of 
DEN treatment, eNOS activity decreases to almost basal levels. This is in agreement with 











Figure 5.8: eNOS and iNOS protein expression measured by densitometry in 






As described above, the changes in transcript levels of iNOS and eNOS during the course 
of DEN treatment did not correlate well with the respective enzyme activities.  
To verify our findings, we also carried out immuno blot (Western blot) analysis with the 
specific iNOS and eNOS antibodies on the liver extracts.  Western blot densitometry 
data, expressed as a percentage of controls at each time point is shown in Figure 5.8. 
eNOS protein levels decrease with time. However, eNOS levels are consistently greater 
than controls, which correspond to findings by others that show increased eNOS in HCC 
and other tumours (Cobbs et al., 1995; Hon et al., 2002). Even though eNOS protein 
levels are higher than controls, eNOS protein shows a downward trend over the duration. 




























From 8 to 10 weeks, eNOS protein levels seem to be fairly stable until 14 to 16 weeks 
when it falls further.  
 
iNOS on the other hand, has protein levels which increased correspondingly with the 
increase in mRNA levels.  From weeks 10 to 12, there appears to be a dramatic increase 
in iNOS activity; however protein and mRNA levels are not increasing drastically. This 
could be due to post-translational regulation on iNOS activity. iNOS levels and activity 
have been found to be increased in various diseases, including liver diseases (Cianchi et 
al., 2003; Hon et al., 2002; Ikeguchi et al., 2002; Peng et al., 2003; Watanabe et al., 
2000).  
Other data suggests that the corresponding eNOS activity changes at week 10 may affect 
iNOS or vice versa. The two NOS isoforms in HCC progression may be interdependent 
on each other. Post-translational mechanisms which affect eNOS and iNOS activities 









Figure 5.9: Caveolin-1, Rac2 and sCG protein expression relative to controls at each 







Increased expression of caveolin-1 has been known to down-regulate the activity eNOS 
(Feron et al., 1998; Goligorsky et al., 2002b; Sbaa et al., 2005). From Figure 5.9, 
caveolin-1 levels increased over time in DEN treated rats. This could explain the 
decreasing eNOS activity in spite of elevated eNOS protein levels. Similarly, Rac2 is also 
increased, albeit with a gentler gradient compared caveolin-1. Rac2 may play a part in the 
increased iNOS activity measured (Kuncewicz et al., 2001). By further immuno blot 
analysis, we observed that sGC levels are generally unchanged in DEN treated rats and 
that the increasing severity or progression of the disease does not affect its expression.  





























From our DEN treatment HCC animal model, we determined that not only does the level 
of systemic NOx
-
 increase with time; we also noted differential expression of the two 
major isoforms of NOS in the liver. Our data from the animal model agree with the 
results from human HCC in that eNOS and iNOS are increased in HCC. At the early 
stages during liver insult, (from 4-8 weeks), there is a general gradual increase in both 
iNOS and eNOS mRNA levels and enzyme activities. This is reflective of host reactions 
towards the liver insult and chemical carcinogenesis. We also found that eNOS and iNOS 
have very distinct patterns of expression in both mRNA and protein levels. More 
importantly, their respective activity levels show divergent changes over the progression 
of the disease. This suggests that at some point during the development of the disease, 
these isoforms of NOS may have more than one role to play in the progression of HCC. 
We have identified significant changes in the levels of post-translational endogenous 
regulators (Caveolin-1 and Rac2) of these isoforms of NOS. These changes may explain 
conflicting results that have plagued NO research previously. Based on these data and 
work done by others, we can surmise that NO, and thus NOS, may be very much 
involved in the progression of HCC. However, whether these changes are indicative of 
NO function as promoter of tumourigenesis, or tumouricidal, is still not clear. Thus, it is 
imperative that we investigate further at which time-point during the disease development 














NO, a signaling molecule, participates in numerous biochemical reactions. Due to the 
physiological consequences of these reactions, NO is vital for normal physiology. 
However, inappropriate overproduction of NO is detrimental to the organism and has 
been implicated in various human pathologies including rheumatoid arthritis, 
autoimmune diseases, neurodegeneration and cancer (Bogdan, 1998; Brennan et al., 
2002; Broholm et al., 2003; Hon et al., 2002).  
 
NO and its derivative peroxynitrite, can attack directly DNA causing deamination, 
leading to single-strand breaks and subsequent mutations and carcinogenesis. NO can 
also indirectly induce DNA damage by irreversibly impairing zinc-containing DNA 
repair enzymes. The interactions of reactive nitrogen species (RNS), including 
peroxynitrites, with other metals or molecules such as amines, thiols and lipids can also 
lead to DNA damage through base modifications or strand breakages. These 
consequently lead to carcinogenesis (Szabo et al., 1997).  
 
Apart from DNA alterations, NO is intimately involved in many signaling pathways that 
affect cell proliferation, metastasis and invasion as well as apoptosis and angiogenesis. 
Each of these could contribute to the progression and growth of the tumour. In earlier 
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studies of breast and ovarian cancer, iNOS activity was found to be elevated in malignant 
patients samples compared to benign tissues. The iNOS activity level correlated to the 
severity of the cancer (Thomsen et al., 1998a; Thomsen et al., 1998b). Since then, animal 
models and patient samples of colonic cancer, pancreatic cancer, head and neck cancer, 
esophageal cancer and prostate cancer have been found to have increased serum 
nitrate/nitrite levels as well as elevated expression of iNOS, either in protein or mRNA or 
both as well as increased iNOS activity (Chen et al., 2004; Cianchi et al., 2003; Cobbs et 
al., 1995; Ohshima et al., 1994; Rao et al., 2002; Rao et al., 1999; Wei et al., 2005b). 
Treatment with iNOS selective inhibitors was shown to decrease foci formation and 
tumour growth in animal studies of colon and esophageal cancers (Chen et al., 2004; 
Crowell et al., 2003; Rao et al., 1999).  This further substantiates iNOS involvement in 
tumour growth and progression.  
 
Angiogenesis is essential for continual tumour growth and subsequently, provide routes 
for metastases. NO has also been shown to increase vascularization in tumours. eNOS, 
through VEGF stimulation, is able to induce the proliferation and migration of 
endothelial cells  (Broholm et al., 2003; Cianchi et al., 2003; Jenkins et al., 1995; Tozer 
et al., 1995). VEGF stimulates eNOS via  the up-regulation of eNOS mRNA or protein 
(Lala et al., 2001).  Experimental murine mammary tumours and matastatic clones from 
the tumours were found to have significant eNOS activity, suggesting that eNOS is 
required for cell invasiveness and metastasis (Lala, 1998; Lala et al., 1998). Treatment 
with eNOS selective inhibitors was able to effectively reduce early increase in blood 
supply to the tumours (Roy et al., 2007). Thus, it is not surprising that NOS inhibitors 
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have been considered as a therapeutic agent in combating these pathologies (Crowell et 
al., 2003; Salerno et al., 2002). Pharmacological agents are able to inhibit or reduce NOS 
activity through action on the principle sites of the enzyme: the substrate-binding site, the 
oxidizing haem site or the co-factor BH4 site. Crystallography studies on human eNOS 
and iNOS catalytic domains show that these isoforms are almost identical (Proskuryakov 
et al., 2005; Saleron et al., 2002). In fact, the amino acid residues of NOS that comes in 
contact with the substrate are highly conserved among the NOS isoforms. The only 
exception to this is the Aspartate in iNOS is replaced by an Asparagine in eNOS at the 
carboxylate binding pocket (Ostrom et al., 2004) resulting in different substrate binding 
efficiency. By utilizing this difference, it is possible to selectively inhibit one isoform 
preferentially.  
 
NO deficiency has been known to contribute to diseases such as hypertension and 
atherosclerosis (Balligand et al., 1997). Furthermore, inhibition of NOS has been found 
to exacerbate liver damage (Nagase et al., 1995), kidney failure in cirrhotic rats (Graebe 
et al., 2004), and promote the alterations of preneoplastic colon lesions carcinogen-
treated rats (Schleiffer et al., 2000). Apart from the detrimental effects of inhibiting NOS, 
induction of iNOS and NO production has been found to prevent tumour promotion. 
While iNOS inhibitors are able to promote transformation process,  conversely, NO was 
found to have both chemopreventive and tumouricidal effects (Dhar et al., 2003).  NO 
produced by macrophages have an important role in host defense against tumour cells. 




From animal to patient samples in both our laboratories and others, cirrhotic and/or 
cancerous samples show increased plasma nitrate/nitrite levels and elevated expressions 
of iNOS and/or eNOS (Goh et al., 2006; Ikeguchi et al., 2002; McNaughton et al., 2002; 
Mohammed et al., 2003; Moriyama et al., 1997; Rahman et al., 2001; Yokomori et al., 
2002). In our animal model of HCC as described in the previous chapter, we found that 
iNOS showed increased expression and activity. On the other hand, eNOS activity 
peaked at about 10 weeks and subsequently reduced as the disease progressed. The 
reduction in activity is possibly due to the elevated expression of its endogenous negative 
regulator, caveolin-1 (Feron et al., 1998; Goligorsky et al., 2002b; Kone et al., 2003a; 
Yokomori et al., 2002).   
 
The above imply that the two isoforms of NOS contribute to the progression of the 
disease differently. Although we were able to track NO (through total nitrate/nitrite 
measurements) and NOS isoforms (through mRNA and protein expression and activity) 
across the onset and progression of HCC, it is still unclear how NO modulates the disease 
progression. Whether the increase in iNOS and the decrease in eNOS are simply part of 
the host’s reaction to the disease, or is part of the carcinogenic process remains unclear. 
To shed further light on the role NO in HCC progression, we treated animals with 










6.2. Specific Materials and Methods 
 
 
Animals were allowed to drink 0.01% (v/v) DEN in drinking water (or water alone for 
control rats) for 10 weeks. Based on our results as described in Chapter 5, after 10 weeks 
of DEN ingestion, malignancy is well established, i.e. removal of the carcinogen did not 
reverse the progression of the disease. After 10 weeks of DEN treatment, animals 
including controls were grouped and given either a regiment of NOS selective inhibitor 
or NO donors at two different dosages in drinking water for 4 consecutive weeks as 
described in Table 6.1. To minimize trauma associated with daily injections, all 
treatments were selected for their ability to be effective via oral administration.  
 
  
Control rats 10 weeks DEN-treated rats        
(HCC rats) 
Water Water 
0.1g/L L-NNA  0.1g/L L-NNA 
0.2g/L L-NNA 0.2g/L L-NNA 
0.015g/L L-NIL 0.015g/L L-NIL 
0.030gL L-NIL 0.030gL L-NIL 
0.12g/L molsidomine 0.12g/L molsidomine 
0.24g/L molsidomine 0.24g/L molsidomine 
1.25g/L ISDN 1.25g/L ISDN 
2.5g/L ISDN 2.5g/L ISDN 
 
Table 6.1: List of NOS selective inhibitors and NO donors given in drinking water of 
normal (or control) rats and in 10 Weeks DEN-treated (or HCC) rats.  Rats were 
chemically induced to have HCC by 10 weeks of 0.01% (v/v) DEN-treatment (Ha et al., 
2001), or water for control rats. After which, these drugs were administered for 4 weeks 
in drinking water. L-N
G
-Nitroarginine (L-NNA) is an eNOS selective inhibitor 
(Lukivskaya et al., 2004). L-N
6
-(1-Iminoethyl)-lysine (L-NIL) is an iNOS selective 
inhibitor (Rangan et al., 2001). Molsidomine (mols) is a NO donor requiring the prior 
metabolism by liver enzymes to release NO (Rangan et al., 2001) and ISDN is a NO that 
spontaneously decomposes to release NO at physiological pH (Qui et al., 2004). These 









There are two major groups of NOS inhibitors: amino acid-based and non-amino acid-
based. The non-amino acid based group encompasses chemical compounds such as 
guanidines, isothioureas, imidazoles, indazoles, amidines, thiazines, pyridines, 
benzoxazoles and pteridines (Fukuto et al., 1995; Saleron et al., 2002). Of interest to us 
are the amino acid-based NOS inhibitors. The most often used are the L-arginine 
analogues, the first of which were mono or di- substituted guanidine analogues of L-
arginine (Griffith et al., 1996). These include N-methyl-L-arginine (L-NMA) and N-
nitro-L-arginine (L-NNA). More recently, further modifications led to the compounds N-
(1-imineothyl)-L-ornithine (L-NIO), N-(1-iminoethyl-L-lysine (L-NIL) among others 
(Fukuto et al., 1995; Saleron et al., 2002).  
  
L-NNA was selected for our study as it was easily accessible and found to be a more 
potent inhibitor of eNOS (IC50 = 5.9µM ) than of iNOS (IC50 = 14µM) (Saleron et al., 
2002). Furthermore, L-NNA has been used previously in a similar HCC animal model 
disease (Lukivskaya et al., 2004). L-NIL was similarly selected for accessibility and its 
potent selelctive inhibition of iNOS ( IC50 = 3.3µM) over eNOS ( IC50 = 92µM) (Salerno 
et al., 2002), which is nearly 28 times more specific against iNOS. Previously, L-NIL, the 
first amino acid-based inhibitor showing specificity for iNOS, was found to be effective 




6.2.2. NO donors 
 
 
Compounds that are able to release NO in specific conditions may be potential 
therapeutics to alleviate NO underproduction. Since the explosion of NO research in the 
early 20
th
 century, exogenous sources of NO were in high demand. Since the mid-1980s, 
new NO donors developed to meet the increasing demand have several added advantages 
over the previous versions of NO donors. Spontaneous NO release, controlled NO release 
and even tissue selective NO release are some of the improvements made. These NO 
donors are structurally dissimilar, resulting in their various properties and chemical 
reactivity and release mechanisms. Generally, NO can be released by three mechanisms: 
1) Spontaneously, through thermal or photochemical decomposition. Examples 
include S-nitrosothiols, diazeniumdiolates and oximes. 
2) Chemically, through reactions with acid, alkali, metal or thiol groups. Examples 
include nitrate and nitrites.  
3) Enzymatically, through metabolic activation by oxidation from hepatic enzymes. 
Examples include syndnonimmines. 
 
A number of organic nitrates that are potent vasodilators have been in use clinically for 
over a hundred years. Although potentially explosive, their use has become 
commonplace.  Since 1897, glyceryl trinitrate, arguably the best known NO donor, has 
been prescribed to relieve attacks of agina pectoris. Isosorbide mononitrate and 
isosorbide dinitrate (ISDN) are also common prescriptions in the twentieth century. ISDN 
has replaced glyceryl trinitrate mainly because ISDN has a longer duration of action as its 
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metabolites, 2-mononitrate and iso-5-mononitrate are cleared relatively slowly.  Due to 
its common use in humans and availability, ISDN was selected as a NO donor from the 
organic nitrates group for our animal studies (Qui et al., 2004).  
 
To determine if increasing NO through administration of NO donors will affect the 
progress HCC, we also used molsidomine (mols). Molsidomine belongs to the group of 
sydnonimines, which unlike organic nitrates, can be stored in neutral conditions at room 
temperature stably for long periods, albeit in the dark. At physiological conditions, 
molsidomine is converted rapidly to its NO-bearing metabolite SIN-1, mainly by the 
action of liver esterase. SIN-1 is then able to release NO. This enables molsidomine to 
release NO specifically within the liver. Molsidomine itself is relatively inactive and 
stable. Its metabolite, SIN-1 however, spontaneously releases NO under physiological pH 
and temperature. Molsidomine has been clinically used for the past quarter of a century 
as an anti-anginal nitrate-like drug for the treatment of coronary heart diseases. Due to 
the need for enzymatic digest to release the active metabolite, molsidomine has a slower 
onset and longer duration of action. As a pharmaceutical agent, it shows very little, if 
any, development of tolerance and higher anti-aggregatory activity of platelets than other 
NO donors used thus far. Although sodium nitroprusside has been extensively used for 
treatment, patients often develop tolerance and prolonged use may lead to accumulation 
of cyanide in the body. Thus, molsidomine was selected as a drug of choice in the 











6.3. Results and Discussion 








































Figure 6.1:  Percentage of liver weight to body weight of the HCC rats with various 
treatments against their respective controls. Body weight was taken prior to liver 
extraction. Normal liver weighs about 3% of the body weight in rats. The ratios of DEN-
treated animals were tested against the respective controls. Control animals given either 
NOS inhibitor or NO donors were not different from controls with no further treatment, 
i.e. showing approximately 3% liver to body weight. This similarity was seen in DEN-
treated with NO donor treatments as well. On the other hand, DEN-treated animals with 
no treatment (water) and those with NOS inhibitor treatments showed significant 
difference. * indicates significant difference in liver to body weight ratio when compared 
DEN-treated against the respective controls, p<0.05. # indicates significance when DEN-











In Figure 6.1, the relative liver to body weight is shown. Body weight (500-600g for 16 
week control animasl) was taken immediately after euthanasia and before excising the 
liver. The ratio of the liver to body weight was then calculated for each group. DEN-
treated or HCC rats that were given only water showed significant increase in liver 
weight when compared to normal controls, likewise the HCC rats receiving the NOS 
inhibitors L-NNA and L-NIL had liver:body weight increase when compared against 
their respective controls. This indicates liver mass had increased disproportionally to 
body mass upon DEN-induction of HCC. This symptom was also evident in our liver 
cancer progression model discussed in the previous chapter. We also noted that HCC rats 
that have received NO donors, either molsidomine or ISDN, showed no significant 
difference in liver to body weight ratios from their respective controls. Furthermore, 
DEN-treated rats with NO donor administration show significant difference with DEN-
treated rats without further treatment. This suggests that either of the NO donors 
administered prevented liver mass from increasing disproportionately or that body mass 




















AST (U/L) ALT (U/L) 
Control HCC Control HCC 
Water 156.00 ±13.86 208.75±32.55 52.00±2.00 87.83±8.336 
LNNA 0.1g/L 136.67±6.75 259.80±46.97 47.17±2.82 86.34±11.598 
LNNA 0.2g/L 167.67±15.69 254.33±39.20 53.00±3.22 80.16±11.634 
L-NIL 0.015g/L 124.83±5.57 146.83±16.09 43.0±1.82 75.34±12.428 
L-NIL 0.03g/L 110.83±5.31 165.83±23.68 41.00±2.94 69.66±10.34 
ISDN 1.25g/L 93.84±6.89 117.67±8.95 32.83±3.56 64.34±8.500 
ISDN 2.5g/L 98.66±12.46 103.16±7.53 32.50±0.61 44.67±3.664 
mols 0.12g/L 143.00±9.82 160.00±13.21 36.50±1.08 59.67±6.556 
mols 0.24g/L 126.67±32.31 115.33±4.32 48.67±5.94 41.83±3.127 
 
Table 6.2: AST and ALT measured from serum by NUH Referral Laboratories. 
Normal SD rat serum values for AST and ALT are 77-157U/L and 24-53U/L 
respectively. Normal values provided by NUH Referral Laboratories. AST and ALT 
presented as U/L ± standard deviation from 6 animals per group. Figures in red indicate 







Serum levels of AST and ALT are part of the liver function panel, a screening test 
commonly used to ascertain liver damage. From Table 6.2, HCC animals (DEN-treated) 
without treatment (water only) and HCC animals with L-NNA treatment show elevations 
in both enzymes. A simplistic diagnosis of this would indicate that HCC and eNOS 
selective inhibition (by L-NNA) is causing liver damage. While AST is not specific to the 
liver (it is also found in the heart, kidney and brain), ALT is mainly found in the liver. 
Healthy controls administered with either NOS inhibitor or NO donors were not different 
from controls without. From the liver:body weight (Figure 6.1) and liver enzyme analysis 
(Table 6.2), it is possible to deduce that DEN is causing growth of liver mass and liver 
damage especially in L-NNA treated HCC livers. L-NIL, iNOS selective inhibitor, also 
shows increasing liver mass coupled with liver damage as deduced from the high levels 
of ALT found (Table 6.2). Both NO donors on the other hand, seem to improve the HCC 
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condition or at least are able to ostensibly reduce liver damage as measured by these 
general parameters. Liver mass in HCC rats given NO donors is not excessive and is very 
similar to the respective controls. AST and ALT levels are also mostly within normal 
range, although at a lower concentration (1.25g/L), ISDN treatment did show elevated 
ALT levels. This suggests that NO donors seem to be effective in the ability to reduce 
liver damage. It must be noted that to be effective in reducing liver damage within these 
parameters, especially a non-liver specific NO donor like ISDN, a certain threshold or 
minimal concentration may be required although there is already some obvious benefit at 
the low concentration used. Correspondingly, a liver specific NO donor like 
molsidomine, is able to prevent liver damage even at lower concentrations because of the 























































Figure 6.2: Livers excised from control and HCC rats with various treatments. 
Legend: Columns on the left marked (1) are control animals with the various treatments, 
columns on the right marked (2) are DEN-treated HCC animals with the various 
treatments. a: water;  b: L-NNA 0.1g/L; c: L-NNA 0.2g/L; d: L-NIL 0.015g/L; e: L-
NIL0.030g/L; f: ISDN 1.25g/L; g : ISDN 2.5g/L; h :molsidomine 0.12g/L; i: 





Figure 6.3: Microscopic sections of livers from control and HCC rats with various 
treatments, stained for GST-π (brown) and counter-stained for nucleic acid (blue). 
Legend: Columns on the left of each panel (1) are control animals with the various 
treatments, columns on the right marked (2) are DEN-treated HCC animals with the 
various treatments. a: water;  b: L-NNA 0.1g/L; c: L-NNA 0.2g/L; d: L-NIL 0.015g/L; e: 
L-NIL0.030g/L; f: ISDN 1.25g/L; g : ISDN 2.5g/L; h: molsidomine 0.12g/L; i: 
molsidomine 0.24g/L. Black arrows show areas where the onset of cirrhosis has occurred. 
Magnification 200x.  
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We sought to examine the livers with greater histological details to ascertain the effects 
of NOS inhibitors and NO donors and their effects on the progression of HCC. Figure 6.2 
shows a representative liver from each group of animals (n = 6 for each group); controls 
and HCC, with the various NOS inhibitor and NO donor treatments (see Table 6.1). It is 
apparent that the control livers have a smooth, shiny surface with no visible cancerous 
foci (Figure 6.2, 1a-i), and treatments with NOS inhibitors or NO donors did not seem to 
adversely affect the liver. On the other hand, livers of the DEN treated rats (Figure 6.2, 
2a-i) show obvious foci formation to various degrees. To judge the extent the NOS 
inhibitors or NO affected the progression of HCC, normal drinking water was used in lieu 
of any treatment after 10 weeks of DEN administration. This shows that removal of DEN 
alone did not result in a regression of HCC as DEN-treated animals given only water also 
had visible tumours on the liver surface (Figure 6.2 a2). Livers from both the L-NNA and 
L-NIL treated groups were found to be no different from water treatment, i.e livers from 
these groups were found to have much of their surfaces covered with foci of various 
sizes. If the inhibitors had altered disease progression, it was not evident to the naked eye. 
ISDN and molsidomine on the other hand, showed remarkable and dramatic reduction in 
foci number and most of the liver surface is smooth and shiny (Figure 6.2, 2f-i), much 
like those of controls. Some foci were still noted on these livers though, albeit less than 
10 foci per liver. ISDN did not show any apparent dose differences on the liver surface, 
unlike that for ALT levels, but molsidomine was more effective (i.e. lesser number of 




To determine if the foci formed were malignant or cancerous, we again used anti-GST-π 
IHC to determine the presence of GST-π, the tumour marker for rat hepatic neoplasms 
(Satoh et al., 2002; Tsuda et al., 2003) as described briefly in Chapter 5. From the liver 
sections, we were also able to see obvious fibrosis and cirrhosis (arrows in Figure 6.3).  
The sections in Figure 6.3 are representative of serial sections done for each animal in 
each group (n=6). Control animals show no GST-π staining or fibrosis, regardless of 
subsequent intervention treatments (Figure 6.3, 1a-i). Typical liver sinusoids are clearly 
visible in control sections. Such sinusoids which enable the liver to function efficiently 
and effectively are not apparent in the DEN-treated liver sections (Figure 6.3, 2a-i). 
 
DEN-treated rats without intervention (i.e. only water) showed distinct fibrosis and high 
intensity of staining for GST-π (Figure 6.3, 2a), suggesting that the foci formed are 
indeed neoplastic lesions. Preneoplastic lesions in our HCC rats’ samples were found to 
have hepatocytes with altered phenotypes, including enlarged nuclei and the proliferation 
of oval cells as described by Ahn et al., 1999. These were also apparent in the L-NNA 
and L-NIL sections where GST-π staining and fibrosis are clearly seen (Figure 6.3, 2b-e). 
There is no apparent difference in the two concentrations of L-NNA used, staining 
intensity of GST-π  and appearance of fibrotic nodules are fairly equivalent to DEN-
treated rats receiving no other treatment. In L-NIL treatments, the higher L-NIL 
concentration (0.03g/L as opposed to 0.015g/L) shows more intense staining of GST-π, 
although the extent of fibrosis was similar. At the lower L-NIL concentration, GST-π 
staining was reduced. This suggests that a limited inhibition of iNOS may be able to 
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retard tumour formation, while inhibition of eNOS via L-NNA is just as ineffective as 
water in retardation of HCC progression.  
 
ISDN and molsidomine showed remarkably low staining of GST-π and fibrosis was also 
surprisingly absent (Figure 6.3, 2f-i). Livers from rats treated with the two different 
concentrations of ISDN were found to show similar low levels of GST-π when compared 
to water on DEN-treated rats. The molsidomine treated group however, appeared to have 
distinctly lower GST-π expression at the higher concentration. This data correlates well 
with those seen in the macroscopic tumour examination shown in Figure 6.2.  
 
These results, taken together, suggest that NO donors, regardless of NO release 
mechanisms, are able to attenuate neoplastic lesion formation and even allow regression 
of tumour formation in our DEN animal model. Furthermore, NO release within the liver 
by the metabolic activation of molsidomine shows more pronounced effect than the 
general NO donor, ISDN.  
 













Figure 6.4: Total NOx
-
 measured in HCC and control animals by Greiss reaction. 
Water: HCC rats with no further treatment. LNA1: L-NNA 0.1g/L treatment; LNA2: L-
NNA 0.2g/L treatment; NIL15: L-NIL 0.015g/L; NIL30: L-NIL 0.03g/L treatment; 
ISDN1: ISDN 1.25g/L treatment, ISDN2: ISDN 2.5g/L treatments; mol12: molsidomine 
0.12g/L, mol24: molsidomine 0.24g/L treatment. N= 6 for each group.  
All DEN-treated animals show elevated NOx
-
 levels when compared to the respective 
controls.  However, * indicates significant difference in NOx
-
 levels in DEN-treated rats 
when compared to normal rats the various treatments respectively, p<0.05.  # indicates 
significant difference in HCC rats with various treatments when compared to HCC rats 
with no treatments (water only), p<0.05. ‘a’ indicates significant difference when of 















































Healthy controls treated with eNOS selective inhibitor, L-NNA, showed significant 
decrease in nitrate/nitrite levels when compared to controls not further treated (Figure 
6.4). However, treatment with iNOS selective inhibitor, L-NIL, was not significantly 
from the controls receiving only water. As expected, treatment of normal rats with the 
NO donors ISDN or molsidomine, resulted in significantly elevated nitrate/nitrite levels 
when compared to controls. 
 
Nitrate/nitrite levels of DEN-treated animals with only water were elevated as expected 
(Figure 6.4) when compared to their respective controls and showed a similar level of 
NOx
-
 as those in the progression model (Figure 5.4) from the previous chapter. L-NNA 
treated HCC rats had significantly elevated nitrate/nitrite levels when compared to 
controls receiving the same inhibitors. L-NIL treatment of HCC rats, conversely, showed 
marked decrease in the nitrate/nitrite levels as compared to their respective controls. 
Treatment with NO donors on HCC rats, also resulted in higher nitrate/nitrite levels as 
compared to their controls, with the exception of molsidomine at the lower concentration.  
Interestingly, the nitrate/nitrite levels were similar in HCC animals that received only 
water and HCC animals that received NO donors. This was not true of the HCC animals 
that received NOS selective inhibitors. L-NNA and L-NIL treated HCC rats showed 
significant decrease in the nitrate/nitrite levels when compared to HCC animals.  
Treatment of HCC animals with NOS inhibitors managed to suppress nitrate/nitrite levels 
significantly. L-NNA (eNOS selective inhibitor) but not L-NIL (iNOS selective inhibitor) 
also decreased nitrate/nitrite in controls animals. This suggests that in healthy controls, 
eNOS is the main source of nitrate/nitrite. L-NIL treatment on HCC rats showed the most 
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decrease when compared to HCC rats receiving only water. This suggests that iNOS is 
the main source of nitrate/nitrite in HCC rats.  
Both NO donors showed elevated nitrate/nitrite levels when compared to their respective 
controls. This was similar to DEN-treated animals. However, the liver enzymes (AST and 
ALT), GST-π expression and liver appearance of HCC rats and with HCC rats with NO 
donor treatments, both macro- and microscopically, were significantly different. This 
suggests that the source of the NO produced might make a difference to the disease 
progression. To clarify if the increased systemic nitrate/nitrite is contributed by the liver, 
we next investigated the mRNA and protein levels of the two isoforms of NOS 

























































Figure 6.5: iNOS mRNA and protein levels in control and DEN-treated animals 
with various treatments. a) iNOS mRNA levels in HCC animals with the various 
treatments and their controls. b) iNOS protein levels in HCC animals with various 
treatments and their controls. mRNA was quantified by real-time PCR and protein by 
densitomtry readings from Western Blot as described in chapter 2.  
Water: HCC rats with no further treatment. LNA1: L-NNA 0.1g/L treatment; LNA2: L-
NNA 0.2g/L treatment; NIL15: L-NIL 0.015g/L; NIL30: L-NIL 0.03g/L treatment; 
ISDN1: ISDN 1.25g/L treatment, ISDN2: ISDN 2.5g/L treatments; mol12: molsidomine 
0.12g/L, mol24: molsidomine 0.24g/L treatment. N = 6 for each group. 
 * indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001. * indicates significant 
difference between DEN-treated animals and their respective controls. # indicates 
significant difference between DEN-treated animals with treatment and DEN-treated 












































































In the healthy control rats, treatment with NO inhibitors as well as NO donors did not 
have any effect on the iNOS mRNA or protein expression (Figures 6.5a and 6.5b). 
iNOS mRNA levels, mainly regulated at the transcriptional level (Nathan et al., 1994a), 
was significantly increased in HCC rats treated with NOS inhibitors compared to their 
respective controls (Figure 6.5a). There was no apparent dose relation observed as both 
concentrations of either L-NNA or L-NIL showed similarly high expression levels. This 
is not surprising as iNOS mRNA had been previously found to be up-regulated in various 
other tumours, including HCC (Ikeguchi et al., 2002; Kandemir et al., 2002; Peng et al., 
2003). However no difference was found in HCC rats with NO donors and their 
respective controls. In contrast, HCC rats treated with molsidomine showed significant 
decrease in iNOS mRNA expression when compared to HCC rats with no further 
treatment.  
 
While there was no difference in iNOS protein levels (Figure 6.5b) amongst control rats 
receiving the different treatments, HCC rats treated with NOS inhibitors was found to be 
show significantly increased iNOS protein expression when compared to their respective 
controls. This was apparent in HCC rats that received no further treatment as well. This 
could be attributed to the elevated mRNA transcription and possible decreased protein 
degradation. L-NNA treatment shows increase of iNOS protein levels (Figure 6.5b) 
compared to its control; at the two dosages given with similarly increased iNOS mRNA 
levels (Figure 6.5a). This suggests that increased iNOS levels could be compensating 
(Luss et al., 1994), for decreased eNOS activity caused by L-NNA (Figure 6.7b). L-NIL 
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treatment also led to enhanced iNOS protein expression. This increase is significantly 
higher iNOS protein than HCC rats without treatment. It is possible that inhibition of the 
activities of NOS by the inhibitors (Figure 6.7) led to a compensatory increase in mRNA 
and protein levels of iNOS in HCC animals.  
 
 Treatment with NO donors did not lead to any change in iNOS transcript or protein 
levels (Figure 6.5a and b). However, in comparison to HCC rats given water, NO donor 
administered HCC rats had markedly lower iNOS mRNA and protein levels. However, 
total NOx
-
 levels were markedly elevated which could be attributed to the exogenous 























































Figure 6.6: eNOS mRNA and protein levels in control and DEN-treated animals 
with various treatments. 
 a) eNOS mRNA expression levels in HCC animals with the various treatments and their 
controls. b) eNOS protein expression levels in HCC animals with various treatments and 
their controls. mRNA was quantified by real-time PCR and protein by densitomtry 
readings from Western Blot as described in chapter 2. 
Water: HCC rats with no further treatment. LNA1: L-NNA 0.1g/L treatment; LNA2: L-
NNA 0.2g/L treatment; NIL15: L-NIL 0.015g/L; NIL30: L-NIL 0.03g/L treatment; 
ISDN1: ISDN 1.25g/L treatment, ISDN2: ISDN 2.5g/L treatments; mol12: molsidomine 
0.12g/L, mol24: molsidomine 0.24g/L treatment. N = 6 for each group. 
* indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001. * indicates significant 
difference between DEN-treated animals and their respective controls. # indicates 
significant difference between DEN-treated animals with treatment and DEN-treated 





































































In healthy controls receiving the various treatments, eNOS mRNA was found to be 
significantly lowered in controls receiving NO donors (Figure 6.6a). On the other hand, 
eNOS mRNA was significantly elevated in the HCC rats when compared to their 
respective controls. 
Protein expression of eNOS was markedly increased in HCC animals with or without 
treatments (Figure 6.6b) when compared to their respective controls. Since eNOS is 
mostly regulated post-translationally (Alderton et al., 2001), the lack of correlation 
between transcript and protein is not critical. Unlike iNOS, the various treatments did not 
affect eNOS protein expression in HCC animals.  
This indicates that in spite of NOS inhibition or an exogenous source of NO, the liver 
nonetheless showed an increase in eNOS protein. This suggests that NO generated from 
eNOS may play a more prominent role in terms of disease progression.  
Hence, to determine if iNOS or eNOS is relevant in disease progression, the activity of 


















































Figure 6.7: NOS activity of HCC as a percentage of their respective controls. 
a) shows the iNOS activity levels in HCC animals with the various treatments and their 
controls. b) shows eNOS activity levels in HCC animals with various treatments and their 
controls.  
 * represents significant difference between DEN-treated and the respective control of the 
various treatment groups; # represents significant difference between HCC animals with 
and without treatments; a represent significant difference between the controls with 
treatment compared to controls without (water). Significance is taken when p < 0.05. 
Water: HCC rats with no further treatment. LNA1: L-NNA 0.1g/L treatment; LNA2: L-
NNA 0.2g/L treatment; NIL15: L-NIL 0.015g/L; NIL30: L-NIL 0.03g/L treatment; 
ISDN1: ISDN 1.25g/L treatment, ISDN2: ISDN 2.5g/L treatments; mol12: molsidomine 





















































From Figure 6.7a, is can be seen that control animals administrated with the various 
treatments showed no difference with the control group receiving water. The only 
exception was the control group that was given L-NIL at the higher concentration 
(0.03g/L).  
Corresponding to its protein expression (Figure 6.6a), iNOS generally shows high levels 
of activity in the water and NOS inhibitor HCC groups when compared to their controls 
(Figure 6.7a).  
As expected, L-NIL treatments on HCC animals suppressed iNOS activity significantly 
when compared to untreated HCC animals. L-NNA at the higher concentration of 0.2g/L 
also showed significant decrease in iNOS activity. This could be due to the highly similar 
3-D structures between the two isoforms that allowed L-NNA to exert a negative effect 
on iNOS activity. However, due to the selective nature of the inhibitor, the non-specific 
inhibition was observed only at the higher concentration and with a less pronounced 
effect than its intended target.  
iNOS activity was also substantially reduced in HCC rats with NO donor treatments as 
compared to untreated HCC rats. Exogenous NO from the two NO donors appeared to 
have acted in a negative feedback fashion and suppressed iNOS activity (Alderton et al., 
2001). 
eNOS activity was reduced significantly in healthy animals treated with L-NNA when 
compared to healthy animals without further treatment (Figure 6.7b). Healthy animals 
with 0.03g/L L-NIL treatment were also found to show reduced eNOS activity. Again, 




Marked reduction of eNOS activity was observed in untreated HCC when compared to 
the corresponding control. Other HCC animals showed comparable eNOS activity levels 
with their respective controls.  
The significant reduction of eNOS activity upon treatment with L-NNA, even in controls, 
suggest that eNOS is essential in normal rats. The reduced eNOS activity in HCC animals 
suggest a dysfunction of eNOS is affected by the onset of HCC.  
Thus far, our data suggest that NO is essential in the delay or prevention of DEN-induced 
carcinogenesis. DEN-treated groups administered with NO donors show the most 
similarities to normal controls, while DEN-treated animals administered NOS inhibitors 
fared similarly to those without treatment. Yet high levels of iNOS and iNOS activity 
alone is not able to effect this delay or prevention. This information, coupled with the 
observation of reduced eNOS activity in HCC animals, suggests that NO specifically 
from eNOS is vital in the delay of progression or prevention of HCC in our animal 
model. However, despite eNOS protein expression being consistently higher in HC 
groups than their controls, the activity is lower or not different from that of the controls. 
To understand this discrepancy between high eNOS protein expression and yet low 
activity, we further analyzed the common endogenous regulators of NOS protein: 


















































































































Figure 6.8: Western blot results of caveolin-1, Rac2 and sGC protein levels in DEN 
treated animals expressed as a percentage against controls.  
Water: HCC rats with no further treatment. LNA1: L-NNA 0.1g/L treatment; LNA2: L-
NNA 0.2g/L treatment; NIL15: L-NIL 0.015g/L; NIL30: L-NIL 0.03g/L treatment; 
ISDN1: ISDN 1.25g/L treatment, ISDN2: ISDN 2.5g/L treatments; mol12: molsidomine 
0.12g/L, mol24: molsidomine 0.24g/L treatment. 
* denotes significant difference between DEN-treated and the respective control of the 
various treatment groups; # represents significant difference between HCC animals with 





Caveolin-1 is a known negative-regulator of eNOS  activity (Feron et al., 1998; 
Goligorsky et al., 2002a). Its high expression in HCC has been noted in both 
experimental and patient tumours (Hon et al., 2002). In control groups, the administration 
of the NOS inhibitors or NO donors did not affect the protein expression of Caveolin-1. 
As such, the decrease of eNOS activity found in control samples treated with L-NNA 
(Figure 6.7b) is more likely to be attributed to the effects of L-NNA than caveolin-1. 
Caveolin-1 protein expression was markedly elevated in all HCC rats compared against 
their control, regardless of treatment (Figure 6.8a). Thus, it is likely that the high levels of 
caveolin-1 negatively regulates eNOS activity (Yokomori et al., 2003), resulting in 
lowered eNOS activity in spite of high eNOS protein levels in our model. The elevated 
mRNA and protein levels of eNOS in HCC samples as compared to controls may also be 
a compensatory response to the repression of eNOS activity by caveolin-1. This was 
apparent even in the NO donor treatment groups, where elevated caveolin-1 also 
repressed eNOS activity levels to levels similar to the controls. In spite of this, NO donor 
groups showed significantly less caveolin-1 expression than HCC rats treated with water 
(Figure 6.8a).  
 
Rac2, has been found to interact with iNOS and modulate its activity positively 
(Kuncewicz et al., 2001; Zhang et al., 2003). Across the controls with various treatments, 
no change in Rac2 levels was noted. However, Rac2 showed increased expression 
(Figure 6.8b) for DEN-treated rats compared against control and this corresponds to the 
high iNOS activity observed in this study (Figure 6.7a) as well as in previous studies 
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(Kone, 2000; Kone et al., 2003a). The increase in Rac2 expression is also observed in 
HCC rats treated with NOS inhibitors and as expected, the presence of the L-NIL 
(0.03g/L) could effective overcome the activation of iNOS by Rac2. This correlation of 
our findings is also seen in the HCC animals administered NO donors. Both iNOS 
activity (Figure 6.7a) and Rac2 levels (Figure 6.8b) show marked reduction of HCC 
animals with NO donor treatments when compared to HCC animals without further 
treatment. This could be in part due to the negative feedback by exogenous NO. Another 
plausible reason could be the low protein expression and availability of iNOS in HCC 
rats receiving NO donors as shown previously in Figure 6.5a and b. 
 
sGC, an effector molecule of NO (Russwurm et al., 2004; Schmidt et al., 1993), was 
found to be similar in DEN-treated rats and healthy controls (Figure 6.8c). This is in 
agreement with results from the human samples in previous chapters, where sGC was 
found to remain unchanged in HCC patients, but elevated in secondary and HBV-infected 
HCC. This implies that the regulation of sGC levels is altered in the development of 
secondary HCC. In our model of primary HCC, sGC expression was not altered during 
the progression or the subsequent intervention with NOS inhibitors or donors. This 
suggests that sGC may not play a prominent role in primary HCC development or 
progression. Or that change to its expression is not part of the progression of HCC.  
 
Taken together, our results suggest that NO has a protective function in the progression 




Supplying exogenous NO either systematically or directed to the liver, was able to reduce 
conventional markers of carcinogenesis.  
Conversely, suppression of eNOS by L-NNA, an eNOS selective inhibitor, led to 
elevated liver mass, malignant growth foci and high expression of GST-π, all indicative 
of HCC formation and progression. However, in DEN-treated rats, high levels of 
caveolin-1 could also negatively regulated eNOS activity, resulting in similar eNOS 
activity in water and L-NNA treatment groups. eNOS activity in the other treatment 
groups were clearly higher than in these two groups. Suppression of eNOS activity by L-
NNA could also exacerbate iNOS activity in the L-NNA treatment group.  
 
In most HCC animal models, chronic inflammation is the main cause of carcinogenesis 
and the main culprit of inflammation is iNOS (Kawanishi et al., 2006). This is coupled 
with findings of elevated nitrate/nitrite and iNOS mRNA and protein in various cancers 
including colon, breast and liver (Moriyama et al., 2000; Reveneau et al., 1999; Sandes et 
al., 2005; Schleiffer et al., 2000).  Conventionally, inhibition of iNOS was applied to 
alleviate nitrosative and oxidative stress brought about by inflammation (Kawamori et 
al., 2000; Rao et al., 2002).  
In our model, inhibition of iNOS by L-NIL showed some improvement in terms of 
decreased GST-π staining at the lower concentration of L-NIL used but not at the higher 
concentration. From the total NOx
-
 and iNOS activity data, it is apparent that iNOS is 
mainly responsible for NO overproduction in our experimental paradigm. Although iNOS 
activity is reduced with L-NIL treatment, it did not improve the outcome of disease 
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progression. Thus, the inhibition of eNOS or iNOS alone was not able to retard or halt 
disease progression. 
Contrary to the above, NO donors, ISDN and molsidomine, showed vast improvement in 
retarding and attenuating foci development. Visible foci were nearly completely missing 
from these groups, and GST- π staining was also dramatically reduced in all 
concentrations of the two NO donors tested. This concurs with a lack of increased liver 
mass and mostly normal liver enzyme profile. Generally, the NO donor recipients show 
significantly lowered iNOS activity and at the same time, significantly higher cNOS 
activity than the other groups.  
 
The results, taken together, leads us to conclude that eNOS plays a protective role for the 
host during tumour formation induced by a chemical carcinogen. In fact, eNOS has also 
been found to exert a protective effect in other diseases (Heeringa et al., 2002; Schoen et 
al., 2001). This should couple with some iNOS inhibition as iNOS is the source of the 
NO overproduction found in our and other HCC models (Ahn et al., 1999; Sun et al., 
2005). However, only inhibiting iNOS is not sufficient therapeutically as our model 
shows. This may explain some contradictory findings of iNOS inhibitors (Crowell et al., 
2003; Lala et al., 1998; Schleiffer et al., 2000) and NO donors (Hussain et al., 2004; 
Rigas et al., 2004; Xu et al., 2001a) in various HCC experimental models (Hon et al., 
2002; Nishikawa et al., 2004).  
 
Much research has gone into explaining how NO from iNOS, due to chronic infection 
and inflammation, leads to cancer formation. However, in our model DEN caused 
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alkylation of DNA, leading to mutagenesis and eventual carcinogenesis. In this method, 
elevated iNOS was also found. Conventionally, inhibiting iNOS was thought to reduce 
inflammation-derived neoplasms (Crowell et al., 2003; Rao et al., 2002). This contradicts 
the findings that NO donors have a beneficial role to play in cancer therapy. The NO 
produced by eNOS could be protective due to the low levels produced (in pmoles) and 
due its location of production. eNOS is a membrane-bound enzyme. Its activity is 
dependent upon shear stress and other post-translational modifications such as membrane 
attachment. Since elevated caveolin-1 in HCC suppresses this activity, it is possible that 
the exogenous NO donors compensate for this. How cancer cells selectively inhibit eNOS 
through over-expression of caveolin-1 remains to be elucidated. More importantly, how 
low sustained levels of NO from eNOS or exogenous NO donors is able to exert a 
protective effect must be determined, as this has interesting therapeutic implications. 
However, this effect is only shown in liver cancer without prior infection by HBV. It 
remains to be seen if iNOS inhibition coupled with NO donor can delay tumourigenesis 















In this thesis, I have examined the roles of NOS in disease progression of HCC. A 
preliminary microarray analyses provided an overview of gene profiles of the various 
human liver pathologies examined. From these results it was possible to observe different 
profiles belonging to the different etiologies of liver disease. In summary, changes in 
expression levels of Calmodulin, HGFA, HGF, IGF2, IGFBP3, iNOS, NTN, NTN2L 
were initially identified by microarray and subsequently confirmed with real time 
quantitative PCR. To address the shortfalls of the microarray studies on the patient 
samples, it is clear that the number of samples analysed and confirmation with real time 
quantitative PCR must be larger. Apart from up-regulated genes, down-regulated genes 
should also be analysed. A particularly confounding aspect of our analysis is the low 
availability of normal samples. With more living donor transplants taking place, it may 
be possible to obtain more normal samples. Alternatively, non-tumourous regions excised 
from areas surrounding tumours have been used for comparisons in many studies 
(Ishikawa et al., 2003; McNaughton et al., 2002; Mohammed et al., 2003). These non-
tumourous sections are more often then not diseased with underlying cirrhosis or fibrosis. 
As such, comparisons with diseased tissues remain inconclusive as these are not 
representative of true normals.  
 
NO and NOS were further studied in greater detail in human samples. All the liver 
pathologies under investigation showed elevated NO and NOS to varying degrees, 
confirming previous reports (Ambs et al., 1998; Franco et al., 2004; Hon et al., 2002; 
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Lala et al., 2001). NOS activity and regulatory elements of NOS were also analysed. 
Increased caveolin-1 could depress eNOS activity (Goligorsky et al., 2002a) while 
increased Rac2 enhances iNOS activity (Kone et al., 2003b; Kuncewicz et al., 2001). 
sGC levels on the other hand, remained unchanged. It would be useful to study the 
activity levels of sGC as well. Although expression levels show no change, its activity 
level and implications in HCC progression is as yet unknown.  
 
Another limitation is that human samples are inevitably available only in the later stages 
of the disease. As such, understanding how NO is involved in the progression of HCC 
must be investigated by a manipulatable animal model.  
Animal models of HCC have conventionally studied how chronic inflammation through 





















Figure 7.1. Overview of the development of HCC.   
a) chronic infection with hepatitis B or C could lead to unabated inflammation and 
fibrosis, eventually leading up to cancer formation 
b) chemical carcinogens which, through alkylation, could result in the development 

















Establishing a HCC model that mimics human disease as closely as possible is essential if 
the information learned is to be relevant to humans. To this effect, we utilized an 
alkylating agent, DEN, which caused the development of neoplasms with a cirrhotic 
background in the liver (Figure 7.1b) As with the human samples, NO and NOS were 
found to be elevated in the later stages during the progression towards neoplasm. 
Interestingly, after 10 weeks of DEN treatment, a divergence in NO and NOS levels was 
observed. It was also determined through visualization of loci on liver surfaces, and 
through GST-π staining in liver sections, that neoplastic lesions are well established by 
this time point. Hence, we had selected the time point of 10 week DEN treatment for 
subsequent studies of intervention with NOS inhibitors and NO donors. The general 





















  ↑ - ↑ - 
iNOS mRNA ↑ ↑ ↑ - 
          Protein ↑ ↑ ↑ - 
          Activity ↑ - ↑ ↑ 
Rac2 - ↑ ↑ ↑ 
eNOS mRNA ↑ - - - 
           Protein ↑ - - - 
           Activity ↓ ↓ ↑ ↑ 
Caveolin-1 ↑ ↑ - - 
sGC - - ↑ ↑ 
 
 
b) 10 WEEKS den 
+ WATER# 
10 WEEKS DEN + 
nos INHIBITORS^ 
10 WEEKSN den + 
NO DONORS^ 
Visible Foci ↑ - ↓ 
GST-π ↑ - ↓ 
NOx
-
  ↑ ↓ - 
iNOS mRNA ↑ - - 
          Protein ↑ - - 
          Activity ↑ - ↓ 
Rac2 ↑ ↑ ↓ 
eNOS mRNA ↑ ↓ ↑ 
           Protein ↑ - - 
           Activity ↓ - ↑ 
Caveolin-1 ↑ ↓ ↓ 
sGC - - - 
Table 7.1. Summary of our findings. 
A) shows NOx
-




, iNOS and eNOS increases in animals during the progression of 
neoplastic lesions. #This model was compared to the respective time point controls 
without DEN treatment. ^ These experimental models were compared to 10 weeks DEN-





By administering NO donors and NOS inhibitors after 10 weeks of DEN treatment, we 
were able to observe the effects these had on the development and progression of 
neoplastic foci. Since NO levels were increased in HCC and in the rat model, it seems 
intuitive to believe that inhibiting NOS would alleviate or delay the progression of 
neoplastic lesions. Unexpectedly, it was the NO donor treatments that showed a 
remarkable regression of the neoplastic phenotype after 10 weeks of DEN administration. 
While our findings raise the potential of NO donors as a treatment option, several 
questions remained unanswered.  
 
How NO is able to delay or prevent lesion formation and progression is an important 
point that should be further investigated. Possible methods could include labeling of NO 
donors and identifying the cellular components that interact with NO released from the 
labeled donors. Our results suggest that caveolin-1 suppression of eNOS activity may 
play a role in lesion formation. Hence, it would be interesting to see if removing the 
inhibition imposed on eNOS by caveolin-1 has the same effect as NO donor 
administration.  
 
Diagnostic technologies and methods to detect early stage liver tumours have yet to be 
fully developed. As such, patients are often diagnosed only at later stages. Thus, it would 
be imperative to learn when NO would be effective in reversing or delaying HCC 
progression. Using our experimental paradigm, DEN treatment could be continued for up 
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to 12 or 14 weeks before NO donor intervention commences. Again, the duration and 
concentration of the reagents used must be refined.  
 
Other studies have shown that iNOS inhibitors are able to limit damage done by 
excessive NO production in various cancers (Malone et al., 2006; Takahashi et al., 2006) 
and cirrhosis (Islas-Carbajal et al., 2005; Wei et al., 2005b). Immunohistochemistry of 3-
nitrotyrosine, a common marker for the nitration of tyrosine residues by peroxynitrite, 
was indeed performed (data not shown). We found that DEN treatment resulted in some 
amount of 3-nitrotyrosine staining in liver sections. Reactive nitrogen species such as 
peroxynitrite, are main inducers of cirrhosis. As such, combinations of iNOS inhibitors 
and NO donors should be explored as potential therapeutics. 
 
Our study used a chemical carcinogen model to develop HCC. Other models such as 
orthotropic tumours (i.e. implanting tumour cells from humans into animals) should be 
tested in future with NO donors as a treatment strategy. This would show if exogenous 
NO is only effective in our chosen model or if the mechanism transcends the etiology of 
other animal models of liver cancer.  
 
By pursuing these other avenues of investigation, the myriad roles of NO in the 
progression of HCC may be clarified.  Such an understanding would hold us in good 
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Appendix A:  






ID Short Gene Name 
Fold 
Difference Long Gene Name 
E01408 
Manganese superoxide 
dismutase 1433.62 Manganese superoxide dismutase 
AB003333 HSP105 beta 339.67 HSP105 beta 
U94728 Calmodulin 176.49 Calmodulin (CALM2) 
M19720 L-myc 151.17 L-myc proto-oncogene 




Gamma-aminobutyric acid (GABA) A 
receptor, alpha 4 
NM_006002 Ubiquitin Thiolesterase 84.84 Ubiquitin Thiolesterase 
X51688 Cyclin A 84.40 Cyclin A 
J04536 CD43 83.33 Sialophorin (CD43) 
U01839 Duffy blood group 77.63 Duffy blood group antigen 
AF043254 HSP75 67.50 Heat shock protein 75 
M19233 Alpha-amylase-1 64.09 Alpha-amylase-1 
M93255 Fli-1 62.87 Friend leukemia virus integration 1 
K03214 C-src 61.59 C-SRC-1 proto-oncogene 
L78440 STAT4 61.10 
Signal transducer and activator of 
transcription 4 (STAT4) 
NM_001740 CALB2 61.00 Calretinin; calbindin 2 
Z23115 Bcl-xL  58.08 BCL2-like 1 
AB031042 Lhx6 56.60 LIM-homeodomain (LHX) protein 6.1b 
X16316 VAV 1 54.02 Vav 1 oncogene 
NM_004929 CALB1 50.92 calbindin 1 
AF015956 
Death Associated 
protein 6 49.15 Death associated protein 6 (DAXX) 
NM_000433 NCF2 49.06 Neutrophil cytosolic factor 2 
X06182 C-kit 49.03 C-kit proto-oncogene 
L24038 A-raf 48.18 
V-raf murine sarcoma 3611 viral 
oncogene homolog 1; A-RAF1 
M33294 TNF-R1 46.67 Tumor necrosis factor receptor I 
L01087 PRKCT 43.99 
Protein Kinase C Protein Kinase C 
Theta Protein kinase C-theta; PRKCT 
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M15990 C-yes-1 43.95 
V-yes-1 Yamaguchi sarcoma viral 
oncogene homolog 1; C-yes-1 
AF007871 TorsinA 43.45 Dystonia 1; torsin A 
NM_004822 Netrin-1 41.31 Netrin 1 
NM_000816 
GABA (A) receptor 
gamma 2 40.35 
Gamma-aminobutyric acid (GABA) A 
receptor, gamma 2 
S82769 
GABAA receptor 
gamma 3 subunit 39.35 GABAA receptor gamma 3 subunit 
M16660 90-kDa HSP 36.55 90-kDa heat-shock protein 1, beta 
X63368 HSJ1 36.46 
Heat shock protein, neuronal DNAJ-
like 1 
NM_000227 LAMA3 35.66 
Laminin, alpha 3 (nicein (150kD), 
kalinin (165kD) 
AB008775 Aquaporin 9 35.01 Aquaporin 9 
D38048 Proteasome Z Subunit 33.92 
Proteasome (prosome, macropain) 




Gamma-aminobutyric acid (GABA) A 
receptor, alpha 6 
U47686 STAT5B 33.72 
Signal transducer and activator of 
transcription Stat5B 
X54079 HSP27 32.34 Heat shock protein HSP27 
M31165 TSG-6 32.30 




gamma 3 subunit 31.28 GABAA receptor gamma 3 subunit 
J02966 ANT1 31.25 
Adenine nucleotide translocator 1 
(skeletal muscle) 
NM_004822 Netrin-1 29.46 Netrin 1 
M87503 IFNRTF 29.18 
Interferon-alpha (IFN) responsive 
transcription factor subunit 
NM_005528 HSPF2 29.10 Heat shock 40kD protein 2; HSPF2 
L09210 
Inducible nitric oxide 
synthase 29.04 Inducible nitric oxide synthase 
Z11933 N-oct3 28.95 
POU domain, class 3, transcription 
factor 2 
U15590 HSPB3 28.88 Heat shock 17kD protein 3 (HSPB3) 
L35253 MAPK 14 28.02 Mitogen-activated protein kinase 14 
X98801 Dynactin 27.92 
Dynactin (p150, Glued (Drosophila) 
homolog) 




Hsp27 ERE-TATA-binding protein 
(HET); Scaffold attachment factor B 
NM_000426 LAMA2 27.48 Laminin, alpha 2 precursor 
NM_004419 DUSP5 27.15 Dual specificity phosphatase 5 
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D38048 Proteasome Z Subunit 27.04 
Proteasome (prosome, macropain) 
subunit, beta type, 7 
U00568 
Immunoglobulin heavy 
chain variable region 26.19 
Immunoglobulin heavy chain variable 
region 
D14520 BTEB2 25.71 
Basic transcription element-binding 
protein 2 (BTEB2) GC-Box binding 
protein 
L12002 Integrin-alpha IV 25.14 Integrin alpha 4 subunit 
NM_000816 
GABA (A) receptor 
gamma 2 25.11 
Gamma-aminobutyric acid (GABA) A 
receptor, gamma 2 
M60854 Ribosomal protein S16 24.66 Ribosomal protein S16 
L19067 P65 24.56 
V-rel avian reticuloendotheliosis viral 
oncogene homolog A (nuclear factor of 
kappa light polypeptide gene enhancer 
in B-cells 3 (p65) 
X07270 HSP86 24.46 Heat shock protein HSP86 
U43188 NERF2 24.20 New Ets-related factor NERF2 
AF002697 BNip3 24.19 
BCL2/adenovirus E1B 19kD-
interacting protein 3 
X54079 HSP27 23.83 Heat shock protein HSP27 
D38048 Proteasome Z Subunit 23.67 
Proteasome (prosome, macropain) 
subunit, beta type, 7 
M99487 
Prostate-specific 
membrane antigen 23.62 
Prostate-specific membrane antigen 
(PSM) 
U96876 
Insulin induced protein 
1 23.43 Insulin induced protein 1 
AF028832 Hsp89-alpha-delta-N 23.36 Hsp89-alpha-delta-N 
X66079 Spi-B 23.07 Spi-B transcription factor 




Gamma-aminobutyric acid (GABA) A 
receptor, alpha 2 
L35253 MAPK 14 22.34 Mitogen-activated protein kinase 14 
L26318 JNK1 22.32 
JNK1; Mitogen-activated protein 
kinase 8 
NM_004929 CALB1 22.29 calbindin 1 
M55284 Protein Kinase C-L 22.14 Protein kinase C-L 
L06622 Endothelin-1 receptor 21.92 Endothelin receptor type A 
M81601 
Transcription 
elongation factor SII 21.35 Transcription elongation factor (SII) 
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X01677 GAPDH 20.71 
Glyceraldehyde-3-phosphate 
dehydrogenase 
M26760 ALDH-2 20.61 
Aldehyde dehydrogenase 2, 
mitochondrial 
AB031042 Lhx6 20.59 LIM-homeodomain (LHX) protein 6.1b 
M62810 
Mitochondrial 
transcription factor 1 19.56 Mitochondrial transcription factor 1 




Gamma-aminobutyric acid (GABA) A 
receptor, alpha 3 
AF129085 CHIP 19.14 
Carboxy terminus of Hsp70-interacting 
protein; CHIP 
NM_004929 CALB1 19.12 calbindin 1 
NM_006002 Ubiquitin Thiolesterase 18.63 Ubiquitin Thiolesterase 
S76992 VAV 2 18.44 VAV oncogene homolog 
L24038 A-raf 18.28 
V-raf murine sarcoma 3611 viral 
oncogene homolog 1; A-RAF1 
NM_000815 
GABA (A) receptor 
delta 1 18.24 
Gamma-aminobutyric acid (GABA) A 
receptor, delta 
D49547 HSP-40 18.21 Heat-shock protein 40 
M55284 Protein Kinase C-L 17.88 Protein kinase C-L 
U94728 Calmodulin 17.82 Calmodulin (CALM2) 
X06820 RhoB 17.75 RhoB 
NM_002290 LAMA4 17.72 Laminin alpha 4 
L31951 JNK2 17.64 
Mitogen-activated protein kinase 9; 
JNK2 
NM_000831 GRIK3 17.57 
Glutamate receptor, ionotropic, kainate 
3 




Gamma-aminobutyric acid (GABA) A 
receptor, alpha 3 
AJ236921 GRM8 17.30 Metabotropic glutamate receptor 8 
U29680 
BCL2-related protein 
A1 17.21 BCL2-related protein A1; Bfl-1; GRS 
L09159 Rho 16.96 
Ras homolog gene family, member A; 
Rho 
NM_001196 BID 16.83 BH3 interacting domain death agonist 
X06182 C-kit 16.78 C-kit proto-oncogene 
K03214 C-src 16.47 C-SRC-1 proto-oncogene 
Z29083 5T4 16.33 5T4 oncofetal trophoblast glycoprotein 
186 
 
Z11933 N-oct3 16.31 
POU domain, class 3, transcription 
factor 2 
L09210 
Inducible nitric oxide 
synthase 16.29 Inducible nitric oxide synthase 
X52192 C-fes 15.97 C-fes proto-oncogene 
K03195 HEPG2 15.97 
Solute carrier family 2 (facilitated 
glucose transporter), member 1 
X60188 Erk1 15.94 
Serine/threonine kinase; Mitogen-
activated protein kinase 3 
J04111 C-jun 15.93 
Transcription factor AP-1; c-jun proto 
oncogene 
U85658 ERF-1 15.89 
AP2 gamma (ERF-1) transcription 
factor 
M36542 OCTF2 15.73 Octamer-binding transcription factor 2 
M81601 
Transcription 
elongation factor SII 15.66 Transcription elongation factor (SII) 
Z71389 Beta-defensin 2 15.57 Beta-defensin 2 
Y11416 P73 15.48 Tumor protein P73 
M21616 PDGFRB 15.44 
Platelet-derived growth factor receptor, 
beta 
M30640 ELAM1 15.36 
Selectin E; Endothelial leukocyte 
adhesion molecule 1 
M55284 Protein Kinase C-L 15.35 Protein kinase C-L 
J02966 ANT1 15.32 
Adenine nucleotide translocator 1 
(skeletal muscle) 
D14520 BTEB2 15.32 
Basic transcription element-binding 
protein 2 (BTEB2) GC-Box binding 
protein 
M61916 LAMB1 15.30 Laminin B1 
M60854 Ribosomal protein S16 15.29 Ribosomal protein S16 
NM_004134 Mortalin-2 15.22 
Heat shock 70kD protein 9B; mortalin-
2; HSPA9B 
U15131 ST5 15.21 Suppression of tumorigenicity 5 
X63368 HSJ1 15.17 
Heat shock protein, neuronal DNAJ-
like 1 
X02811 PDGFB 15.16 Platelet-derived growth factor beta 
NM_001538 HSF4 15.07 Heat shock transcription factor 4 
NM_000843 GRM6 14.92 Glutamate receptor, metabotropic 6 
NM_000812 
GABA (A) receptor 
beta-1 14.92 
Gamma-aminobutyric acid (GABA) A 
receptor, beta 1 
Z70519 CD95 14.84 
FAS/Apo 1; CD95;Tumor necrosis 
factor receptor superfamily, member 6 
AF088982 HSP40-3 14.77 Heat shock protein hsp40-3 
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L24038 A-raf 14.77 
V-raf murine sarcoma 3611 viral 
oncogene homolog 1; A-RAF1 
AF143315 PTEN 14.66 PTEN 
M93255 Fli-1 14.62 Friend leukemia virus integration 1 
M13975 
Protein Kinase C Beta 
II  14.59 Protein kinase C beta-II 
X56773 IGF-I 14.38 
Insulin-like growth factor 1 
(somatomedin C) 
D14012 HGF activator 14.30 
Hepatocyte growth factor (HGF) 
activator precursor 
M95712 B-raf 14.23 
V-raf murine sarcoma viral oncogene 
homolog B1; B-raf 
M59828 HSP70-1 14.21 MHC class III HSP70-1 
AF129085 CHIP 14.20 
Carboxy terminus of Hsp70-interacting 
protein; CHIP 
AF020760 OMI 14.16 Serine protease; OMI 
L31951 JNK2 14.13 
Mitogen-activated protein kinase 9; 
JNK2 




Gamma-aminobutyric acid (GABA) A 
receptor, alpha 6 
NM_001165 API2 13.85 Apoptosis inhibitor 2 
U33052 PRK2 13.84 Lipid-activated protein kinase PRK2 
X01677 GAPDH 13.76 
Glyceraldehyde-3-phosphate 
dehydrogenase 
NM_000227 LAMA3 13.54 
Laminin, alpha 3 (nicein (150kD), 
kalinin (165kD) 
X74142 BF-1 13.31 transcription factor BF-1 
M60854 Ribosomal protein S16 13.30 Ribosomal protein S16 
S82769 
GABAA receptor 
gamma 3 subunit 13.24 GABAA receptor gamma 3 subunit 
L06801 IL13 13.24 Interleukin 13 
L12002 Integrin-alpha IV 13.17 Integrin alpha 4 subunit 
U01134 VEGFR1 13.09 
Vascular endothelial cell growth factor 
receptor 
K03195 HEPG2 13.01 
Solute carrier family 2 (facilitated 
glucose transporter), member 1 
U75898 
Heat shock 27kD 
protein 2 12.91 Heat shock 27kD protein 2 
NM_000227 LAMA3 12.83 
Laminin, alpha 3 (nicein (150kD), 
kalinin (165kD) 
L19067 P65 12.82 
V-rel avian reticuloendotheliosis viral 
oncogene homolog A (nuclear factor of 
kappa light polypeptide gene enhancer 
in B-cells 3 (p65) 
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X16707 Fra-1 12.78 Fra-1; Fos-Related Antigen 1 
X63368 HSJ1 12.63 
Heat shock protein, neuronal DNAJ-
like 1 
U11732 Ets-like 12.61 Ets variant gene 6 (TEL oncogene) 
AF043254 HSP75 12.59 Heat shock protein 75 
L31951 JNK2 12.57 
Mitogen-activated protein kinase 9; 
JNK2 
X07270 HSP86 12.54 Heat shock protein HSP86 
NM_000426 LAMA2 12.54 Laminin, alpha 2 precursor 
X01394 TNF 12.53 Tumor necrosis factor 
M26760 ALDH-2 12.53 
Aldehyde dehydrogenase 2, 
mitochondrial 
NM_005526 HSF1 12.33 Heat shock transcription factor 1 
M91083 HRC1 12.31 
Chromosome 11 open reading frame 
13; DNA-binding protein (HRC1) 
NM_000816 
GABA (A) receptor 
gamma 2 12.22 
Gamma-aminobutyric acid (GABA) A 
receptor, gamma 2 
X02317 SOD 12.09 
Superoxide dismutase 1, soluble 
(amyotrophic lateral sclerosis 1 (adult)) 
U15306 NFX1 12.04 
Cysteine-rich sequence-specific DNA-
binding protein NFX1 
M95809 BTF2 12.03 
Basic transcription factor 62kD subunit 
(BTF2) 
U96876 
Insulin induced protein 
1 11.99 Insulin induced protein 1 
M21574 PDGFRA 11.95 
Platelet-derivied growth factor 
receptor, alpha 
AB031042 Lhx6 11.85 LIM-homeodomain (LHX) protein 6.1b 
D14520 BTEB2 11.72 
Basic transcription element-binding 
protein 2 (BTEB2) GC-Box binding 
protein 
Z11933 N-oct3 11.72 
POU domain, class 3, transcription 
factor 2 
X76132 DCC 11.71 Deleted in colorectal carcinoma 
J04536 CD43 11.71 Sialophorin (CD43) 
M91083 HRC1 11.67 
Chromosome 11 open reading frame 
13; DNA-binding protein (HRC1) 
X06234 Calgranulin A 11.58 
S100 Calcium-binding protein A8 
(calgranulin A) 
U14680 BRCA 1 11.56 Breast and ovarian cancer susceptibility 
M96577 E2F1 11.44 E2F transcription factor 1 
M87290 Angiotensin receptor I 11.44 ANGIOTENSIN II RECEPTOR type 1 
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K03222 TGF-alpha 11.43 Transforming growth factor-alpha 
S76992 VAV 2 11.41 VAV oncogene homolog 
L16464 ETS oncogene 11.39 ETS oncogene (PEP1) 
M97935 STAT1 11.30 
Signal transducer and activator of 
transcription 1 
AF043254 HSP75 11.20 Heat shock protein 75 
M15990 C-yes-1 11.18 
V-yes-1 Yamaguchi sarcoma viral 
oncogene homolog 1; C-yes-1 
NM_006597 HSC71 11.16 
Heat shock 70kD protein 10; HSC71; 
HSPA10 
U01839 Duffy blood group 11.14 Duffy blood group antigen 
J03358 FER 11.14 
Fer (fps/fes related) tyrosine kinase 
(phosphoprotein NCP94) 
M13228 N-myc 11.10 N-myc oncogene 
U43746 BRCA2 11.05 
Breast cancer susceptibility (BRCA2) 
gene 
AB017167 SLIT1 10.96 Slit-1 
AF088982 HSP40-3 10.95 Heat shock protein hsp40-3 
L09159 Rho 10.90 
Ras homolog gene family, member A; 
Rho 
AF064019 CAD 10.85 
DNA fragmentation factor, 40 kD, beta 
subuni 
AB011421 DRAK2 10.84 
Serine/threonine kinase 17b (apoptosis-
inducing) 
D26156 BRG1 10.82 
SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily a, member 4 
U35113 
Metastasis Associated 
MTA1 10.80 Metastasis-associated protein MTA1 
NM_001165 API2 10.79 Apoptosis inhibitor 2 
NM_000814 
GABA (A) beta 3 
receptor 10.78 
Gamma-aminobutyric acid (GABA) A 
receptor, beta 3 
AF047386 
Telomerase RNA 
subunit 10.75 Telomerase RNA subunit 
AF174487 BOK 10.71 
BCL-2-related ovarian killer protein; 
BOK 
NM_000426 LAMA2 10.67 Laminin, alpha 2 precursor 
U60519 Caspase-10 10.62 
Caspase 10, apoptosis-related cysteine 
protease 
K03214 C-src 10.39 C-SRC-1 proto-oncogene 
M23452 MIP1-ALPHA 10.37 
Macrophage inflammatory protein; 
Small inducible cytokine A3 
(homologous to mouse Mip-1a) 
U10149 HSPA-2 10.34 heat shock protein; HSPA-2 
M59828 HSP70-1 10.32 MHC class III HSP70-1 
U33841 ATM 10.27 Ataxia telangiectasia gene 
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M97935 STAT1 10.26 





Hsp27 ERE-TATA-binding protein 
(HET); Scaffold attachment factor B 
X67951 PAG-A 10.26 
Proliferation-associated gene A (natural 
killer-enhancing factor A) 
AB023420 APG-2 10.11 
Heat shock protein apg-2; HS24/p52; 
hsp70 
X60003 Delta CREB1 10.10 
Delta CREB ; cAMP-responsive 
element binding 
NM_000831 GRIK3 10.02 
Glutamate receptor, ionotropic, kainate 
3 
M21574 PDGFRA 9.97 
Platelet-derivied growth factor 
receptor, alpha 
D10495 
Protein Kinase C delta 
2 9.91 Protein kinase C delta 
M74178 HGFL 9.82 
Macrophage stimulating 1 (hepatocyte 
growth factor-like) 
U25278 Erk5 9.74 ERK5 
M60278 
Heparin-binding 
epidermal growth factor 9.74 
Diphtheria toxin receptor (heparin-
binding epidermal growth factor-like 
growth factor) 
M30640 ELAM1 9.74 
Selectin E; Endothelial leukocyte 
adhesion molecule 1 
U85658 ERF-1 9.72 
AP2 gamma (ERF-1) transcription 
factor 
NM_005526 HSF1 9.71 Heat shock transcription factor 1 
M93255 Fli-1 9.68 Friend leukemia virus integration 1 
D10495 
Protein Kinase C delta 
2 9.59 Protein kinase C delta 
AB023421 APG-1 9.57 
Heat shock protein apg-1 (HSP110 
family) 
U23853 PAC1 9.52 
Ual-specific phosphoprotein 
phosphatase 
X06374 PDGFA 9.51 Platelet-derived growth factor alpha 
U15590 HSPB3 9.45 Heat shock 17kD protein 3 (HSPB3) 
M57732 
Hepatic nuclear factor 
1-alpha 9.42 
Transcription factor 1, hepatic; LF-B1, 
hepatic nuclear factor (HNF1), albumin 
proximal factor 
U15642 E2F5 9.39 Transcription factor E2F-5 
X66365 CDK6 9.37 Cyclin-dependent kinase 6 
L26081 Sema III 9.32 semaphorin-III 
U02619 TFIIIC 9.24 
General transcription factor IIIC, 
polypeptide 1 (alpha subunit, 220kD ) 
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J03241 TGFB3 9.21 Transforming growth factor-beta 3 
U24166 EB1 9.20 EB1 
M90813 Cyclin D2 9.17 D-type cyclin (CCND2) 
U43142 VEGFC 9.15 
Vascular endothelial growth factor 
related protein VRP 
U75898 
Heat shock 27kD 
protein 2 9.12 Heat shock 27kD protein 2 
X76132 DCC 9.11 Deleted in colorectal carcinoma 
AB003334 HSP105 alpha 9.11 HSP105 alpha 
M34065 Cdc25C 9.09 Cell division cycle 25C; Cdc25C 
X66365 CDK6 9.07 Cyclin-dependent kinase 6 
L14283 Protein Kinase C Zeta 9.07 Protein kinase C zeta 
L26081 Sema III 9.00 semaphorin-III 
U28838 HTFIIIB90 9.00 
Transcription factor TFIIIB 90 kDa 
subunit 
L01087 PRKCT 8.97 
Protein Kinase C Protein Kinase C 
Theta Protein kinase C-theta; PRKCT 
U29680 
BCL2-related protein 
A1 8.92 BCL2-related protein A1; Bfl-1; GRS 
M36542 OCTF2 8.91 Octamer-binding transcription factor 2 
J03133 TSFP1 8.90 Transcription factor SP1 
M31732 BCL 3 8.89 B-cell CLL/lymphoma 3 
D14012 HGF activator 8.89 
Hepatocyte growth factor (HGF) 
activator precursor 
NM_005528 HSPF2 8.83 Heat shock 40kD protein 2; HSPF2 
X55122 GATA-3 8.81 GATA-binding protein 3 
AF007871 TorsinA 8.79 Dystonia 1; torsin A 
U43142 VEGFC 8.76 
Vascular endothelial growth factor 
related protein VRP 
X06234 Calgranulin A 8.76 
S100 Calcium-binding protein A8 
(calgranulin A) 
X02751 NRas 8.68 
Neuroblastoma RAS viral (v-ras) 
oncogene homolog 
X56681 JunD 8.65 JunD 
M33294 TNF-R1 8.60 Tumor necrosis factor receptor I 
M61916 LAMB1 8.55 Laminin B1 
U10117 EMAP2 8.55 
ENDOTHELIAL-MONOCYTE 
ACTIVATING POLYPEPTIDE II 
AF133270 SLIT2 8.53 SLIT2 
M60278 
Heparin-binding 
epidermal growth factor 8.52 
Diphtheria toxin receptor (heparin-
binding epidermal growth factor-like 
growth factor) 
D14497 Map3K8 8.48 
Mitogen-activated protein kinase 
kinase kinase 8 
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Z29083 5T4 8.45 5T4 oncofetal trophoblast glycoprotein 
AF133270 SLIT2 8.44 SLIT2 
M99487 
Prostate-specific 
membrane antigen 8.42 
Prostate-specific membrane antigen 
(PSM) 
AF078078 GADD45 8.34 
Growth arrest and DNA-damage-
inducible protein 
U02368 FKHR 8.30 
Forkhead (Drosophila) homolog 1 
(rhabdomyosarcoma) 
NM_004419 DUSP5 8.25 Dual specificity phosphatase 5 
U60519 Caspase-10 8.25 
Caspase 10, apoptosis-related cysteine 
protease 
NM_004263 SemaW 8.17 Semaphorin W 
U17760 LAMB3 8.14 Laminin S B3 chain; LAMB3 
U08015 NF-ATc 8.12 
Nuclear factor of activated T-cells, 
cytoplasmic 1 
X79483 Erk6 8.10 
ERK6;Mitogen-activated protein kinase 
12 
J04101 ETS 1 8.03 
V-ets avian erythroblastosis virus E26 
oncogene homolog 1 
M15990 C-yes-1 8.00 
V-yes-1 Yamaguchi sarcoma viral 
oncogene homolog 1; C-yes-1 
AF003595 
8-oxoguanine DNA 
glyosylase 1 8.00 8-oxoguanine DNA glycosylase 1 
U15460 B-ATF 7.97 
Activating transcription factor B; 
bZip;B-ATF 
L26081 Sema III 7.96 semaphorin-III 
NM_007034 HLJ1 7.93 DnaJ-like heat shock protein 40; HLJ1 
AF007872 TorsinB 7.90 Dystonia 1; TorsinB 
AF174487 BOK 7.84 
BCL-2-related ovarian killer protein; 
BOK 
X07270 HSP86 7.72 Heat shock protein HSP86 
L41690 TRADD 7.71 
TNF receptor-1 associated protein; 
TRADD 
X52541 EGR1 7.70 
Early growth response protein 1 
(EGR1); transcription factor ETR103 
U40343 
CDK inhibitor 
p19INK4d 7.65 Cyclin dependent kinase inhibitor 2D 
M23452 MIP1-ALPHA 7.63 
Macrophage inflammatory protein; 
Small inducible cytokine A3 




Gamma-aminobutyric acid (GABA) A 
receptor, alpha 3 
J04111 C-jun 7.48 




U15460 B-ATF 7.46 
Activating transcription factor B; 
bZip;B-ATF 
U15642 E2F5 7.42 Transcription factor E2F-5 




Gamma-aminobutyric acid (GABA) A 
receptor, alpha 2 
AB016193 Elk1 7.38 
ELK1, member of ETS oncogene 
family 
NM_001740 CALB2 7.36 Calretinin; calbindin 2 
AF087438 PPP2R1B 7.36 
Protein phosphatase 2 subunit A 
isoform beta 
M65217 HSF2 7.35 
Heat shock transcription factor 2 
(HSTF2) 
U01134 VEGFR1 7.32 
Vascular endothelial cell growth factor 
receptor 
L06801 IL13 7.30 Interleukin 13 
X52104 p68 7.21 
DEAD/H (Asp-Glu-Ala-Asp/His) box 
polypeptide 5 (RNA helicase, 68kD); 
p68 
X16316 VAV 1 7.18 Vav 1 oncogene 
D49547 HSP-40 7.18 Heat-shock protein 40 
M23452 MIP1-ALPHA 7.16 
Macrophage inflammatory protein; 
Small inducible cytokine A3 
(homologous to mouse Mip-1a) 
X52541 EGR1 7.11 
Early growth response protein 1 
(EGR1); transcription factor ETR103 
X77166 HKIB9 7.09 Kunitz-type protease inhibitor, HKIB9 
U43142 VEGFC 7.06 
Vascular endothelial growth factor 
related protein VRP 
AB003334 HSP105 alpha 7.05 HSP105 alpha 
X57110 C-cbl 7.03 C-cbl proto-oncogene 
AF068754 HSFBP1 7.03 
Heat shock factor binding protein 1 
HSBP1 
M19720 L-myc 7.02 L-myc proto-oncogene 
U31176 ERV1 7.01 ERV1 
U18671 STAT2 6.98 
Signal transducer and activator of 
transcription 2 (STAT2) 
M26760 ALDH-2 6.92 
Aldehyde dehydrogenase 2, 
mitochondrial 
X76132 DCC 6.91 Deleted in colorectal carcinoma 
X06182 C-kit 6.91 C-kit proto-oncogene 
D15050 TCF8 6.84 
Transcription factor 8 (represses 
interleukin 2 expression) 
NM_002111 HD 6.79 Huntington Disease 
X75962 OX40 homologue  6.73 
Tumor necrosis factor receptor 
superfamily, member 4 
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AJ236921 GRM8 6.71 Metabotropic glutamate receptor 8 
M54915 Pim-1 6.71 Pim-1 proto-oncogene 
M65217 HSF2 6.67 
Heat shock transcription factor 2 
(HSTF2) 
M21616 PDGFRB 6.66 
Platelet-derived growth factor receptor, 
beta 
U16296 TIAM1 6.65 
T-lymphoma invasion and metastasis 
inducing 
AB023420 APG-2 6.65 
Heat shock protein apg-2; HS24/p52; 
hsp70 
J03133 TSFP1 6.54 Transcription factor SP1 
M21574 PDGFRA 6.52 
Platelet-derivied growth factor 
receptor, alpha 
U73036 IRF-7 6.52 Interferon regulatory factor 7 
M19720 L-myc 6.50 L-myc proto-oncogene 
D26156 BRG1 6.45 
SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily a, member 4 
NM_000069 CACNA1S 6.44 
Calcium channel, voltage-dependent, L 
type, alpha 1S subunit 
NM_001752 CAT 6.39 Catalase 
NM_002157 HSPE1 6.37 Heat shock 10kD protein 1 
AF088982 HSP40-3 6.33 Heat shock protein hsp40-3 
M31165 TSG-6 6.26 
Tumor necrosis factor, alpha-induced 
protein 6 
NM_002290 LAMA4 6.23 Laminin alpha 4 
NM_006871 RIP3  6.22  Receptor-interacting protein 3 
U17760 LAMB3 6.21 Laminin S B3 chain; LAMB3 
X57110 C-cbl 6.19 C-cbl proto-oncogene 
AB017169 SLIT3 6.16 Slit-3 
NM_002156 HSPD1 6.12 Heat shock 60kD protein 1 
M59829 HSP70-like 1 6.12 
MHC class III HSP70-HOM (HLA); 
Heat shock 70kD protein-like 1 
U96876 
Insulin induced protein 
1 6.12 Insulin induced protein 1 
U66075 
GATA-binding protein 
6 6.10 GATA-binding protein 6 
U15590 HSPB3 6.09 Heat shock 17kD protein 3 (HSPB3) 
J03358 FER 6.09 
Fer (fps/fes related) tyrosine kinase 
(phosphoprotein NCP94) 
NM_000402 G6PD 6.03 Glucose-6-phosphate dehydrogenase 
AF129085 CHIP 6.02 




AF010309 Pig3 5.96 Quinone oxidoreductase homolog 
X66079 Spi-B 5.95 Spi-B transcription factor 
X02751 NRas 5.91 
Neuroblastoma RAS viral (v-ras) 
oncogene homolog 
U11732 Ets-like 5.91 Ets variant gene 6 (TEL oncogene) 
L06105 Squalene Synthase 5.90 
Farnesyl-diphosphate 
farnesyltransferase 1; Squalene 
Synthase 
L16785 PM5 protein 5.88 
PM5 protein; c-myc transcription factor 
(puf) 
M57732 
Hepatic nuclear factor 
1-alpha 5.84 
Transcription factor 1, hepatic; LF-B1, 
hepatic nuclear factor (HNF1), albumin 
proximal factor 
U31201 Laminin 5.84 Laminin, gamma 2; Nicein; 
L08069 E. coli DnaJ homolog 5.84 
Heat shock protein, E. coli DnaJ 
homologue 
NM_005528 HSPF2 5.80 Heat shock 40kD protein 2; HSPF2 
X65550 Mki67a 5.78 
Antigen identified by monoclonal 
antibody Ki-67 
U43747 Frataxin 5.77 Frataxin; Friedreich ataxia 
NM_007031 HSF2 5.75 
Heat shock transcription factor 2 
binding protein 
NM_001752 CAT 5.74 Catalase 
AF068754 HSFBP1 5.73 
Heat shock factor binding protein 1 
HSBP1 
U43188 NERF2 5.68 New Ets-related factor NERF2 
NM_001196 BID 5.68 BH3 interacting domain death agonist 
U15131 ST5 5.65 Suppression of tumorigenicity 5 
L27211 p16-INK4  5.61  CDK4-inhibitor 
M95712 B-raf 5.61 
V-raf murine sarcoma viral oncogene 
homolog B1; B-raf 
AB017167 SLIT1 5.58 Slit-1 
Z29646 IPP-2 5.57 Inhibitor 2 of protein phosphatase 1 
M65217 HSF2 5.56 
Heat shock transcription factor 2 
(HSTF2) 




Gamma-aminobutyric acid (GABA) A 
receptor, alpha 4 
M87503 IFNRTF 5.47 
Interferon-alpha (IFN) responsive 
transcription factor subunit 
X52056 Spi-1 5.45 
Spleen focus forming virus (SFFV) 
proviral integration oncogene; Spi1 
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L26318 JNK1 5.43 
JNK1; Mitogen-activated protein 
kinase 8 
D12614 TNF-beta 5.42 Lymphotoxin (TNF-beta) 
U43747 Frataxin 5.38 Frataxin; Friedreich ataxia 
M92287 Cyclin D3 5.38 Cyclin D3 (CCND3) 
U17760 LAMB3 5.38 Laminin S B3 chain; LAMB3 
M61916 LAMB1 5.37 Laminin B1 
X53961 Lactotransferrin 5.36 Lactotransferrin; LACTOFERRIN 
U18671 STAT2 5.32 
Signal transducer and activator of 
transcription 2 (STAT2) 
Z30094 BTF2p44 5.30 Basic transcription 2 factor 44 kD 
NM_000815 
GABA (A) receptor 
delta 1 5.28 
Gamma-aminobutyric acid (GABA) A 
receptor, delta 
M34353 ROS1 5.27 
Transmembrane tyrosine-specific 
protein kinase (ROS1) 
X51688 Cyclin A 5.27 Cyclin A 
NM_007031 HSF2 5.26 




antichymotrypsin 5.23 Alpha-1-antichymotrypsin 
U15306 NFX1 5.18 
Cysteine-rich sequence-specific DNA-
binding protein NFX1 
X03484 Raf1 5.17 Raf1 oncogene 
M57732 
Hepatic nuclear factor 
1-alpha 5.15 
Transcription factor 1, hepatic; LF-B1, 
hepatic nuclear factor (HNF1), albumin 
proximal factor 
X52056 Spi-1 5.14 
Spleen focus forming virus (SFFV) 
proviral integration oncogene; Spi1 
NM_006597 HSC71 5.12 
Heat shock 70kD protein 10; HSC71; 
HSPA10 
X52192 C-fes 5.10 C-fes proto-oncogene 
U35113 
Metastasis Associated 
MTA1 5.10 Metastasis-associated protein MTA1 
K03222 TGF-alpha 5.10 Transforming growth factor-alpha 
AF020760 OMI 5.09 Serine protease; OMI 
X54079 HSP27 5.07 Heat shock protein HSP27 
X60003 Delta CREB1 5.06 




factor receptor 5.06 Platelet activating factor receptor 
X87949 BiP 5.04 
BiP;Heat shock 70kD protein 5 
(glucose-regulated protein, 78kD) 
M91083 HRC1 5.04 
Chromosome 11 open reading frame 
13; DNA-binding protein (HRC1) 
X07024 CCG1p 5.00 
TATA box binding protein (TBP)-




U24166 EB1 4.97 EB1 
X75042 C-rel 4.96 
V-rel avian reticuloendotheliosis viral 
oncogene homolog; C-rel 
AF068754 HSFBP1 4.88 




glyosylase 1 4.83 8-oxoguanine DNA glycosylase 1 
V00507 Dihydrofolate reductase 4.83 
Dihydrofolic acid (Dihydrofolate) 
reductase 
M33294 TNF-R1 4.77 Tumor necrosis factor receptor I 
M74178 HGFL 4.75 
Macrophage stimulating 1 (hepatocyte 
growth factor-like) 
L06139 TEK Receptor 4.71 ANGIOPOIETIN 1 RECEPTOR 
Y11416 P73 4.70 Tumor protein P73 
M15400 Rb 4.70 Retinoblastoma susceptibility gene, Rb 
D10202 
Platelet activating 
factor receptor 4.67 Platelet activating factor receptor 
AB003334 HSP105 alpha 4.65 HSP105 alpha 
X06234 Calgranulin A 4.64 
S100 Calcium-binding protein A8 
(calgranulin A) 
U10149 HSPA-2 4.60 heat shock protein; HSPA-2 
U77088 Thymidine kinase 2 4.59 Thymidine kinase 2 (TK2) 
S76992 VAV 2 4.58 VAV oncogene homolog 
NM_000844 GRM7 4.52 Glutamate receptor, metabotropic 7 
X59798 PRAD1 4.51 
Cyclin D1; PRAD1; parathyroid 
adenomatosis 1 
U43188 NERF2 4.49 New Ets-related factor NERF2 
M92843 
Zinc finger 
transcriptional regulator 4.46 
Zinc finger protein homologous to Zfp-
36 in mouse 
L06801 IL13 4.46 Interleukin 13 
AF002697 BNip3 4.43 
BCL2/adenovirus E1B 19kD-
interacting protein 3 
M95809 BTF2 4.42 
Basic transcription factor 62kD subunit 
(BTF2) 
X56773 IGF-I 4.41 
Insulin-like growth factor 1 
(somatomedin C) 
J04536 CD43 4.38 Sialophorin (CD43) 
AF020760 OMI 4.37 Serine protease; OMI 
D15050 TCF8 4.34 
Transcription factor 8 (represses 
interleukin 2 expression) 
NM_000813 
GABA (A) beta-2 
receptor 4.28 
Gamma-aminobutyric acid (GABA) A 
receptor, beta 2 
J05081 Endothelin 3 4.28 Endothelin 3 
M74178 HGFL 4.17 







Telomerase reverse transcriptase, 
catalytic subunit 
M14091 TBG 4.13 Thyroxine-binding globulin 
M54915 Pim-1 4.12 Pim-1 proto-oncogene 
AB016193 Elk1 4.11 
ELK1, member of ETS oncogene 
family 
AF075601 HSJ2 4.09 Heat shock J2 protein; HSJ2 
U66075 
GATA-binding protein 
6 4.08 GATA-binding protein 6 
AF133270 SLIT2 4.05 SLIT2 
M81934 Cdc25B 4.04 Cell division cycle 25B; Cdc25b 
M76766 TFIIB 4.04 Transcription factor IIB (GTF2B) 
AF075601 HSJ2 4.00 Heat shock J2 protein; HSJ2 
M54915 Pim-1 3.97 Pim-1 proto-oncogene 
Y10479 E2F3 3.96 E2F-3 transcription factor 
U33841 ATM 3.94 Ataxia telangiectasia gene 
M19233 Alpha-amylase-1 3.94 Alpha-amylase-1 
U94728 Calmodulin 3.91 Calmodulin (CALM2) 
AF015956 
Death Associated 
protein 6 3.91 Death associated protein 6 (DAXX) 
U73036 IRF-7 3.90 Interferon regulatory factor 7 
X98801 Dynactin 3.89 





Gamma-aminobutyric acid (GABA) A 
receptor, alpha 4 
NM_004822 Netrin-1 3.85 Netrin 1 
U24166 EB1 3.85 EB1 
M87290 Angiotensin receptor I 3.85 ANGIOTENSIN II RECEPTOR type 1 
X66365 CDK6 3.84 Cyclin-dependent kinase 6 
AB007836 HIC-5 3.83 
Hic-5; Transforming growth factor beta 
1 induced transcript 1 
AF041835 LAMC3 3.82 
Laminin gamma 3 chain precursor; 
LAMC3 
NM_001740 CALB2 3.82 Calretinin; calbindin 2 
NM_004263 SemaW 3.80 Semaphorin W 
U31201 Laminin 3.80 Laminin, gamma 2; Nicein; 
M63167 Rac-alpha 3.79 
V-akt murine thymoma viral oncogene 
homolog 1; rac protein kinase alpha 
Y11416 P73 3.78 Tumor protein P73 
NM_001715 Blk 3.75 B lymphoid tyrosine kinase 
V00568 C-myc 3.73 C-myc oncogene 
X79981 VE-cadherin 3.73 VE-cadherin 
U02368 FKHR 3.73 
Forkhead (Drosophila) homolog 1 
(rhabdomyosarcoma) 
NM_001166 API1 3.71 Apoptosis inhibitor 1 (API1) 
L08069 E. coli DnaJ homolog 3.69 




U15642 E2F5 3.68 Transcription factor E2F-5 
AF143315 PTEN 3.68 PTEN 
L14283 Protein Kinase C Zeta 3.67 Protein kinase C zeta 
X83688 Purinergic receptor P2X 3.64 
Purinergic receptor P2X, ligand-gated 
ion channel 1; P2X PURINOCEPTOR 
1 
X01394 TNF 3.64 Tumor necrosis factor 
AF041835 LAMC3 3.62 
Laminin gamma 3 chain precursor; 
LAMC3 
U56390 Caspase-9  3.61 
 Cysteine protease; ICE-
LAP6;Caspase-9 
U86759 Netrin-2 like 3.57 Netrin-2 Like protein 
D12614 TNF-beta 3.56 Lymphotoxin (TNF-beta) 
X56681 JunD 3.52 JunD 
NM_002156 HSPD1 3.51 Heat shock 60kD protein 1 
K03195 HEPG2 3.47 
Solute carrier family 2 (facilitated 
glucose transporter), member 1 
X55122 GATA-3 3.47 GATA-binding protein 3 
V00568 C-myc 3.44 C-myc oncogene 
X55122 GATA-3 3.41 GATA-binding protein 3 
M59828 HSP70-1 3.41 MHC class III HSP70-1 
U33052 PRK2 3.39 Lipid-activated protein kinase PRK2 
AF143315 PTEN 3.38 PTEN 
U47741 Creb-binding protein 3.36 CREB-binding protein (CBP) 
X56681 JunD 3.36 JunD 
U00568 
Immunoglobulin heavy 
chain variable region 3.35 
Immunoglobulin heavy chain variable 
region 
X51757 HSP70B 3.33 Heat-shock protein HSP70B' 
M90813 Cyclin D2 3.28 D-type cyclin (CCND2) 
X52192 C-fes 3.25 C-fes proto-oncogene 
M87290 Angiotensin receptor I 3.22 ANGIOTENSIN II RECEPTOR type 1 
M63167 Rac-alpha 3.19 
V-akt murine thymoma viral oncogene 
homolog 1; rac protein kinase alpha 
U10117 EMAP2 3.16 
ENDOTHELIAL-MONOCYTE 
ACTIVATING POLYPEPTIDE II 
AF007872 TorsinB 3.15 Dystonia 1; TorsinB 
NM_004417 DUSP1 3.13 Dual specificity phosphatase 1 
J04111 C-jun 3.13 
Transcription factor AP-1; c-jun proto 
oncogene 
U02619 TFIIIC 3.13 
General transcription factor IIIC, 
polypeptide 1 (alpha subunit, 220kD ) 
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NM_002419 MAP3K11 3.12 Mitogen-activated protein kinase 11 
M87503 IFNRTF 3.12 
Interferon-alpha (IFN) responsive 
transcription factor subunit 
Z23115 Bcl-xL  3.11 BCL2-like 1 
U14417 RalGDS 3.10 
Ral guanine nucleotide dissociation 
stimulator; RalGDS 
L09210 
Inducible nitric oxide 
synthase 3.08 Inducible nitric oxide synthase 
AB003333 HSP105 beta 3.04 HSP105 beta 
M34353 ROS1 3.00 
Transmembrane tyrosine-specific 
protein kinase (ROS1) 
M14752 ABL1 2.98 
V-abl Abelson murine leukemia viral 
oncogene homolog 1 
NM_000484 Amyloid beta precursor 2.98 Amyloid beta precursor 
K01500 
Alpha-1-
antichymotrypsin 2.97 Alpha-1-antichymotrypsin 
U33841 ATM 2.97 Ataxia telangiectasia gene 
AB023420 APG-2 2.97 
Heat shock protein apg-2; HS24/p52; 
hsp70 
X80692 Erk3 2.92 ERK3 
J03241 TGFB3 2.89 Transforming growth factor-beta 3 
U31176 ERV1 2.89 ERV1 
Z30094 BTF2p44 2.88 Basic transcription 2 factor 44 kD 
U19727 Tau 2.88 
Microtubule-associated protein 4 
(MAP4) 
M14752 ABL1 2.85 
V-abl Abelson murine leukemia viral 
oncogene homolog 1 
X59869 TCF7 2.85 
Transcription factor 7 (T-cell specific, 
HMG-box) 
M31732 BCL 3 2.85 B-cell CLL/lymphoma 3 
X02751 NRas 2.82 
Neuroblastoma RAS viral (v-ras) 
oncogene homolog 
U37448 Caspase-7 2.81 Apoptosis-related cysteine protease 
NM_006597 HSC71 2.80 
Heat shock 70kD protein 10; HSC71; 
HSPA10 
D29013 DNA polymerase beta 2.77 DNA polymerase beta 
AF010309 Pig3 2.75 Quinone oxidoreductase homolog 
U16296 TIAM1 2.74 
T-lymphoma invasion and metastasis 
inducing 
L08069 E. coli DnaJ homolog 2.72 
Heat shock protein, E. coli DnaJ 
homologue 
U11732 Ets-like 2.70 Ets variant gene 6 (TEL oncogene) 
NM_000402 G6PD 2.68 Glucose-6-phosphate dehydrogenase 
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X02811 PDGFB 2.67 Platelet-derived growth factor beta 
J04101 ETS 1 2.66 
V-ets avian erythroblastosis virus E26 
oncogene homolog 1 
X79981 VE-cadherin 2.65 VE-cadherin 
X66079 Spi-B 2.64 Spi-B transcription factor 
U14680 BRCA 1 2.64 Breast and ovarian cancer susceptibility 
U73036 IRF-7 2.62 Interferon regulatory factor 7 
NM_000812 
GABA (A) receptor 
beta-1 2.61 
Gamma-aminobutyric acid (GABA) A 
receptor, beta 1 
NM_003244 TGIF 2.61 
TG-interacting factor (TALE family 
homeobox) 
X65550 Mki67a 2.60 
Antigen identified by monoclonal 
antibody Ki-67 
M13228 N-myc 2.60 N-myc oncogene 
M62810 
Mitochondrial 
transcription factor 1 2.59 Mitochondrial transcription factor 1 
NM_002156 HSPD1 2.56 Heat shock 60kD protein 1 
E01408 
Manganese superoxide 
dismutase 2.54 Manganese superoxide dismutase 
Z29083 5T4 2.50 5T4 oncofetal trophoblast glycoprotein 
NM_002043 
GABA (A) rho-2 
receptor 2.47 
Gamma-aminobutyric acid (GABA) 
receptor, rho 2 
L27211 p16-INK4  2.47  CDK4-inhibitor 
D10495 
Protein Kinase C delta 
2 2.46 Protein kinase C delta 
AF009616 Flame-1 2.41 Flame-1 
L35253 MAPK 14 2.33 Mitogen-activated protein kinase 14 
U02619 TFIIIC 2.32 
General transcription factor IIIC, 
polypeptide 1 (alpha subunit, 220kD ) 
Z50101 
NADP 
Transhydrogenase 2.32 NAD(P) transhydrogenase 
M64240 MAX 2.27 Helix-loop-helix zipper protein (max) 
U28838 HTFIIIB90 2.24 
Transcription factor TFIIIB 90 kDa 
subunit 
M83308 COX6A 2.22 
Mitochondrial cytochrome c oxidase 
subunit VIa polypeptide 1 
NM_000433 NCF2 2.19 Neutrophil cytosolic factor 2 
Z23115 Bcl-xL  2.15 BCL2-like 1 
NM_006871 RIP3  2.14  Receptor-interacting protein 3 
NM_002290 LAMA4 2.14 Laminin alpha 4 
X53961 Lactotransferrin 2.13 Lactotransferrin; LACTOFERRIN 
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U23853 PAC1 2.12 
Ual-specific phosphoprotein 
phosphatase 
U43746 BRCA2 2.11 
Breast cancer susceptibility (BRCA2) 
gene 
AF028832 Hsp89-alpha-delta-N 2.11 Hsp89-alpha-delta-N 
M34353 ROS1 2.10 
Transmembrane tyrosine-specific 
protein kinase (ROS1) 
NM_001196 BID 2.09 BH3 interacting domain death agonist 
U43746 BRCA2 2.07 
Breast cancer susceptibility (BRCA2) 
gene 
X75042 C-rel 2.07 
V-rel avian reticuloendotheliosis viral 
oncogene homolog; C-rel 
M14745 Bcl-2 2.05 B-cell CLL/lymphoma 2 
D26156 BRG1 2.03 
SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily a, member 4 
X02317 SOD 2.00 
Superoxide dismutase 1, soluble 
(amyotrophic lateral sclerosis 1 (adult)) 
 
Table A1: Liver Cirrhosis compared with normal, genes up regulated by at least 2 fold in 






ID Short Gene Name 
Fold 
Difference Long Gene Name 
U10906 p27 64.52 
Cyclin-dependent kinase inhibitor; 
p27 
AF009616 Flame-1 57.97 Flame-1 
X87949 BiP 25.16 
BiP;Heat shock 70kD protein 5 
(glucose-regulated protein, 78kD) 
L78440 STAT4 21.28 
Signal transducer and activator of 
transcription 4 (STAT4) 
X06233 Calgranulin B 15.50 
S100 Calcium-binding protein A9 
(calgranulin B) 
L16785 PM5 protein 13.03 
PM5 protein; c-myc transcription 
factor (puf) 
NM_001165 API2 12.82 Apoptosis inhibitor 2 
U56390 Caspase-9  10.90 
 Cysteine protease; ICE-
LAP6;Caspase-9 
NM_004417 DUSP1 7.34 Dual specificity phosphatase 1 
NM_000069 CACNA1S 6.56 
Calcium channel, voltage-dependent, 
L type, alpha 1S subunit 
U22398 P57kip2 5.83 Cdk-inhibitor; p57KIP2; KIP2 
U31176 ERV1 4.09 ERV1 
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AF002697 BNip3 3.88 
BCL2/adenovirus E1B 19kD-
interacting protein 3 
NM_002157 HSPE1 3.69 Heat shock 10kD protein 1 
J04101 ETS 1 3.66 
V-ets avian erythroblastosis virus 
E26 oncogene homolog 1 
NM_004419 DUSP5 3.43 Dual specificity phosphatase 5 
M81601 
Transcription elongation 
factor SII 3.36 Transcription elongation factor (SII) 
D10202 
Platelet activating factor 
receptor 3.34 Platelet activating factor receptor 
X01394 TNF 3.17 Tumor necrosis factor 
M95809 BTF2 3.09 
Basic transcription factor 62kD 
subunit (BTF2) 
M21616 PDGFRB 2.73 
Platelet-derived growth factor 
receptor, beta 
X06374 PDGFA 2.56 Platelet-derived growth factor alpha 
AB007144 ZIP kinase 2.51 ZIP-kinase 
Z11531 EF-1 Gamma 2.31 Elongation factor-1-gamma 
L41690 TRADD 2.27 
TNF receptor-1 associated protein; 
TRADD 
X06233 Calgranulin B 2.15 
S100 Calcium-binding protein A9 
(calgranulin B) 
M14745 Bcl-2 2.10 B-cell CLL/lymphoma 2 
X52541 EGR1 2.08 
Early growth response protein 1 
(EGR1); transcription factor ETR103 
M81933 Cdc25A 2.06 Cell division cycle 25A; Cdc25a 
 
Table A2: Liver Cirrhosis compared with normal, genes down regulated by at least 2 






Gene Bank ID Short Gene Name 
Fold 
Difference Long Gene Name 
X66365 CDK6 367.06 Cyclin-dependent kinase 6 
L26318 JNK1 297.47 
JNK1; Mitogen-activated protein kinase 
8 
M87503 IFNRTF 112.12 
Interferon-alpha (IFN) responsive 
transcription factor subunit 
M55284 Protein Kinase C-L 84.66 Protein kinase C-L 
AF174487 BOK 82.87 




M23452 MIP1-ALPHA 76.75 
Macrophage inflammatory protein; 
Small inducible cytokine A3 
(homologous to mouse Mip-1a) 
NM_002043 
GABA (A) rho-2 
receptor 76.61 
Gamma-aminobutyric acid (GABA) 
receptor, rho 2 
M19233 Alpha-amylase-1 75.18 Alpha-amylase-1 
E01408 
Manganese 
superoxide dismutase 74.42 Manganese superoxide dismutase 
NM_000069 CACNA1S 63.84 
Calcium channel, voltage-dependent, L 
type, alpha 1S subunit 
X76132 DCC 54.91 Deleted in colorectal carcinoma 
AB031042 Lhx6 40.71 LIM-homeodomain (LHX) protein 6.1b 
M14694 P53 37.16 P53 cellular tumor antigen 
AF007871 TorsinA 36.43 Dystonia 1; torsin A 
AB031042 Lhx6 34.98 LIM-homeodomain (LHX) protein 6.1b 
AF064019 CAD 32.78 
DNA fragmentation factor, 40 kD, beta 
subuni 
X52192 C-fes 31.06 C-fes proto-oncogene 
U13021 Caspase-2 30.56 
Positive regulator of programmed cell 
death; ICH-1L 
M63167 Rac-alpha 25.94 
V-akt murine thymoma viral oncogene 
homolog 1; rac protein kinase alpha 
L35253 MAPK 14 24.90 Mitogen-activated protein kinase 14 
Y11416 P73 24.65 Tumor protein P73 
L06622 
Endothelin-1 




Gamma-aminobutyric acid (GABA) A 
receptor, alpha 6 
NM_004929 CALB1 20.66 calbindin 1 
X56681 JunD 20.29 JunD 
J04101 ETS 1 20.00 
V-ets avian erythroblastosis virus E26 
oncogene homolog 1 
U28838 HTFIIIB90 19.48 
Transcription factor TFIIIB 90 kDa 
subunit 
AF064019 CAD 19.41 
DNA fragmentation factor, 40 kD, beta 
subuni 
X51757 HSP70B 19.27 Heat-shock protein HSP70B' 
U35113 
Metastasis 
Associated MTA1 19.27 Metastasis-associated protein MTA1 
U35835 DNA-PK 19.26 




membrane antigen 17.72 




elongation factor SII 17.49 Transcription elongation factor (SII) 
NM_004419 DUSP5 17.21 Dual specificity phosphatase 5 
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M55284 Protein Kinase C-L 17.06 Protein kinase C-L 
AB023420 APG-2 16.49 
Heat shock protein apg-2; HS24/p52; 
hsp70 
L41690 TRADD 16.33 
TNF receptor-1 associated protein; 
TRADD 
NM_004929 CALB1 16.25 calbindin 1 
L06105 Squalene Synthase 16.15 
Farnesyl-diphosphate 
farnesyltransferase 1; Squalene 
Synthase 
U01134 VEGFR1 15.73 
Vascular endothelial cell growth factor 
receptor 
AB003334 HSP105 alpha 15.54 HSP105 alpha 
Z11531 EF-1 Gamma 14.94 Elongation factor-1-gamma 
L41690 TRADD 14.94 
TNF receptor-1 associated protein; 
TRADD 
X75042 C-rel 14.91 
V-rel avian reticuloendotheliosis viral 
oncogene homolog; C-rel 
AB017169 SLIT3 14.33 Slit-3 
U18671 STAT2 14.23 
Signal transducer and activator of 
transcription 2 (STAT2) 
X54079 HSP27 14.17 Heat shock protein HSP27 
L41690 TRADD 13.91 
TNF receptor-1 associated protein; 
TRADD 
NM_004417 DUSP1 13.76 Dual specificity phosphatase 1 
M31165 TSG-6 13.71 
Tumor necrosis factor, alpha-induced 
protein 6 
X56681 JunD 13.18 JunD 
AF002697 BNip3 13.07 
BCL2/adenovirus E1B 19kD-interacting 
protein 3 
D15050 TCF8 12.92 
Transcription factor 8 (represses 
interleukin 2 expression) 
X52192 C-fes 12.88 C-fes proto-oncogene 
K03214 C-src 12.81 C-SRC-1 proto-oncogene 
M34353 ROS1 12.79 
Transmembrane tyrosine-specific 
protein kinase (ROS1) 
M54915 Pim-1 12.63 Pim-1 proto-oncogene 
M14745 Bcl-2 12.59 B-cell CLL/lymphoma 2 
L25081 RhoC 12.51 Ras homolog gene family, member C 
AF075601 HSJ2 12.47 Heat shock J2 protein; HSJ2 
M81601 
Transcription 
elongation factor SII 12.43 Transcription elongation factor (SII) 
X52541 EGR1 12.10 
Early growth response protein 1 
(EGR1); transcription factor ETR103 
X65550 Mki67a 11.82 






protein 1 11.74 Insulin induced protein 1 
U43142 VEGFC 11.70 
Vascular endothelial growth factor 
related protein VRP 
X06182 C-kit 11.45 C-kit proto-oncogene 
M99487 
Prostate-specific 
membrane antigen 11.41 
Prostate-specific membrane antigen 
(PSM) 
M13975 
Protein Kinase C 
Beta II  11.22 Protein kinase C beta-II 
X89986 Bik 10.99 NBK apoptotic inducer protein 
NM_005528 HSPF2 10.79 Heat shock 40kD protein 2; HSPF2 
NM_001166 API1 10.79 Apoptosis inhibitor 1 (API1) 
NM_007031 HSF2 10.72 
Heat shock transcription factor 2 
binding protein 
X59798 PRAD1 10.68 
Cyclin D1; PRAD1; parathyroid 
adenomatosis 1 
X07024 CCG1p 10.64 
TATA box binding protein (TBP)-
associated factor, RNA polymerase II, 
A, 250kD 
M97935 STAT1 10.62 
Signal transducer and activator of 
transcription 1 
M14745 Bcl-2 10.47 B-cell CLL/lymphoma 2 
U15131 ST5 10.46 Suppression of tumorigenicity 5 
AF005774 CLARP 10.36 
Caspase-like apoptosis regulatory 
protein (CLARP) 
X65550 Mki67a 10.35 
Antigen identified by monoclonal 
antibody Ki-67 
NM_006871 RIP3  10.27  Receptor-interacting protein 3 
D13316 
Respiratory factor-2 
subunit gamma 2 10.21 
GA-binding protein transcription factor, 
beta subunit 2 (47kD) 
AF068754 HSFBP1 10.19 
Heat shock factor binding protein 1 
HSBP1 
AF129085 CHIP 10.18 
Carboxy terminus of Hsp70-interacting 
protein; CHIP 
M15400 Rb 10.08 Retinoblastoma susceptibility gene, Rb 
X07024 CCG1p 10.05 
TATA box binding protein (TBP)-
associated factor, RNA polymerase II, 
A, 250kD 
NM_001715 Blk 9.94 B lymphoid tyrosine kinase 
X52541 EGR1 9.94 
Early growth response protein 1 
(EGR1); transcription factor ETR103 
NM_004419 DUSP5 9.93 Dual specificity phosphatase 5 
M91083 HRC1 9.87 
Chromosome 11 open reading frame 13; 
DNA-binding protein (HRC1) 
X89986 Bik 9.83 NBK apoptotic inducer protein 
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AB003334 HSP105 alpha 9.83 HSP105 alpha 
D26156 BRG1 9.72 
SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily a, member 4 
L24038 A-raf 9.62 
V-raf murine sarcoma 3611 viral 
oncogene homolog 1; A-RAF1 
U15590 HSPB3 9.58 Heat shock 17kD protein 3 (HSPB3) 
M55284 Protein Kinase C-L 9.58 Protein kinase C-L 
NM_000426 LAMA2 9.56 Laminin, alpha 2 precursor 
S82769 
GABAA receptor 
gamma 3 subunit 9.51 GABAA receptor gamma 3 subunit 
M60854 
Ribosomal protein 
S16 9.50 Ribosomal protein S16 
Z23115 Bcl-xL  9.35 BCL2-like 1 
NM_006597 HSC71 9.22 





Gamma-aminobutyric acid (GABA) A 
receptor, alpha 2 
NM_004929 CALB1 9.03 calbindin 1 
AB023421 APG-1 8.87 




protein 6 8.85 GATA-binding protein 6 
S76992 VAV 2 8.81 VAV oncogene homolog 
U02619 TFIIIC 8.74 
General transcription factor IIIC, 
polypeptide 1 (alpha subunit, 220kD ) 
AF009616 Flame-1 8.71 Flame-1 
J02966 ANT1 8.63 
Adenine nucleotide translocator 1 
(skeletal muscle) 
Z11933 N-oct3 8.51 
POU domain, class 3, transcription 
factor 2 
AF007872 TorsinB 8.48 Dystonia 1; TorsinB 
X52192 C-fes 8.47 C-fes proto-oncogene 
M64240 MAX 8.40 Helix-loop-helix zipper protein (max) 
AF043254 HSP75 8.40 Heat shock protein 75 
Z50101 
NADP 
Transhydrogenase 8.36 NAD(P) transhydrogenase 
NM_001166 API1 8.35 Apoptosis inhibitor 1 (API1) 
J02966 ANT1 8.33 
Adenine nucleotide translocator 1 
(skeletal muscle) 
AF143315 PTEN 8.32 PTEN 
J03133 TSFP1 8.26 Transcription factor SP1 
L78440 STAT4 8.20 
Signal transducer and activator of 
transcription 4 (STAT4) 
U18671 STAT2 8.18 
Signal transducer and activator of 
transcription 2 (STAT2) 
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X52056 Spi-1 8.13 
Spleen focus forming virus (SFFV) 
proviral integration oncogene; Spi1 
AB007144 ZIP kinase 8.12 ZIP-kinase 
K03214 C-src 8.11 C-SRC-1 proto-oncogene 
U60519 Caspase-10 8.03 
Caspase 10, apoptosis-related cysteine 
protease 
M31732 BCL 3 7.98 B-cell CLL/lymphoma 3 
X52056 Spi-1 7.98 
Spleen focus forming virus (SFFV) 
proviral integration oncogene; Spi1 
X75962 OX40 homologue  7.97 
Tumor necrosis factor receptor 
superfamily, member 4 
J03358 FER 7.96 
Fer (fps/fes related) tyrosine kinase 
(phosphoprotein NCP94) 
M21574 PDGFRA 7.95 





Hsp27 ERE-TATA-binding protein 
(HET); Scaffold attachment factor B 
M21574 PDGFRA 7.84 
Platelet-derivied growth factor receptor, 
alpha 
NM_001165 API2 7.78 Apoptosis inhibitor 2 
NM_002157 HSPE1 7.74 Heat shock 10kD protein 1 
L09210 
Inducible nitric oxide 
synthase 7.58 Inducible nitric oxide synthase 
L24038 A-raf 7.51 
V-raf murine sarcoma 3611 viral 
oncogene homolog 1; A-RAF1 
X03484 Raf1 7.42 Raf1 oncogene 
U16296 TIAM1 7.38 
T-lymphoma invasion and metastasis 
inducing 
L26318 JNK1 7.36 
JNK1; Mitogen-activated protein kinase 
8 
L09210 
Inducible nitric oxide 
synthase 7.34 Inducible nitric oxide synthase 
NM_006597 HSC71 7.33 
Heat shock 70kD protein 10; HSC71; 
HSPA10 
NM_004263 SemaW 7.31 Semaphorin W 
M36542 OCTF2 7.27 Octamer-binding transcription factor 2 
L35253 MAPK 14 7.16 Mitogen-activated protein kinase 14 
AB031042 Lhx6 7.11 LIM-homeodomain (LHX) protein 6.1b 
J04111 C-jun 7.10 
Transcription factor AP-1; c-jun proto 
oncogene 
U15306 NFX1 7.09 
Cysteine-rich sequence-specific DNA-
binding protein NFX1 





Zinc finger protein homologous to Zfp-
36 in mouse 
L26081 Sema III 6.88 semaphorin-III 
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X01394 TNF 6.70 Tumor necrosis factor 
J04111 C-jun 6.67 
Transcription factor AP-1; c-jun proto 
oncogene 
M23452 MIP1-ALPHA 6.65 
Macrophage inflammatory protein; 
Small inducible cytokine A3 
(homologous to mouse Mip-1a) 
Y10479 E2F3 6.64 E2F-3 transcription factor 
AF002697 BNip3 6.63 
BCL2/adenovirus E1B 19kD-interacting 
protein 3 
AF087438 PPP2R1B 6.51 
Protein phosphatase 2 subunit A isoform 
beta 
L19067 P65 6.47 
V-rel avian reticuloendotheliosis viral 
oncogene homolog A (nuclear factor of 
kappa light polypeptide gene enhancer 
in B-cells 3 (p65) 
AF129085 CHIP 6.47 
Carboxy terminus of Hsp70-interacting 
protein; CHIP 
X74142 BF-1 6.46 transcription factor BF-1 
AF005774 CLARP 6.45 
Caspase-like apoptosis regulatory 
protein (CLARP) 
X56681 JunD 6.42 JunD 
X01677 GAPDH 6.40 
Glyceraldehyde-3-phosphate 
dehydrogenase 
M34353 ROS1 6.39 
Transmembrane tyrosine-specific 
protein kinase (ROS1) 
NM_001196 BID 6.37 BH3 interacting domain death agonist 
NM_000815 
GABA (A) receptor 
delta 1 6.30 
Gamma-aminobutyric acid (GABA) A 
receptor, delta 
U31201 Laminin 6.30 Laminin, gamma 2; Nicein; 
M31165 TSG-6 6.30 
Tumor necrosis factor, alpha-induced 
protein 6 
L16464 ETS oncogene 6.29 ETS oncogene (PEP1) 
X02751 NRas 6.25 
Neuroblastoma RAS viral (v-ras) 
oncogene homolog 
AB008775 Aquaporin 9 6.19 Aquaporin 9 
NM_002156 HSPD1 6.16 Heat shock 60kD protein 1 
AF028832 Hsp89-alpha-delta-N 6.10 Hsp89-alpha-delta-N 
M64240 MAX 5.96 Helix-loop-helix zipper protein (max) 
U15460 B-ATF 5.96 
Activating transcription factor B; 
bZip;B-ATF 
AB023420 APG-2 5.95 
Heat shock protein apg-2; HS24/p52; 
hsp70 
X75042 C-rel 5.94 
V-rel avian reticuloendotheliosis viral 
oncogene homolog; C-rel 
M19720 L-myc 5.93 L-myc proto-oncogene 
AB023420 APG-2 5.92 




NM_000843 GRM6 5.89 Glutamate receptor, metabotropic 6 
NM_001715 Blk 5.88 B lymphoid tyrosine kinase 
M21616 PDGFRB 5.86 
Platelet-derived growth factor receptor, 
beta 
X07024 CCG1p 5.86 
TATA box binding protein (TBP)-
associated factor, RNA polymerase II, 
A, 250kD 
U24166 EB1 5.84 EB1 
NM_002156 HSPD1 5.82 Heat shock 60kD protein 1 
D14520 BTEB2 5.81 
Basic transcription element-binding 
protein 2 (BTEB2) GC-Box binding 
protein 
NM_001166 API1 5.76 Apoptosis inhibitor 1 (API1) 
U86759 Netrin-2 like 5.75 Netrin-2 Like protein 
M14745 Bcl-2 5.72 B-cell CLL/lymphoma 2 
U29680 
BCL2-related protein 
A1 5.72 BCL2-related protein A1; Bfl-1; GRS 
J03241 TGFB3 5.69 Transforming growth factor-beta 3 
L24038 A-raf 5.67 
V-raf murine sarcoma 3611 viral 
oncogene homolog 1; A-RAF1 
X98801 Dynactin 5.67 
Dynactin (p150, Glued (Drosophila) 
homolog) 
AF043254 HSP75 5.63 Heat shock protein 75 
L33075 IQGAP1 5.63 
Ras GTPase-activating-like protein; 
IQGAP1 
S76992 VAV 2 5.59 VAV oncogene homolog 
L08069 
E. coli DnaJ 
homolog 5.59 
Heat shock protein, E. coli DnaJ 
homologue 
NM_007031 HSF2 5.58 
Heat shock transcription factor 2 
binding protein 
AB023421 APG-1 5.49 
Heat shock protein apg-1 (HSP110 
family) 
U31201 Laminin 5.47 Laminin, gamma 2; Nicein; 
NM_000816 
GABA (A) receptor 
gamma 2 5.45 
Gamma-aminobutyric acid (GABA) A 
receptor, gamma 2 
U43746 BRCA2 5.45 
Breast cancer susceptibility (BRCA2) 
gene 
Z23115 Bcl-xL  5.42 BCL2-like 1 
U60519 Caspase-10 5.39 
Caspase 10, apoptosis-related cysteine 
protease 
AF007872 TorsinB 5.36 Dystonia 1; TorsinB 
U43746 BRCA2 5.34 
Breast cancer susceptibility (BRCA2) 
gene 
M14328 Alpha Enolase 5.27 




M95712 B-raf 5.26 
V-raf murine sarcoma viral oncogene 
homolog B1; B-raf 
U15590 HSPB3 5.21 Heat shock 17kD protein 3 (HSPB3) 
M91083 HRC1 5.20 
Chromosome 11 open reading frame 13; 
DNA-binding protein (HRC1) 
U02368 FKHR 5.20 




Thiolesterase 5.19 Ubiquitin Thiolesterase 
AF134397 Apaf-1 5.19 
Apoptotic protease activating factor-1 
long isoform 
U43746 BRCA2 5.18 
Breast cancer susceptibility (BRCA2) 
gene 
Z23115 Bcl-xL  5.16 BCL2-like 1 
M95712 B-raf 5.09 
V-raf murine sarcoma viral oncogene 
homolog B1; B-raf 
NM_004822 Netrin-1 5.08 Netrin 1 
J02966 ANT1 5.07 
Adenine nucleotide translocator 1 
(skeletal muscle) 
U23765 Bak  5.07 Bak protein 
X06182 C-kit 5.07 C-kit proto-oncogene 
U11732 Ets-like 5.06 Ets variant gene 6 (TEL oncogene) 
AF009616 Flame-1 5.05 Flame-1 
M31732 BCL 3 5.03 B-cell CLL/lymphoma 3 
M21616 PDGFRB 5.02 
Platelet-derived growth factor receptor, 
beta 
U18671 STAT2 5.02 
Signal transducer and activator of 
transcription 2 (STAT2) 
X06182 C-kit 5.00 C-kit proto-oncogene 
NM_004134 Mortalin-2 4.99 
Heat shock 70kD protein 9B; mortalin-
2; HSPA9B 
U37448 Caspase-7 4.98 Apoptosis-related cysteine protease 
D15050 TCF8 4.98 
Transcription factor 8 (represses 
interleukin 2 expression) 
L78440 STAT4 4.98 
Signal transducer and activator of 
transcription 4 (STAT4) 
NM_000426 LAMA2 4.93 Laminin, alpha 2 precursor 
AF064019 CAD 4.92 
DNA fragmentation factor, 40 kD, beta 
subuni 
M54915 Pim-1 4.92 Pim-1 proto-oncogene 
M59829 HSP70-like 1 4.92 
MHC class III HSP70-HOM (HLA); 
Heat shock 70kD protein-like 1 
M59828 HSP70-1 4.91 MHC class III HSP70-1 
M57732 
Hepatic nuclear 
factor 1-alpha 4.89 
Transcription factor 1, hepatic; LF-B1, 




M97935 STAT1 4.89 





Hsp27 ERE-TATA-binding protein 
(HET); Scaffold attachment factor B 
U60519 Caspase-10 4.86 




p19INK4d 4.85 Cyclin dependent kinase inhibitor 2D 
L06622 
Endothelin-1 
receptor 4.82 Endothelin receptor type A 
U16296 TIAM1 4.82 
T-lymphoma invasion and metastasis 
inducing 
X63368 HSJ1 4.81 
Heat shock protein, neuronal DNAJ-like 
1 
AB011421 DRAK2 4.79 
Serine/threonine kinase 17b (apoptosis-
inducing) 
NM_000227 LAMA3 4.77 
Laminin, alpha 3 (nicein (150kD), 
kalinin (165kD) 
M61916 LAMB1 4.76 Laminin B1 
X74142 BF-1 4.75 transcription factor BF-1 
D26156 BRG1 4.73 
SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily a, member 4 
X16707 Fra-1 4.72 Fra-1; Fos-Related Antigen 1 
L16464 ETS oncogene 4.72 ETS oncogene (PEP1) 
U94728 Calmodulin 4.72 Calmodulin (CALM2) 
M65217 HSF2 4.70 
Heat shock transcription factor 2 
(HSTF2) 
U11732 Ets-like 4.67 Ets variant gene 6 (TEL oncogene) 
AF010309 Pig3 4.65 Quinone oxidoreductase homolog 
NM_001740 CALB2 4.64 Calretinin; calbindin 2 
NM_007031 HSF2 4.62 
Heat shock transcription factor 2 
binding protein 
X07270 HSP86 4.60 Heat shock protein HSP86 
X16316 VAV 1 4.56 Vav 1 oncogene 
M97935 STAT1 4.56 
Signal transducer and activator of 
transcription 1 
NM_007034 HLJ1 4.55 DnaJ-like heat shock protein 40; HLJ1 
AB017167 SLIT1 4.55 Slit-1 
J04101 ETS 1 4.54 
V-ets avian erythroblastosis virus E26 
oncogene homolog 1 
U75898 
Heat shock 27kD 
protein 2 4.53 Heat shock 27kD protein 2 
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X56773 IGF-I 4.49 
Insulin-like growth factor 1 
(somatomedin C) 
M13228 N-myc 4.47 N-myc oncogene 
U77088 Thymidine kinase 2 4.45 Thymidine kinase 2 (TK2) 
M95809 BTF2 4.45 
Basic transcription factor 62kD subunit 
(BTF2) 
L08069 
E. coli DnaJ 
homolog 4.45 




Associated MTA1 4.44 Metastasis-associated protein MTA1 
NM_004417 DUSP1 4.42 Dual specificity phosphatase 1 
L16464 ETS oncogene 4.39 ETS oncogene (PEP1) 
E01408 
Manganese 
superoxide dismutase 4.39 Manganese superoxide dismutase 
M19720 L-myc 4.34 L-myc proto-oncogene 
Z12020 MDM2 4.28 
Homolog of mouse double minute 2; 
p53-binding protein 
U43188 NERF2 4.26 New Ets-related factor NERF2 
NM_001715 Blk 4.24 B lymphoid tyrosine kinase 
NM_000815 
GABA (A) receptor 
delta 1 4.24 
Gamma-aminobutyric acid (GABA) A 
receptor, delta 
NM_001196 BID 4.22 BH3 interacting domain death agonist 
X63368 HSJ1 4.18 
Heat shock protein, neuronal DNAJ-like 
1 
AB011421 DRAK2 4.15 
Serine/threonine kinase 17b (apoptosis-
inducing) 
L35253 MAPK 14 4.14 Mitogen-activated protein kinase 14 
X07270 HSP86 4.14 Heat shock protein HSP86 
M30640 ELAM1 4.13 
Selectin E; Endothelial leukocyte 
adhesion molecule 1 
AF134397 Apaf-1 4.12 
Apoptotic protease activating factor-1 
long isoform 
X52056 Spi-1 4.11 
Spleen focus forming virus (SFFV) 
proviral integration oncogene; Spi1 
M96577 E2F1 4.10 E2F transcription factor 1 
U43188 NERF2 4.06 New Ets-related factor NERF2 
M54915 Pim-1 4.05 Pim-1 proto-oncogene 
U10149 HSPA-2 4.02 heat shock protein; HSPA-2 
AF143315 PTEN 4.01 PTEN 
U15460 B-ATF 3.97 




M59829 HSP70-like 1 3.93 
MHC class III HSP70-HOM (HLA); 
Heat shock 70kD protein-like 1 
AF015956 
Death Associated 





Zinc finger protein homologous to Zfp-
36 in mouse 
M93255 Fli-1 3.89 Friend leukemia virus integration 1 
M59828 HSP70-1 3.85 MHC class III HSP70-1 
AF143315 PTEN 3.84 PTEN 
K03214 C-src 3.81 C-SRC-1 proto-oncogene 
M65217 HSF2 3.79 
Heat shock transcription factor 2 
(HSTF2) 
X07270 HSP86 3.77 Heat shock protein HSP86 
S82769 
GABAA receptor 
gamma 3 subunit 3.77 GABAA receptor gamma 3 subunit 
L06622 
Endothelin-1 
receptor 3.76 Endothelin receptor type A 
NM_001538 HSF4 3.72 Heat shock transcription factor 4 
X53961 Lactotransferrin 3.71 Lactotransferrin; LACTOFERRIN 
U20536 Caspase-6 3.61 




S16 3.61 Ribosomal protein S16 




Gamma-aminobutyric acid (GABA) A 
receptor, alpha 2 
AB003333 HSP105 beta 3.57 HSP105 beta 
D15050 TCF8 3.57 
Transcription factor 8 (represses 




Gamma-aminobutyric acid (GABA) A 
receptor, alpha 3 




Telomerase reverse transcriptase, 
catalytic subunit 
NM_004134 Mortalin-2 3.53 
Heat shock 70kD protein 9B; mortalin-
2; HSPA9B 
M95809 BTF2 3.52 
Basic transcription factor 62kD subunit 
(BTF2) 
M13228 N-myc 3.51 N-myc oncogene 
X66079 Spi-B 3.51 Spi-B transcription factor 
X79981 VE-cadherin 3.49 VE-cadherin 
M61916 LAMB1 3.48 Laminin B1 
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U15306 NFX1 3.47 
Cysteine-rich sequence-specific DNA-
binding protein NFX1 
U96876 
Insulin induced 
protein 1 3.47 Insulin induced protein 1 
U10149 HSPA-2 3.42 heat shock protein; HSPA-2 
V00568 C-myc 3.39 C-myc oncogene 
M76766 TFIIB 3.36 Transcription factor IIB (GTF2B) 
NM_000816 
GABA (A) receptor 
gamma 2 3.35 
Gamma-aminobutyric acid (GABA) A 
receptor, gamma 2 
Z30094 BTF2p44 3.35 Basic transcription 2 factor 44 kD 
NM_001165 API2 3.35 Apoptosis inhibitor 2 
X79981 VE-cadherin 3.34 VE-cadherin 
AF009616 Flame-1 3.26 Flame-1 
U11732 Ets-like 3.26 Ets variant gene 6 (TEL oncogene) 
X80692 Erk3 3.25 ERK3 
U86759 Netrin-2 like 3.24 Netrin-2 Like protein 
M15990 C-yes-1 3.22 
V-yes-1 Yamaguchi sarcoma viral 
oncogene homolog 1; C-yes-1 
AF010309 Pig3 3.21 Quinone oxidoreductase homolog 
U43142 VEGFC 3.20 
Vascular endothelial growth factor 
related protein VRP 
U86759 Netrin-2 like 3.20 Netrin-2 Like protein 
M26760 ALDH-2 3.19 
Aldehyde dehydrogenase 2, 
mitochondrial 
X97567 Arfaptin 2 3.19 Partner of RAC1 (arfaptin 2);por1 
M13228 N-myc 3.16 N-myc oncogene 
NM_004419 DUSP5 3.15 Dual specificity phosphatase 5 
U29680 
BCL2-related protein 
A1 3.13 BCL2-related protein A1; Bfl-1; GRS 




Gamma-aminobutyric acid (GABA) A 
receptor, alpha 6 
Z29083 5T4 3.07 5T4 oncofetal trophoblast glycoprotein 
M31165 TSG-6 3.07 
Tumor necrosis factor, alpha-induced 
protein 6 
Z29646 IPP-2 3.05 Inhibitor 2 of protein phosphatase 1 
D14520 BTEB2 3.02 
Basic transcription element-binding 
protein 2 (BTEB2) GC-Box binding 
protein 
NM_001740 CALB2 3.00 Calretinin; calbindin 2 
NM_004417 DUSP1 2.97 Dual specificity phosphatase 1 
J03358 FER 2.94 




AF010309 Pig3 2.93 Quinone oxidoreductase homolog 
X06234 Calgranulin A 2.93 
S100 Calcium-binding protein A8 
(calgranulin A) 
X66079 Spi-B 2.92 Spi-B transcription factor 
U02368 FKHR 2.91 
Forkhead (Drosophila) homolog 1 
(rhabdomyosarcoma) 
AF129085 CHIP 2.91 
Carboxy terminus of Hsp70-interacting 
protein; CHIP 




Gamma-aminobutyric acid (GABA) A 




Hsp27 ERE-TATA-binding protein 
(HET); Scaffold attachment factor B 
X80692 Erk3 2.84 ERK3 
U94728 Calmodulin 2.83 Calmodulin (CALM2) 
AB003333 HSP105 beta 2.81 HSP105 beta 
AB007144 ZIP kinase 2.80 ZIP-kinase 
M19720 L-myc 2.79 L-myc proto-oncogene 
M96577 E2F1 2.78 E2F transcription factor 1 
X16707 Fra-1 2.78 Fra-1; Fos-Related Antigen 1 
AF174487 BOK 2.76 
BCL-2-related ovarian killer protein; 
BOK 
V00568 C-myc 2.75 C-myc oncogene 
V00568 C-myc 2.73 C-myc oncogene 
NM_002156 HSPD1 2.72 Heat shock 60kD protein 1 
X79483 Erk6 2.71 
ERK6;Mitogen-activated protein kinase 
12 
AF020760 OMI 2.70 Serine protease; OMI 
J03133 TSFP1 2.70 Transcription factor SP1 
M13975 
Protein Kinase C 
Beta II  2.69 Protein kinase C beta-II 
NM_004263 SemaW 2.69 Semaphorin W 
X52541 EGR1 2.68 
Early growth response protein 1 
(EGR1); transcription factor ETR103 
X02751 NRas 2.67 
Neuroblastoma RAS viral (v-ras) 
oncogene homolog 
AF174487 BOK 2.66 
BCL-2-related ovarian killer protein; 
BOK 
U75898 
Heat shock 27kD 
protein 2 2.64 Heat shock 27kD protein 2 
U14417 RalGDS 2.62 
Ral guanine nucleotide dissociation 
stimulator; RalGDS 
X02751 NRas 2.61 
Neuroblastoma RAS viral (v-ras) 
oncogene homolog 
D14012 HGF activator 2.61 




X79981 VE-cadherin 2.60 VE-cadherin 
NM_007034 HLJ1 2.59 DnaJ-like heat shock protein 40; HLJ1 
AB017169 SLIT3 2.55 Slit-3 
U56390 Caspase-9  2.51 
 Cysteine protease; ICE-LAP6;Caspase-
9 
X97567 Arfaptin 2 2.49 Partner of RAC1 (arfaptin 2);por1 
M57732 
Hepatic nuclear 
factor 1-alpha 2.47 
Transcription factor 1, hepatic; LF-B1, 
hepatic nuclear factor (HNF1), albumin 
proximal factor 
X87949 BiP 2.45 
BiP;Heat shock 70kD protein 5 
(glucose-regulated protein, 78kD) 
NM_005526 HSF1 2.45 Heat shock transcription factor 1 
NM_007034 HLJ1 2.45 DnaJ-like heat shock protein 40; HLJ1 
D14497 Map3K8 2.43 
Mitogen-activated protein kinase kinase 
kinase 8 
M16660 90-kDa HSP 2.39 90-kDa heat-shock protein 1, beta 
U17760 LAMB3 2.37 Laminin S B3 chain; LAMB3 
U43188 NERF2 2.36 New Ets-related factor NERF2 
U96876 
Insulin induced 
protein 1 2.36 Insulin induced protein 1 
L19067 P65 2.35 
V-rel avian reticuloendotheliosis viral 
oncogene homolog A (nuclear factor of 
kappa light polypeptide gene enhancer 
in B-cells 3 (p65) 
AB016193 Elk1 2.34 ELK1, member of ETS oncogene family 
D13316 
Respiratory factor-2 
subunit gamma 2 2.28 
GA-binding protein transcription factor, 
beta subunit 2 (47kD) 
M87290 
Angiotensin receptor 




Gamma-aminobutyric acid (GABA) A 
receptor, alpha 3 
NM_000843 GRM6 2.23 Glutamate receptor, metabotropic 6 
M62810 
Mitochondrial 
transcription factor 1 2.22 Mitochondrial transcription factor 1 
AF087438 PPP2R1B 2.21 
Protein phosphatase 2 subunit A isoform 
beta 
X67951 PAG-A 2.19 
Proliferation-associated gene A (natural 
killer-enhancing factor A) 
M76766 TFIIB 2.18 Transcription factor IIB (GTF2B) 
X98801 Dynactin 2.16 




AF005774 CLARP 2.15 





Proteasome (prosome, macropain) 
subunit, beta type, 7 
L26081 Sema III 2.14 semaphorin-III 
X67951 PAG-A 2.08 
Proliferation-associated gene A (natural 
killer-enhancing factor A) 
X16316 VAV 1 2.07 Vav 1 oncogene 
U94728 Calmodulin 2.06 Calmodulin (CALM2) 
M14752 ABL1 2.05 
V-abl Abelson murine leukemia viral 
oncogene homolog 1 
Table A3: Liver Cirrhosis with HBV infection compared with normal, genes up 







ID Short Gene Name 
Fold 
Difference Long Gene Name 
D12614 TNF-beta 300.00 Lymphotoxin (TNF-beta) 
M87290 
Angiotensin 
receptor I 103.45 
ANGIOTENSIN II RECEPTOR type 
1 
K03195 HEPG2 88.24 
Solute carrier family 2 (facilitated 
glucose transporter), member 1 
L33075 IQGAP1 81.08 
Ras GTPase-activating-like protein; 
IQGAP1 
U14680 BRCA 1 30.00 
Breast and ovarian cancer 
susceptibility 
NM_000433 NCF2 14.22 Neutrophil cytosolic factor 2 
AF134397 Apaf-1 12.93 
Apoptotic protease activating factor-
1 long isoform 
U15642 E2F5 12.10 Transcription factor E2F-5 
NM_000318 PMP35 9.32 Peroxisomal membrane protein 3 
U15642 E2F5 9.23 Transcription factor E2F-5 
NM_000069 CACNA1S 8.80 
Calcium channel, voltage-dependent, 
L type, alpha 1S subunit 
D14012 HGF activator 8.43 
Hepatocyte growth factor (HGF) 
activator precursor 
L16785 PM5 protein 8.13 




L26318 JNK1 7.18 
JNK1; Mitogen-activated protein 
kinase 8 
NM_002111 HD 6.88 Huntington Disease 
J05081 Endothelin 3 6.24 Endothelin 3 
Y09392 TNFR 12 6.12 
Tumor necrosis factor receptor, 
member 12 (translocating chain-
association membrane protein) 
U73036 IRF-7 5.74 Interferon regulatory factor 7 
AF068754 HSFBP1 5.55 
Heat shock factor binding protein 1 
HSBP1 
U33841 ATM 5.21 Ataxia telangiectasia gene 
NM_000816 
GABA (A) 
receptor gamma 2 4.14 
Gamma-aminobutyric acid (GABA) 
A receptor, gamma 2 
M99487 
Prostate-specific 
membrane antigen 4.02 
Prostate-specific membrane antigen 
(PSM) 
AF078078 GADD45 3.83 
Growth arrest and DNA-damage-
inducible protein 
U22398 P57kip2 3.65 Cdk-inhibitor; p57KIP2; KIP2 
Z71389 Beta-defensin 2 3.58 Beta-defensin 2 
Z29083 5T4 3.44 
5T4 oncofetal trophoblast 
glycoprotein 
NM_002157 HSPE1 3.41 Heat shock 10kD protein 1 
NM_000844 GRM7 3.34 Glutamate receptor, metabotropic 7 
NM_001752 CAT 3.31 Catalase 
X16316 VAV 1 3.19 Vav 1 oncogene 
X53961 Lactotransferrin 2.93 Lactotransferrin; LACTOFERRIN 
L06139 TEK Receptor 2.93 ANGIOPOIETIN 1 RECEPTOR 




variable region 2.78 
Immunoglobulin heavy chain 
variable region 
NM_002043 
GABA (A) rho-2 
receptor 2.75 
Gamma-aminobutyric acid (GABA) 
receptor, rho 2 
NM_002157 HSPE1 2.75 Heat shock 10kD protein 1 
U47686 STAT5B 2.59 
Signal transducer and activator of 
transcription Stat5B 
X66365 CDK6 2.53 Cyclin-dependent kinase 6 
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U23765 Bak  2.50 Bak protein 
X56773 IGF-I 2.50 
Insulin-like growth factor 1 
(somatomedin C) 
J04536 CD43 2.33 Sialophorin (CD43) 
NM_001752 CAT 2.25 Catalase 
U47686 STAT5B 2.25 
Signal transducer and activator of 
transcription Stat5B 
M64240 MAX 2.20 
Helix-loop-helix zipper protein 
(max) 
S76992 VAV 2 2.17 VAV oncogene homolog 
NM_001752 CAT 2.16 Catalase 
U25278 Erk5 2.16 ERK5 
S82769 
GABAA receptor 




Gamma-aminobutyric acid (GABA) 
A receptor, alpha 4 
AF088982 HSP40-3 2.07 Heat shock protein hsp40-3 
Y10479 E2F3 2.03 E2F-3 transcription factor 
 
Table A4: Liver Cirrhosis with HBV infection compared with normal, genes down 







ID Short Gene Name 
Fold 
Diffrence Long Gene Name 
M31165 TSG-6 3310.53 
Tumor necrosis factor, alpha-induced 
protein 6 
NM_004929 CALB1 193.07 calbindin 1 
X67951 PAG-A 104.99 
Proliferation-associated gene A 
(natural killer-enhancing factor A) 
Z30094 BTF2p44 104.81 Basic transcription 2 factor 44 kD 
AB003334 HSP105 alpha 74.39 HSP105 alpha 
D10495 
Protein Kinase C 
delta 2 73.76 Protein kinase C delta 
X07270 HSP86 66.25 Heat shock protein HSP86 
M87503 IFNRTF 60.71 
Interferon-alpha (IFN) responsive 
transcription factor subunit 
U60519 Caspase-10 58.75 




L27211 p16-INK4  54.08  CDK4-inhibitor 
X89986 Bik 48.30 NBK apoptotic inducer protein 
AB017169 SLIT3 39.72 Slit-3 
D14012 HGF activator 29.84 




factor receptor 28.74 Platelet activating factor receptor 
J04536 CD43 26.19 Sialophorin (CD43) 
NM_005528 HSPF2 24.88 Heat shock 40kD protein 2; HSPF2 
X59869 TCF7 23.71 
Transcription factor 7 (T-cell specific, 
HMG-box) 
M97935 STAT1 23.28 
Signal transducer and activator of 
transcription 1 
Y10479 E2F3 21.53 E2F-3 transcription factor 
X54079 HSP27 21.17 Heat shock protein HSP27 
X57110 C-cbl 20.96 C-cbl proto-oncogene 
X06820 RhoB 19.54 RhoB 
L06622 
Endothelin-1 
receptor 19.11 Endothelin receptor type A 
M91083 HRC1 17.24 
Chromosome 11 open reading frame 
13; DNA-binding protein (HRC1) 
U28838 HTFIIIB90 16.95 
Transcription factor TFIIIB 90 kDa 
subunit 
L08069 
E. coli DnaJ 
homolog 16.57 




catalytic subunit 16.54 
Telomerase reverse transcriptase, 
catalytic subunit 
NM_000843 GRM6 16.35 Glutamate receptor, metabotropic 6 
M30640 ELAM1 16.23 
Selectin E; Endothelial leukocyte 
adhesion molecule 1 
X98801 Dynactin 15.61 
Dynactin (p150, Glued (Drosophila) 
homolog) 
X52056 Spi-1 15.33 
Spleen focus forming virus (SFFV) 
proviral integration oncogene; Spi1 
X52104 p68 14.92 
DEAD/H (Asp-Glu-Ala-Asp/His) box 
polypeptide 5 (RNA helicase, 68kD); 
p68 
U43188 NERF2 14.68 New Ets-related factor NERF2 
U17760 LAMB3 14.09 Laminin S B3 chain; LAMB3 
D26156 BRG1 13.98 
SWI/SNF related, matrix associated, 
actin dependent regulator of 
chromatin, subfamily a, member 4 
M14328 Alpha Enolase 13.91 
Ferritin, heavy polypeptide 1; alpha 
enolase 
U72355 Hsp27 ERE- 13.86 Hsp27 ERE-TATA-binding protein 
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TATA-binding (HET); Scaffold attachment factor B 
X60003 Delta CREB1 13.62 




Thiolesterase 13.61 Ubiquitin Thiolesterase 
NM_005528 HSPF2 13.47 Heat shock 40kD protein 2; HSPF2 
L16785 PM5 protein 13.47 
PM5 protein; c-myc transcription 
factor (puf) 
M34065 Cdc25C 13.34 Cell division cycle 25C; Cdc25C 
X06233 Calgranulin B 13.04 
S100 Calcium-binding protein A9 
(calgranulin B) 
U15460 B-ATF 12.99 
Activating transcription factor B; 
bZip;B-ATF 
X56681 JunD 12.87 JunD 
AF028832 
Hsp89-alpha-delta-
N 12.32 Hsp89-alpha-delta-N 
M13975 
Protein Kinase C 
Beta II  12.07 Protein kinase C beta-II 
L26081 Sema III 12.00 semaphorin-III 
X98801 Dynactin 11.57 
Dynactin (p150, Glued (Drosophila) 
homolog) 
X51757 HSP70B 11.53 Heat-shock protein HSP70B' 
J04111 C-jun 10.58 
Transcription factor AP-1; c-jun proto 
oncogene 
L35253 MAPK 14 10.57 Mitogen-activated protein kinase 14 




SII 10.55 Transcription elongation factor (SII) 
U29680 
BCL2-related 
protein A1 10.27 BCL2-related protein A1; Bfl-1; GRS 
AF005774 CLARP 10.10 




gamma 3 subunit 9.90 GABAA receptor gamma 3 subunit 
X55122 GATA-3 9.84 GATA-binding protein 3 
X67951 PAG-A 9.81 
Proliferation-associated gene A 
(natural killer-enhancing factor A) 
X06234 Calgranulin A 9.71 
S100 Calcium-binding protein A8 
(calgranulin A) 
S76992 VAV 2 9.65 VAV oncogene homolog 
U86759 Netrin-2 like 9.55 Netrin-2 Like protein 
M14091 TBG 9.44 Thyroxine-binding globulin 
M87290 
Angiotensin 
receptor I 9.37 






receptor gamma 2 9.20 
Gamma-aminobutyric acid (GABA) A 
receptor, gamma 2 
Z29083 5T4 9.18 5T4 oncofetal trophoblast glycoprotein 
Z29083 5T4 9.13 5T4 oncofetal trophoblast glycoprotein 
D14497 Map3K8 9.09 
Mitogen-activated protein kinase 
kinase kinase 8 
X03484 Raf1 8.86 Raf1 oncogene 
M30640 ELAM1 8.75 
Selectin E; Endothelial leukocyte 
adhesion molecule 1 
M26760 ALDH-2 8.60 
Aldehyde dehydrogenase 2, 
mitochondrial 
D26156 BRG1 8.55 
SWI/SNF related, matrix associated, 
actin dependent regulator of 
chromatin, subfamily a, member 4 
U15306 NFX1 8.50 
Cysteine-rich sequence-specific DNA-
binding protein NFX1 
X55122 GATA-3 8.47 GATA-binding protein 3 
M30640 ELAM1 8.46 
Selectin E; Endothelial leukocyte 
adhesion molecule 1 
NM_000816 
GABA (A) 
receptor gamma 2 8.42 
Gamma-aminobutyric acid (GABA) A 
receptor, gamma 2 
L26081 Sema III 8.22 semaphorin-III 
M21616 PDGFRB 8.21 
Platelet-derived growth factor 
receptor, beta 
X02317 SOD 8.11 
Superoxide dismutase 1, soluble 
(amyotrophic lateral sclerosis 1 
(adult)) 
U85658 ERF-1 8.05 
AP2 gamma (ERF-1) transcription 
factor 
U33052 PRK2 7.83 Lipid-activated protein kinase PRK2 
U22398 P57kip2 7.74 Cdk-inhibitor; p57KIP2; KIP2 
M55284 Protein Kinase C-L 7.74 Protein kinase C-L 
AF015950 
Telomerase 
catalytic subunit 7.66 
Telomerase reverse transcriptase, 
catalytic subunit 
J03358 FER 7.61 
Fer (fps/fes related) tyrosine kinase 
(phosphoprotein NCP94) 
J04101 ETS 1 7.53 
V-ets avian erythroblastosis virus E26 
oncogene homolog 1 
U77088 
Thymidine kinase 
2 7.50 Thymidine kinase 2 (TK2) 
U15460 B-ATF 7.17 
Activating transcription factor B; 
bZip;B-ATF 
U15642 E2F5 7.16 Transcription factor E2F-5 
M81601 TEF (SII) 7.15 Transcription elongation factor (SII) 
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D26156 BRG1 7.06 
SWI/SNF related, matrix associated, 
actin dependent regulator of 
chromatin, subfamily a, member 4 
NM_000426 LAMA2 6.95 Laminin, alpha 2 precursor 
J04111 C-jun 6.85 
Transcription factor AP-1; c-jun proto 
oncogene 
U31201 Laminin 6.83 Laminin, gamma 2; Nicein; 
X07024 CCG1p 6.82 
TATA box binding protein (TBP)-
associated factor, RNA polymerase II, 
A, 250kD 
X57110 C-cbl 6.80 C-cbl proto-oncogene 
J04111 C-jun 6.68 










Gamma-aminobutyric acid (GABA) A 
receptor, alpha 2 
AB031042 Lhx6 6.61 
LIM-homeodomain (LHX) protein 
6.1b 
J03133 TSFP1 6.58 Transcription factor SP1 
U02368 FKHR 6.49 





Gamma-aminobutyric acid (GABA) A 
receptor, alpha 3 
M14694 P53 6.36 P53 cellular tumor antigen 
AF087438 PPP2R1B 6.35 




Thiolesterase 6.33 Ubiquitin Thiolesterase 
L31951 JNK2 6.31 
Mitogen-activated protein kinase 9; 
JNK2 
X52541 EGR1 6.31 
Early growth response protein 1 
(EGR1); transcription factor ETR103 
X77166 HKIB9 6.29 Kunitz-type protease inhibitor, HKIB9 
AB031042 Lhx6 6.28 
LIM-homeodomain (LHX) protein 
6.1b 
M87503 IFNRTF 6.21 
Interferon-alpha (IFN) responsive 
transcription factor subunit 
NM_000816 
GABA (A) 
receptor gamma 2 6.09 
Gamma-aminobutyric acid (GABA) A 
receptor, gamma 2 
NM_000227 LAMA3 6.08 
Laminin, alpha 3 (nicein (150kD), 
kalinin (165kD) 
NM_001740 CALB2 6.08 Calretinin; calbindin 2 
M33294 TNF-R1 5.96 Tumor necrosis factor receptor I 
NM_000809 GABA(A) receptor 5.96 Gamma-aminobutyric acid (GABA) A 
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alpha-4 receptor, alpha 4 
U14417 RalGDS 5.95 
Ral guanine nucleotide dissociation 
stimulator; RalGDS 
M55284 Protein Kinase C-L 5.94 Protein kinase C-L 
M14328 Alpha Enolase 5.94 
Ferritin, heavy polypeptide 1; alpha 
enolase 
M14091 TBG 5.91 Thyroxine-binding globulin 
U15306 NFX1 5.84 
Cysteine-rich sequence-specific DNA-
binding protein NFX1 
U43142 VEGFC 5.79 
Vascular endothelial growth factor 
related protein VRP 
U24166 EB1 5.76 EB1 
U31201 Laminin 5.75 Laminin, gamma 2; Nicein; 
X79981 VE-cadherin 5.71 VE-cadherin 
X79483 Erk6 5.68 
ERK6;Mitogen-activated protein 
kinase 12 
AF068754 HSFBP1 5.66 
Heat shock factor binding protein 1 
HSBP1 
X76132 DCC 5.65 Deleted in colorectal carcinoma 
U15642 E2F5 5.65 Transcription factor E2F-5 
NM_001166 API1 5.59 Apoptosis inhibitor 1 (API1) 
X52541 EGR1 5.53 
Early growth response protein 1 
(EGR1); transcription factor ETR103 
M14745 Bcl-2 5.38 B-cell CLL/lymphoma 2 
M87290 
Angiotensin 
receptor I 5.31 
ANGIOTENSIN II RECEPTOR type 
1 
AF005774 CLARP 5.31 





Proteasome (prosome, macropain) 
subunit, beta type, 7 
U56390 Caspase-9  5.25 
 Cysteine protease; ICE-
LAP6;Caspase-9 
AF010309 Pig3 5.22 Quinone oxidoreductase homolog 
U28838 HTFIIIB90 5.22 




protein 6 5.16 GATA-binding protein 6 
Y09392 TNFR 12 5.12 
Tumor necrosis factor receptor, 
member 12 (translocating chain-
association membrane protein) 
Z29646 IPP-2 5.09 Inhibitor 2 of protein phosphatase 1 
M21574 PDGFRA 5.09 
Platelet-derivied growth factor 
receptor, alpha 
J04101 ETS 1 5.07 
V-ets avian erythroblastosis virus E26 
oncogene homolog 1 
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U15460 B-ATF 5.05 
Activating transcription factor B; 
bZip;B-ATF 
M61916 LAMB1 5.05 Laminin B1 
AB007144 ZIP kinase 5.00 ZIP-kinase 
U16296 TIAM1 4.95 
T-lymphoma invasion and metastasis 
inducing 
U60519 Caspase-10 4.91 





variable region 4.87 
Immunoglobulin heavy chain variable 
region 
U73036 IRF-7 4.86 Interferon regulatory factor 7 
NM_004929 CALB1 4.84 calbindin 1 
X07024 CCG1p 4.82 
TATA box binding protein (TBP)-
associated factor, RNA polymerase II, 
A, 250kD 
D12614 TNF-beta 4.76 Lymphotoxin (TNF-beta) 
L31951 JNK2 4.75 
Mitogen-activated protein kinase 9; 
JNK2 
U18671 STAT2 4.74 
Signal transducer and activator of 
transcription 2 (STAT2) 
NM_000227 LAMA3 4.73 
Laminin, alpha 3 (nicein (150kD), 
kalinin (165kD) 
AF007872 TorsinB 4.72 Dystonia 1; TorsinB 
X03484 Raf1 4.71 Raf1 oncogene 
M97935 STAT1 4.68 
Signal transducer and activator of 
transcription 1 
X06820 RhoB 4.60 RhoB 
L33075 IQGAP1 4.58 
Ras GTPase-activating-like protein; 
IQGAP1 
NM_001165 API2 4.55 Apoptosis inhibitor 2 
AF007871 TorsinA 4.45 Dystonia 1; torsin A 





Zinc finger protein homologous to 
Zfp-36 in mouse 
NM_004822 Netrin-1 4.40 Netrin 1 
D13316 
Respiratory factor-
2 subunit gamma 2 4.39 
GA-binding protein transcription 
factor, beta subunit 2 (47kD) 
AF007872 TorsinB 4.36 Dystonia 1; TorsinB 
U18671 STAT2 4.32 
Signal transducer and activator of 
transcription 2 (STAT2) 
U43747 Frataxin 4.25 Frataxin; Friedreich ataxia 
U94728 Calmodulin 4.24 Calmodulin (CALM2) 
Z29646 IPP-2 4.24 Inhibitor 2 of protein phosphatase 1 
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U14680 BRCA 1 4.21 




protein 1 4.18 Insulin induced protein 1 




Gamma-aminobutyric acid (GABA) A 
receptor, alpha 2 
U11732 Ets-like 4.12 Ets variant gene 6 (TEL oncogene) 
M13228 N-myc 4.10 N-myc oncogene 
M21574 PDGFRA 4.07 
Platelet-derivied growth factor 
receptor, alpha 
L26318 JNK1 4.02 





Gamma-aminobutyric acid (GABA) A 
receptor, alpha 4 
AF007872 TorsinB 4.01 Dystonia 1; TorsinB 
U31176 ERV1 3.99 ERV1 
Y09392 TNFR 12 3.99 
Tumor necrosis factor receptor, 
member 12 (translocating chain-
association membrane protein) 
NM_000815 
GABA (A) 
receptor delta 1 3.97 
Gamma-aminobutyric acid (GABA) A 
receptor, delta 
U86759 Netrin-2 like 3.87 Netrin-2 Like protein 
X01677 GAPDH 3.81 
Glyceraldehyde-3-phosphate 
dehydrogenase 
L41690 TRADD 3.80 
TNF receptor-1 associated protein; 
TRADD 
NM_004822 Netrin-1 3.79 Netrin 1 
U94728 Calmodulin 3.78 Calmodulin (CALM2) 
U94728 Calmodulin 3.78 Calmodulin (CALM2) 
AF174487 BOK 3.70 
BCL-2-related ovarian killer protein; 
BOK 
X63368 HSJ1 3.66 




receptor I 3.64 
ANGIOTENSIN II RECEPTOR type 
1 
AF068754 HSFBP1 3.60 
Heat shock factor binding protein 1 
HSBP1 
L12002 Integrin-alpha IV 3.59 Integrin alpha 4 subunit 
Z23115 Bcl-xL  3.58 BCL2-like 1 
NM_003824 FADD 3.54 
Fas (TNFRSF6)-associated via death 
domain (FADD) 
X07270 HSP86 3.50 Heat shock protein HSP86 
U14680 BRCA 1 3.49 




U35835 DNA-PK 3.47 
DNA-dependent protein kinase 
catalytic subunit 
X63368 HSJ1 3.43 
Heat shock protein, neuronal DNAJ-
like 1 
S76992 VAV 2 3.42 VAV oncogene homolog 
X77166 HKIB9 3.40 Kunitz-type protease inhibitor, HKIB9 
U43142 VEGFC 3.35 
Vascular endothelial growth factor 
related protein VRP 
AF028832 
Hsp89-alpha-delta-
N 3.35 Hsp89-alpha-delta-N 




Gamma-aminobutyric acid (GABA) A 
receptor, alpha 4 
M81933 Cdc25A 3.32 Cell division cycle 25A; Cdc25a 
D14497 Map3K8 3.28 
Mitogen-activated protein kinase 
kinase kinase 8 
NM_000843 GRM6 3.27 Glutamate receptor, metabotropic 6 
AB011421 DRAK2 3.24 
Serine/threonine kinase 17b 
(apoptosis-inducing) 




Gamma-aminobutyric acid (GABA) A 
receptor, alpha 3 
NM_001165 API2 3.23 Apoptosis inhibitor 2 
M91083 HRC1 3.22 
Chromosome 11 open reading frame 
13; DNA-binding protein (HRC1) 




SII 3.17 Transcription elongation factor (SII) 
M15990 C-yes-1 3.16 
V-yes-1 Yamaguchi sarcoma viral 
oncogene homolog 1; C-yes-1 
AF087438 PPP2R1B 3.14 
Protein phosphatase 2 subunit A 
isoform beta 
AB017169 SLIT3 3.13 Slit-3 
NM_001740 CALB2 3.10 Calretinin; calbindin 2 
AB003333 HSP105 beta 3.10 HSP105 beta 
J03358 FER 3.08 
Fer (fps/fes related) tyrosine kinase 
(phosphoprotein NCP94) 
X79981 VE-cadherin 3.08 VE-cadherin 
L41690 TRADD 3.08 
TNF receptor-1 associated protein; 
TRADD 





Zinc finger protein homologous to 
Zfp-36 in mouse 
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M14091 TBG 2.97 Thyroxine-binding globulin 
M63167 Rac-alpha 2.97 
V-akt murine thymoma viral oncogene 




Gamma-aminobutyric acid (GABA) A 
receptor, alpha 2 
AB017167 SLIT1 2.97 Slit-1 
Z11933 N-oct3 2.96 
POU domain, class 3, transcription 
factor 2 
AB003334 HSP105 alpha 2.96 HSP105 alpha 
NM_005526 HSF1 2.95 Heat shock transcription factor 1 
X66365 CDK6 2.91 Cyclin-dependent kinase 6 
X79483 Erk6 2.87 
ERK6;Mitogen-activated protein 
kinase 12 
X06233 Calgranulin B 2.86 
S100 Calcium-binding protein A9 
(calgranulin B) 
X77166 HKIB9 2.86 Kunitz-type protease inhibitor, HKIB9 
M23452 MIP1-ALPHA 2.84 
Macrophage inflammatory protein; 
Small inducible cytokine A3 
(homologous to mouse Mip-1a) 
Z11933 N-oct3 2.83 
POU domain, class 3, transcription 
factor 2 
NM_001715 Blk 2.83 B lymphoid tyrosine kinase 
S82769 
GABAA receptor 
gamma 3 subunit 2.82 GABAA receptor gamma 3 subunit 
D10495 
Protein Kinase C 
delta 2 2.81 Protein kinase C delta 
AF068754 HSFBP1 2.79 
Heat shock factor binding protein 1 
HSBP1 
L33075 IQGAP1 2.71 
Ras GTPase-activating-like protein; 
IQGAP1 
X63368 HSJ1 2.68 
Heat shock protein, neuronal DNAJ-
like 1 
M74178 HGFL 2.67 
Macrophage stimulating 1 (hepatocyte 
growth factor-like) 
X67951 PAG-A 2.67 
Proliferation-associated gene A 
(natural killer-enhancing factor A) 
X76132 DCC 2.67 Deleted in colorectal carcinoma 
L09210 
Inducible nitric 
oxide synthase 2.65 Inducible nitric oxide synthase 
X16707 Fra-1 2.62 Fra-1; Fos-Related Antigen 1 
M29870 Rac1 2.57 
Ras-related C3 botulinum toxin 
substrate 1 (rho family, small GTP 
binding protein Rac1) 
U75898 
Heat shock 27kD 
protein 2 2.56 Heat shock 27kD protein 2 
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dismutase 2.52 Manganese superoxide dismutase 
Y10479 E2F3 2.46 E2F-3 transcription factor 
NM_001166 API1 2.43 Apoptosis inhibitor 1 (API1) 
NM_000227 LAMA3 2.42 
Laminin, alpha 3 (nicein (150kD), 
kalinin (165kD) 
M61916 LAMB1 2.41 Laminin B1 
J03133 TSFP1 2.39 Transcription factor SP1 
AF087438 PPP2R1B 2.39 
Protein phosphatase 2 subunit A 
isoform beta 
M31165 TSG-6 2.38 
Tumor necrosis factor, alpha-induced 
protein 6 
M90813 Cyclin D2 2.36 D-type cyclin (CCND2) 
AF174487 BOK 2.32 
BCL-2-related ovarian killer protein; 
BOK 
M26760 ALDH-2 2.23 
Aldehyde dehydrogenase 2, 
mitochondrial 
U43746 BRCA2 2.21 




protein A1 2.20 BCL2-related protein A1; Bfl-1; GRS 
U14680 BRCA 1 2.19 
Breast and ovarian cancer 
susceptibility 
AB017167 SLIT1 2.16 Slit-1 
NM_005526 HSF1 2.15 Heat shock transcription factor 1 
M21616 PDGFRB 2.14 




2 2.14 Thymidine kinase 2 (TK2) 
U20657 
Ubiquitin Specific 
Protease 2.12 Ubiquitin Specific Protease 
NM_005528 HSPF2 2.12 Heat shock 40kD protein 2; HSPF2 
X06234 Calgranulin A 2.11 
S100 Calcium-binding protein A8 
(calgranulin A) 
U75898 
Heat shock 27kD 
protein 2 2.11 Heat shock 27kD protein 2 
M81933 Cdc25A 2.10 Cell division cycle 25A; Cdc25a 
NM_000843 GRM6 2.10 Glutamate receptor, metabotropic 6 




Hsp27 ERE-TATA-binding protein 
(HET); Scaffold attachment factor B 
Z23115 Bcl-xL  2.05 BCL2-like 1 




U02368 FKHR 2.04 
Forkhead (Drosophila) homolog 1 
(rhabdomyosarcoma) 
Y11416 P73 2.03 Tumor protein P73 
L26318 JNK1 2.03 
JNK1; Mitogen-activated protein 
kinase 8 
Table A5: Primary HCC compared with normal, genes up regulated by at least 2 fold in 








Diffrence Long Gene Name 
M65217 HSF2 69.77 





dismutase 55.56 Manganese superoxide dismutase 
J03358 FER 54.55 
Fer (fps/fes related) tyrosine kinase 
(phosphoprotein NCP94) 
U75898 
Heat shock 27kD 
protein 2 42.25 Heat shock 27kD protein 2 
M59828 HSP70-1 40.54 MHC class III HSP70-1 
AF088982 HSP40-3 39.47 Heat shock protein hsp40-3 
NM_004419 DUSP5 36.59 Dual specificity phosphatase 5 
X89986 Bik 29.41 NBK apoptotic inducer protein 
NM_001196 BID 26.79 




beta 25.42 DNA polymerase beta 
M13228 N-myc 24.39 N-myc oncogene 
M29870 Rac1 23.08 
Ras-related C3 botulinum toxin 
substrate 1 (rho family, small GTP 
binding protein Rac1) 
M34353 ROS1 17.86 
Transmembrane tyrosine-specific 
protein kinase (ROS1) 
AF028832 
Hsp89-alpha-
delta-N 12.66 Hsp89-alpha-delta-N 
L35253 MAPK 14 9.32 Mitogen-activated protein kinase 14 
M15400 Rb 9.09 
Retinoblastoma susceptibility gene, 
Rb 
NM_003244 TGIF 8.11 




U19727 Tau 6.85 
Microtubule-associated protein 4 
(MAP4) 
M36542 OCTF2 6.32 
Octamer-binding transcription 
factor 2 
M63167 Rac-alpha 6.13 
V-akt murine thymoma viral 
oncogene homolog 1; rac protein 
kinase alpha 
NM_001752 CAT 6.12 Catalase 
NM_007031 HSF2 5.92 





variable region 5.86 
Immunoglobulin heavy chain 
variable region 
L09159 Rho 5.55 
Ras homolog gene family, member 
A; Rho 
M13975 
Protein Kinase C 
Beta II  5.52 Protein kinase C beta-II 
AB023420 APG-2 5.50 
Heat shock protein apg-2; 
HS24/p52; hsp70 
X02811 PDGFB 5.17 Platelet-derived growth factor beta 
M15990 C-yes-1 4.68 
V-yes-1 Yamaguchi sarcoma viral 
oncogene homolog 1; C-yes-1 
X79981 VE-cadherin 4.17 VE-cadherin 
NM_000426 LAMA2 4.11 Laminin, alpha 2 precursor 





Zinc finger protein homologous to 
Zfp-36 in mouse 
L09159 Rho 3.83 
Ras homolog gene family, member 
A; Rho 
U43747 Frataxin 3.69 Frataxin; Friedreich ataxia 
M23452 MIP1-ALPHA 3.64 
Macrophage inflammatory protein; 
Small inducible cytokine A3 
(homologous to mouse Mip-1a) 
L14283 
Protein Kinase C 
Zeta 3.61 Protein kinase C zeta 
M64240 MAX 3.55 
Helix-loop-helix zipper protein 
(max) 
U33841 ATM 3.55 Ataxia telangiectasia gene 
D14497 Map3K8 3.47 
Mitogen-activated protein kinase 
kinase kinase 8 
M31732 BCL 3 3.47 B-cell CLL/lymphoma 3 
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AF010309 Pig3 3.38 Quinone oxidoreductase homolog 
U96876 
Insulin induced 
protein 1 3.33 Insulin induced protein 1 
M34353 ROS1 3.20 
Transmembrane tyrosine-specific 
protein kinase (ROS1) 
M57732 
Hepatic nuclear 
factor 1-alpha 3.17 
Transcription factor 1, hepatic; LF-
B1, hepatic nuclear factor (HNF1), 
albumin proximal factor 
AF075601 HSJ2 3.11 Heat shock J2 protein; HSJ2 
X01394 TNF 3.06 Tumor necrosis factor 
AF015956 
Death Associated 
protein 6 3.02 Death associated protein 6 (DAXX) 
V00568 C-myc 3.02 C-myc oncogene 
NM_000808 
GABA(A) 
receptor alpha-3 3.00 
Gamma-aminobutyric acid (GABA) 
A receptor, alpha 3 
Z23115 Bcl-xL  2.95 BCL2-like 1 
M95712 B-raf 2.82 
V-raf murine sarcoma viral 




gamma 2 2.80 
GA-binding protein transcription 




1 2.76 8-oxoguanine DNA glycosylase 1 
NM_001715 Blk 2.70 B lymphoid tyrosine kinase 
AB017169 SLIT3 2.69 Slit-3 
M96577 E2F1 2.60 E2F transcription factor 1 
X59798 PRAD1 2.41 
Cyclin D1; PRAD1; parathyroid 
adenomatosis 1 
L33075 IQGAP1 2.34 
Ras GTPase-activating-like protein; 
IQGAP1 
M65217 HSF2 2.32 








factor 1 2.27 Mitochondrial transcription factor 1 
M14694 P53 2.26 P53 cellular tumor antigen 
U29680 
BCL2-related 
protein A1 2.24 
BCL2-related protein A1; Bfl-1; 
GRS 
X01394 TNF 2.20 Tumor necrosis factor 
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X52104 p68 2.16 
DEAD/H (Asp-Glu-Ala-Asp/His) 
box polypeptide 5 (RNA helicase, 
68kD); p68 
U24166 EB1 2.14 EB1 
AB023421 APG-1 2.06 




protein 6 2.04 GATA-binding protein 6 
M93255 Fli-1 2.00 Friend leukemia virus integration 1 
Table A6: Primary HCC compared with normal, genes down regulated by at least 2 fold 






Gene Symbol Fold 
Difference 
Long Gene Name 
AA702737 PPP6C 40.07 protein phosphatase 6, catalytic subunit 
W72473 PIK3CA 36.79 phosphoinositide-3-kinase, catalytic, alpha 
polypeptide 
N93214 KIAA0318 20.75 RIM binding protein 2 
R94360 PRLR 20.65 prolactin receptor 
AA406372 ZFX 14.60 zinc finger protein, X-linked 
AA700222 SCAM-1 14.46 vinexin beta (SH3-containing adaptor molecule-1) 
AA088857 LIPH 13.59 lipase, member H 
AA633931 ZFP28 13.54 zinc finger protein 28 homolog (mouse) 
H09613 CTPS 13.36 CTP synthase 
AA165409 SEMA3D 12.89 sema domain, immunoglobulin domain (Ig), short 
basic domain, secreted, (semaphorin) 3D 
AA702013 SLC22A1 12.24 solute carrier family 22 (organic cation 
transporter), member 1 
AA417012 ZNF336 11.62 zinc finger protein 336 
AA181978 COQ4 11.17 coenzyme Q4 homolog (yeast) 
AA425821 RER1 11.03 RER1 homolog (S. cerevisiae) 
N78927 MYL2 10.76 myosin, light polypeptide 2, regulatory, cardiac, 
slow 
AI654715 PEX16 10.74 peroxisomal biogenesis factor 16 
W86853 TIGD2 10.69 tigger transposable element derived 2 
R35941 FGF14 10.39 **fibroblast growth factor 14 
H68922 ITGA1 9.90 integrin, alpha 1 
AA478752 DKK3 9.14 dickkopf homolog 3 (Xenopus laevis) 
W46773 TRUB2 9.07 TruB pseudouridine (psi) synthase homolog 2 (E. 
coli) 
AA779415 ZNF11B 8.63 zinc finger protein 11b (KOX 2) 
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AI362062 NOVA1 8.61 neuro-oncological ventral antigen 1 
AA973337 PCF11 8.56 pre-mRNA cleavage complex II protein Pcf11 
R68463 JAM2 8.25 junctional adhesion molecule 2 
AA455428 SIAH1 8.10 seven in absentia homolog 1 (Drosophila) 
AA035657 LUM 8.08 lumican 
AI922402 GARP 8.06 glycoprotein A repetitions predominant 
AA600184 OVOS2 7.98 ovostatin 2 
N91246 TRNT1 7.91 tRNA nucleotidyl transferase, CCA-adding, 1 
AA879437 RGS5 7.80 regulator of G-protein signalling 5 
AI241258 TINAG 7.78 tubulointerstitial nephritis antigen 
AA284589 TFAP4 7.68 transcription factor AP-4 (activating enhancer 
binding protein 4) 
AA486570 GSTM4 7.60 glutathione S-transferase M4 
AA255900 STK38L 7.23 serine/threonine kinase 38 like 
AA022600 THRB 7.21 thyroid hormone receptor, beta (erythroblastic 
leukemia viral (v-erb-a) oncogene homolog 2, 
avian) 
H05800 MCF2 7.01 MCF.2 cell line derived transforming sequence 
AA486085 TMSB10 6.89 thymosin, beta 10 
AI675504 SEMG2 6.55 semenogelin II 
AA427595 SHB 6.48 SHB (Src homology 2 domain containing) adaptor 
protein B 
AA173625 CD2AP 6.30 CD2-associated protein 
H06675 ALDH5A1 6.28 aldehyde dehydrogenase 5 family, member A1 
(succinate-semialdehyde dehydrogenase) 
AA708440 MYADM 6.21 myeloid-associated differentiation marker 
AA176453 NDUFS6 6.16 NADH dehydrogenase (ubiquinone) Fe-S protein 
6, 13kDa (NADH-coenzyme Q reductase) 
AA443688 GCH1 5.96 GTP cyclohydrolase 1 (dopa-responsive dystonia) 
AI097227 NEURL2 5.88 neuralized-like 2 (Drosophila) 
R11979 STAU2 5.87 **staufen, RNA binding protein, homolog 2 
(Drosophila) 
AA609640 FBXO15 5.84 F-box protein 15 
AA911690 ZCCHC2 5.56 zinc finger, CCHC domain containing 2 
AA468451 ALOX15B 5.56 arachidonate 15-lipoxygenase, second type 
AA070357 TKT 5.51 transketolase (Wernicke-Korsakoff syndrome) 
AA054714 KPNA1 5.50 karyopherin alpha 1 (importin alpha 5) 
T99311 MTB 5.49 more than blood homolog 
AA431126 CITED1 5.48 **Cbp/p300-interacting transactivator, with 
Glu/Asp-rich carboxy-terminal domain, 1 
AI796687 SOLH 5.35 small optic lobes homolog (Drosophila) 
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AI004671 38231.00 5.26 **strand-exchange protein 1 
R22977 MSN 5.16 moesin 
H46487 MGAT3 5.07 mannosyl (beta-1,4-)-glycoprotein beta-1,4-N-
acetylglucosaminyltransferase 
AA719257 FBS1 5.04 fibrosin 1 
AI955961 VPS41 5.03 vacuolar protein sorting 41 (yeast) 
N73301 SRP46 4.93 Splicing factor, arginine/serine-rich, 46kD 
W91980 TMPIT 4.82 transmembrane protein induced by tumor necrosis 
factor alpha 
N71001 EIF4EL3 4.73 eukaryotic translation initiation factor 4E-like 3 
AA427490 KCNH2 4.64 potassium voltage-gated channel, subfamily H 
(eag-related), member 2 
AA485027 NAPSB 4.64 napsin B aspartic peptidase pseudogene 
AA446565 RBM25 4.64 RNA binding motif protein 25 
AA775453 CGI-105 4.60 CGI-105 protein 
AI023541 CA9 4.60 carbonic anhydrase IX 
AA146826 RUNX1 4.58 runt-related transcription factor 1 (acute myeloid 
leukemia 1; aml1 oncogene) 
AA969508 HEYL 4.45 hairy/enhancer-of-split related with YRPW motif-
like 
H28209 FABP4 4.43 fatty acid binding protein 4, adipocyte 
AA778392 BENE 4.36 BENE protein 
AA631098 SCLY 4.36 selenocysteine lyase 
AA513640 SCGB2A2 4.36 secretoglobin, family 2A, member 2 
AA443181 RAB5B 4.34 RAB5B, member RAS oncogene family 
AA443982 PPP1CA 4.24 protein phosphatase 1, catalytic subunit, alpha 
isoform 
AA489700 CD37 4.13 CD37 antigen 
AA838691 EPHX1 4.13 epoxide hydrolase 1, microsomal (xenobiotic) 
R74467 RHOB 4.09 ras homolog gene family, member B 
AA937899 ZG16 4.03 zymogen granule protein 16 
AA431226 PRPF18 4.03 **PRP18 pre-mRNA processing factor 18 
homolog (yeast) 
AA464525 IL1R1 3.90 interleukin 1 receptor, type I 
AA490462 AEBP1 3.84 AE binding protein 1 
AI053446 IQGAP3 3.76 IQ motif containing GTPase activating protein 3 
AA284113 NOTCH3 3.74 Notch homolog 3 (Drosophila) 
AI273242 KIAA0861 3.63 Rho family guanine-nucleotide exchange factor 
W37752 CLN3 3.62 **ceroid-lipofuscinosis, neuronal 3, juvenile 
(Batten, Spielmeyer-Vogt disease) 
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AA044151 FABP3 3.55 fatty acid binding protein 3, muscle and heart 
(mammary-derived growth inhibitor) 
W46976 LXN 3.55 latexin 
H25413 PQLC2 3.49 PQ loop repeat containing 2 
R20106 WRNIP1 3.47 Werner helicase interacting protein 1 
AA876054 HFE 3.44 hemochromatosis 
AA719131 MGAT1 3.42 mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-
acetylglucosaminyltransferase 
AA478606 MDS006 3.42 x 006 protein 
AA446222 MYO18A 3.41 myosin XVIIIA 
AA100787 GLS 3.33 glutaminase 
AA459392 RPC155 3.33 polymerase (RNA) III (DNA directed) (155kD) 
T61547 FBXL15 3.30 F-box and leucine-rich repeat protein 15 
AA862529 SUMO3 3.29 **SMT3 suppressor of mif two 3 homolog 3 
(yeast) 
AA970851 LRRC19 3.29 leucine rich repeat containing 19 
T51539 MSTP9 3.28 macrophage stimulating, pseudogene 9 
N75028 PSPH 3.28 phosphoserine phosphatase 
AA974248 SORCS2 3.26 sortilin-related VPS10 domain containing receptor 
2 
AA132502 TTLL2 3.20 tubulin tyrosine ligase-like family, member 2 
AA894437 BTBD9 3.19 BTB (POZ) domain containing 9 
R12840 FOS 3.14 v-fos FBJ murine osteosarcoma viral oncogene 
homolog 
AA873341 PBEF1 3.12 **pre-B-cell colony enhancing factor 1 
AI361560 HOXC9 3.12 homeo box C9 
R26732 PMP22 3.11 peripheral myelin protein 22 
W74418 K6IRS3 3.11 keratin 6 irs3 
AA430331 SEC31L2 3.09 SEC31-like 2 (S. cerevisiae) 
W72140 PFKL 3.08 phosphofructokinase, liver 
AA010974 C7orf9 3.07 chromosome 7 open reading frame 9 
AA705306 MLR2 3.04 ligand-dependent corepressor 
AA644587 LOC117584 3.00 fring 
AA487864 U1SNRNPBP 2.99 U11/U12 snRNP 35K 
AA425545 RP42 2.99 RP42 homolog 
AA488895 STYX 2.98 serine/threonine/tyrosine interacting protein 
AA626240 RICS 2.98 Rho GTPase-activating protein 
AA704995 GLYAT 2.98 glycine-N-acyltransferase 
AA443624 ZDHHC8 2.97 zinc finger, DHHC domain containing 8 
AA188768 WRNIP1 2.97 Werner helicase interacting protein 1 
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AA921815 SLC22A14 2.89 solute carrier family 22 (organic cation 
transporter), member 14 
AA137072 PTPRS 2.87 protein tyrosine phosphatase, receptor type, S 
AA937342 SPATS2 2.87 spermatogenesis associated, serine-rich 2 
H05654 CROC4 2.86 transcriptional activator of the c-fos promoter 
AA406362 PTGER3 2.84 prostaglandin E receptor 3 (subtype EP3) 
AA953069 TPK1 2.77 thiamin pyrophosphokinase 1 
AA664237 SYNPO 2.72 synaptopodin 
AA421099 SLC41A3 2.71 solute carrier family 41, member 3 
AA114250 ARMCX2 2.71 armadillo repeat containing, X-linked 2 
R73909 PSG11 2.67 pregnancy specific beta-1-glycoprotein 11 
AA947914 GRIA3 2.66 glutamate receptor, ionotrophic, AMPA 3 
AA001835 ZNF262 2.66 zinc finger protein 262 
AA844818 AMY2B 2.66 amylase, alpha 2B; pancreatic 
AA448569 SRPX 2.65 sushi-repeat-containing protein, X-linked 
AI652142 ACACA 2.62 acetyl-Coenzyme A carboxylase alpha 
AA973391 CAS1 2.61 O-acetyltransferase 
AA489386 QKI 2.58 quaking homolog, KH domain RNA binding 
(mouse) 
AI668612 PLA2R1 2.57 phospholipase A2 receptor 1, 180kDa 
AA088748 CIDE-3 2.57 cell death activator CIDE-3 
AA425934 S100A1 2.54 S100 calcium binding protein A1 
AA278169 THAP1 2.52 THAP domain containing, apoptosis associated 
protein 1 
AI358848 MARS 2.50 methionine-tRNA synthetase 
AA434420 PTPN9 2.49 protein tyrosine phosphatase, non-receptor type 9 
AI003528 AP1G2 2.48 adaptor-related protein complex 1, gamma 2 
subunit 
AI522311 ZNF237 2.47 zinc finger protein 237 
H73241 VIPR1 2.45 vasoactive intestinal peptide receptor 1 
AA670382 MAP1B 2.45 microtubule-associated protein 1B 
AA278426 ZNF469 2.44 zinc finger protein 469 
T68274 C8B 2.43 complement component 8, beta polypeptide 
AA447797 PLAT 2.43 plasminogen activator, tissue 
AI055825 FCER2 2.42 Fc fragment of IgE, low affinity II, receptor for 
(CD23A) 
N95433 SNX9 2.42 sorting nexin 9 
AI023726 ZNF335 2.40 zinc finger protein 335 
AA969969 PAOX 2.40 polyamine oxidase (exo-N4-amino) 
AI094626 OSBPL6 2.39 oxysterol binding protein-like 6 
AA431988 FAAH 2.37 fatty acid amide hydrolase 
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AA450055 ING1 2.36 inhibitor of growth family, member 1 
AA487527 MPEG1 2.24 macrophage expressed gene 1 
AA458982 SCNN1A 2.23 sodium channel, nonvoltage-gated 1 alpha 
T57877  2.20 Similar to Zinc finger protein 20 (Zinc finger 
protein KOX13) (DKFZp572P0920) 
(LOC342970), mRNA 
AA393596 PPP2R5E 2.14 protein phosphatase 2, regulatory subunit B (B56), 
epsilon isoform 
R25016 TNFRSF7 2.14 tumor necrosis factor receptor superfamily, 
member 7 
AA463188 NEK6 2.13 NIMA (never in mitosis gene a)-related kinase 6 
T68859 SERPINF2 2.12 serine (or cysteine) proteinase inhibitor, clade F 
(alpha-2 antiplasmin, pigment epithelium derived 
factor), member 2 
W92764 TNFAIP6 2.09 tumor necrosis factor, alpha-induced protein 6 
AA406285 DRAP1 2.08 DR1-associated protein 1 (negative cofactor 2 
alpha) 
AI668571 ATP6V1B1 2.05 ATPase, H+ transporting, lysosomal 56/58kDa, 
V1 subunit B, isoform 1 (Renal tubular acidosis 
with deafness) 
AA043416 CES1 2.02 carboxylesterase 1 (monocyte/macrophage serine 
esterase 1) 
Table A7: Primary HCC compared with normal, genes up regulated by at least 2 fold in 







ID Gene Symbol 
Fold 
difference Long Gene Name 
R24333 FLJ20516 8.42 timeless-interacting protein 
AA485373 VMP1 7.94 
likely ortholog of rat vacuole membrane 
protein 1 
AA025165 FUS 7.80 
fusion (involved in t(12;16) in malignant 
liposarcoma) 
AA644092 NME1 6.06 
non-metastatic cells 1, protein (NM23A) 
expressed in 
AI049502 TUSC3 5.90 tumor suppressor candidate 3 
AA448395 HSPE1 5.76 **heat shock 10kDa protein 1 (chaperonin 10) 
AW004605 POLR2K 5.35 
polymerase (RNA) II (DNA directed) 
polypeptide K, 7.0kDa 
AA487521 GOT2 4.94 
glutamic-oxaloacetic transaminase 2, 
mitochondrial (aspartate aminotransferase 2) 
AA100145 STX16 4.83 syntaxin 16 
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AA460685 BIRC5 4.83 baculoviral IAP repeat-containing 5 (survivin) 
N66278 JUND 4.76 jun D proto-oncogene 
AA468759 SPEC1 4.66 **small protein effector 1 of Cdc42 
AA489583 PEMT 4.60 phosphatidylethanolamine N-methyltransferase 
AA134861 IRS2 4.58 insulin receptor substrate 2 
AA455786 MCM3 4.42 
MCM3 minichromosome maintenance 
deficient 3 (S. cerevisiae) 
AA454935 NRF1 4.34 nuclear respiratory factor 1 
AA625632   4.21 
Similar to similarity to 
monoubiquitin/carboxy-extension protein 
fusion (LOC149329), mRNA 
AA452531 QKI 4.13 
**quaking homolog, KH domain RNA binding 
(mouse) 
T66154 LOC401152 4.01 HCV F-transactivated protein 1 
AA668811 H3F3A 3.97 H3 histone, family 3A 
AA598863 EIF3S8 3.94 
eukaryotic translation initiation factor 3, 
subunit 8, 110kDa 
AA664241 NACA 3.92 
nascent-polypeptide-associated complex alpha 
polypeptide 
AA983905 WDR4 3.88 WD repeat domain 4 
AI015641 SDC1 3.84 syndecan 1 
H85355 ATP2A2 3.75 
ATPase, Ca++ transporting, cardiac muscle, 
slow twitch 2 
AA490256 GNAI3 3.73 
guanine nucleotide binding protein (G protein), 
alpha inhibiting activity polypeptide 3 
AI366195 SRP68 3.72 signal recognition particle 68kDa 
R63318 ZNF444 3.67 zinc finger protein 444 
N21329 TFRC 3.65 transferrin receptor (p90, CD71) 
AA284265 e(y)2 3.64 e(y)2 protein 
AA477226 LASS2 3.61 
LAG1 longevity assurance homolog 2 (S. 
cerevisiae) 
AA708342 ENO1 3.54 enolase 1, (alpha) 
AA541802 B3GNT5 3.51 
**UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 5 
AA291772 TETRAN 3.51 tetracycline transporter-like protein 
AI333932 ZFP106 3.49 zinc finger protein 106 homolog (mouse) 
AA676836 SMPDL3A 3.47 sphingomyelin phosphodiesterase, acid-like 3A 
AI359981 SOX3 3.39 SRY (sex determining region Y)-box 3 
AA629897 LAMR1 3.39 




AA699770 LASS2 3.38 
LAG1 longevity assurance homolog 2 (S. 
cerevisiae) 
W81684 TCEB1 3.29 
transcription elongation factor B (SIII), 
polypeptide 1 (15kDa, elongin C) 
AI346026 PLEKHA1 3.28 
pleckstrin homology domain containing, 
family A (phosphoinositide binding specific) 
member 1 
AA452095 SMC4L1 3.27 
**SMC4 structural maintenance of 
chromosomes 4-like 1 (yeast) 
R26186 PPP1CB 3.24 
protein phosphatase 1, catalytic subunit, beta 
isoform 
AA448164 KBTBD2 3.23 
kelch repeat and BTB (POZ) domain 
containing 2 
AA115186 GTF2I 3.22 **general transcription factor II, i 
AA664067 HSBP1 3.21 heat shock factor binding protein 1 
AA427468 CLDN4 3.19 claudin 4 
AA485965 SUCLG1 3.19 
succinate-CoA ligase, GDP-forming, alpha 
subunit 
W96163 TOB1 3.19 transducer of ERBB2, 1 
N53133 STRBP 3.18 spermatid perinuclear RNA binding protein 
AA100289 PSME2 3.18 
proteasome (prosome, macropain) activator 
subunit 2 (PA28 beta) 
AA159620 EVI2B 3.18 ecotropic viral integration site 2B 
T72088 AGXT2 3.18 alanine-glyoxylate aminotransferase 2 
T63046 ITM2B 3.16 integral membrane protein 2B 
AA129397 DAZ4 3.15 deleted in azoospermia 4 
T40899 TAS2R14 3.14 taste receptor, type 2, member 14 
AA292964 CKS2 3.12 CDC28 protein kinase regulatory subunit 2 
AA188647 TRIM33 3.12 tripartite motif-containing 33 
AA535703 REG4 3.11 regenerating islet-derived family, member 4 
H05489 DCK 3.09 deoxycytidine kinase 
N24059 MDN1 3.07 MDN1, midasin homolog (yeast) 
AA044993 CTGF 3.06 connective tissue growth factor 
AA150505 C1QR1 3.06 
complement component 1, q subcomponent, 
receptor 1 
T56221 MT1F 3.06 metallothionein 1F (functional) 
AI985214 TFPI 3.01 
tissue factor pathway inhibitor (lipoprotein-
associated coagulation inhibitor) 
AA465237 PSMA3 3.00 
proteasome (prosome, macropain) subunit, 
alpha type, 3 
AW006596 CS 2.98 citrate synthase 
AA495935 MGST1 2.97 microsomal glutathione S-transferase 1 
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AA608514 H3F3B 2.97 H3 histone, family 3B (H3.3B) 
AA922326 NDUFV2 2.95 
NADH dehydrogenase (ubiquinone) 
flavoprotein 2, 24kDa 
AA454585 SFRS2 2.95 splicing factor, arginine/serine-rich 2 
AA455544 PSK-1 2.95 
type I transmembrane receptor (seizure-related 
protein) 
H26841 UBE2D3 2.95 
ubiquitin-conjugating enzyme E2D 3 (UBC4/5 
homolog, yeast) 
R38685 MI-ER1 2.91 **mesoderm induction early response 1 
R27585 PSMA1 2.91 
proteasome (prosome, macropain) subunit, 
alpha type, 1 
R87699 ADAM11 2.89 a disintegrin and metalloproteinase domain 11 
AA418670 JUND 2.89 jun D proto-oncogene 
T57556 HINT1 2.87 histidine triad nucleotide binding protein 1 
AA126913 GMDS 2.86 GDP-mannose 4,6-dehydratase 
AI343840 TERF2 2.85 telomeric repeat binding factor 2 
H37989 OK/SW-cl.56 2.85 beta 5-tubulin 
R83223 RIN2 2.82 Ras and Rab interactor 2 
AA488782 ROCK1 2.81 
Rho-associated, coiled-coil containing protein 
kinase 1 
AA452257 CKLFSF5 2.81 chemokine-like factor super family 5 
AA961071 RPN1 2.76 ribophorin I 
AA196465 SLN 2.75 sarcolipin 
AA169355 TTC17 2.74 **tetratricopeptide repeat domain 17 
AA661722 FLJ23471 2.72 MICAL-like 2 
AA775509 PERP 2.72 PERP, TP53 apoptosis effector 
AW074796 COMTD1 2.72 
catechol-O-methyltransferase domain 
containing 1 
AA489245 MAPK8IP3 2.72 
**mitogen-activated protein kinase 8 
interacting protein 3 
AA040169 ACTA2 2.70 actin, alpha 2, smooth muscle, aorta 
N50654 CP 2.70 ceruloplasmin (ferroxidase) 
AA159669 VMP1 2.68 
likely ortholog of rat vacuole membrane 
protein 1 
N64706 ZNF526 2.66 **zinc finger protein 526 
AA043679 RAB7 2.65 RAB7, member RAS oncogene family 
T63998 GNA11 2.65 
guanine nucleotide binding protein (G protein), 
alpha 11 (Gq class) 
AA598486 SAE1 2.64 SUMO-1 activating enzyme subunit 1 
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AA994038   2.57 
Similar to ataxin 2 binding protein 1 isoform 
gamma; hexaribonucleotide binding protein 1 
(LOC339162), mRNA 
AA599102 CLDN12 2.56 claudin 12 
N62348 COL4A3BP 2.54 
collagen, type IV, alpha 3 (Goodpasture 
antigen) binding protein 
AI732296 ANXA2 2.53 annexin A2 
T47814 PSME1 2.52 
proteasome (prosome, macropain) activator 
subunit 1 (PA28 alpha) 
N93865 EPB41 2.50 
erythrocyte membrane protein band 4.1 
(elliptocytosis 1, RH-linked) 
H25560 DGAT2 2.49 
diacylglycerol O-acyltransferase homolog 2 
(mouse) 
AI017237 SLC39A4 2.46 
**solute carrier family 39 (zinc transporter), 
member 4 
AA983252 STAT2 2.45 
signal transducer and activator of transcription 
2, 113kDa 
AA598754 PEG10 2.42 **paternally expressed 10 
AA708905 WASF2 2.40 WAS protein family, member 2 
W80692 SEPHS1 2.39 selenophosphate synthetase 1 
AA455942 WWP1 2.39 WW domain-containing protein 1 
AA434024 LSS 2.38 
lanosterol synthase (2,3-oxidosqualene-
lanosterol cyclase) 
R56055 TUB 2.38 **tubby homolog (mouse) 
AA081106 SLC38A2 2.36 solute carrier family 38, member 2 
H89996 CTCF 2.34 CCCTC-binding factor (zinc finger protein) 
N50859 TNIP2 2.33 TNFAIP3 interacting protein 2 
AA458661 HADH2 2.32 
hydroxyacyl-Coenzyme A dehydrogenase, 
type II 
W73892 RBM5 2.32 RNA binding motif protein 5 
AA916752 VPS35 2.31 vacuolar protein sorting 35 (yeast) 
AA953747 PLS3 2.30 plastin 3 (T isoform) 
R36515 GJA5 2.30 
gap junction protein, alpha 5, 40kDa (connexin 
40) 
AA699707 FNBP1 2.29 formin binding protein 1 
H29484 SSB 2.29 Sjogren syndrome antigen B (autoantigen La) 
T53219 FABP1 2.29 fatty acid binding protein 1, liver 
AA434408 CCNI 2.29 cyclin I 
AA788767 GGCX 2.29 gamma-glutamyl carboxylase 
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T47454 TFPI 2.28 
tissue factor pathway inhibitor (lipoprotein-
associated coagulation inhibitor) 
AA416685 UNC13B 2.26 unc-13 homolog B (C. elegans) 
AA864681 MAP2K7 2.21 mitogen-activated protein kinase kinase 7 
AI820509 PB1 2.21 polybromo 1 
AW006512 PSME3 2.21 
proteasome (prosome, macropain) activator 
subunit 3 (PA28 gamma; Ki) 
AA481248 CGGBP1 2.21 CGG triplet repeat binding protein 1 
AA193380 AOF2 2.20 amine oxidase (flavin containing) domain 2 
AA679454 STAR 2.19 steroidogenic acute regulator 
AI636025 ZBTB11 2.19 zinc finger and BTB domain containing 11 
AI246829 SDCCAG1 2.18 serologically defined colon cancer antigen 1 
N66948 LOC56902 2.18 putatative 28 kDa protein 
AA599574 LIPG 2.17 lipase, endothelial 
H50238 LIPE 2.16 lipase, hormone-sensitive 
AI061063 MLH3 2.16 **mutL homolog 3 (E. coli) 
AA045463 SPARC 2.16 
secreted protein, acidic, cysteine-rich 
(osteonectin) 
AA190871 ALPI 2.16 alkaline phosphatase, intestinal 





AA609218 DNAI1 2.15 dynein, axonemal, intermediate polypeptide 1 
AA664009 SCP2 2.14 sterol carrier protein 2 
AA070618 PSMB6 2.14 
proteasome (prosome, macropain) subunit, 
beta type, 6 
AI024999 VCP 2.13 valosin-containing protein 
H37817 USP42 2.12 ubiquitin specific protease 42 
H51065 LEPR 2.11 leptin receptor 
AA609598 YWHAZ 2.11 
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta 
polypeptide 
AA490721 SFRS9 2.10 splicing factor, arginine/serine-rich 9 
AA872402 EIF4B 2.10 eukaryotic translation initiation factor 4B 
AI935290 CSRP1 2.10 cysteine and glycine-rich protein 1 
T49984 DKFZP586A0522 2.10 DKFZP586A0522 protein 
AA991590 APOC1 2.10 apolipoprotein C-I 
W85854 EBPL 2.09 emopamil binding protein-like 
AA449362 CHD2 2.09 




AI452900 JPH2 2.08 junctophilin 2 
AI300352 GPD1 2.07 
glycerol-3-phosphate dehydrogenase 1 
(soluble) 
R52964 PPHLN1 2.06 periphilin 1 
AA172012 GNPDA2 2.05 glucosamine-6-phosphate deaminase 2 
AA190558 NUP133 2.05 nucleoporin 133kDa 
N92443 UBTF 2.05 
**upstream binding transcription factor, RNA 
polymerase I 
AA599741 SLICK 2.05 
sodium- and chloride-activated ATP-sensitive 
potassium channel 
AA626327 TTC15 2.05 tetratricopeptide repeat domain 15 
AA583574 S100A7 2.04 S100 calcium binding protein A7 (psoriasin 1) 
N59089   2.04 
**Human HepG2 partial cDNA, clone 
hmd5d04m5. 
AA504272 HNRPM 2.02 heterogeneous nuclear ribonucleoprotein M 
AA046090 FABP4 2.01 fatty acid binding protein 4, adipocyte 
AI083844 NFIX 2.01 
nuclear factor I/X (CCAAT-binding 
transcription factor) 
AA435999 LACTB2 2.01 lactamase, beta 2 
Table A8: Primary HCC compared with normal, genes down regulated by at least 2 fold 
in the Stanford array. 
